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Aromatase inhibitors (AIs) have an established role in the treatment of estrogen receptor 
alpha positive (ER
+
) post-menopausal breast cancer. However, response rates are only 
50-70% in the neoadjuvant setting and lower in advanced disease. There is a need to 
identify pre- or early on-treatment biomarkers to predict sensitivity which outperform 
those currently used, in a move towards stratified treatments and improved patient care. 
Given the heterogeneity known to exist in the breast cancer population, and the limited 
availability of matched pre- and on-treatment clinical material, this study also sought to 
develop novel data integration approaches allowing for the inclusion of similar 
previously published datasets, thus maximising the power of this study. 
Experimental Design 
Pre- and on-treatment (at 14 days and 3-months) biopsies were obtained from 34 post-
menopausal women with ER+ breast cancer receiving 3 months of neoadjuvant 
letrozole. Illumina Beadarray gene expression data from these samples were combined 
with Affymetrix GeneChip data from a similar published study (n=55) and cross-
platform integration approaches were evaluated. Dynamic clinical response was assessed 
for each patient from periodic 3D ultrasound measurements during treatment.  
Results 
Despite intrinsic differences between different microarray technologies, suitably similar 
studies can be directly integrated for robust and meaningful meta-analysis with 
improved statistical power. After mapping probe sequences to Ensembl genes it was 
demonstrated that, ComBat and cross platform normalisation (XPN), significantly 
outperform mean-centering and distance-weighted discrimination (DWD) in terms of 
minimising inter-platform variance. In particular it was observed that DWD, a popular 
method used in a number of previous studies, removed systematic bias at the expense of 
genuine biological variability, potentially reducing legitimate biological differences 
from integrated datasets. A pipeline for the successful integration of microarray datasets 




Using this approach a classifier of clinical response to endocrine therapy in the 
neoadjuvant setting based on the expression of 4 genes was developed which predicted 
response with 96% and 91% accuracy in training (n=73) and independent validation 
(n=44) datasets respectively. An early on-treatment biopsy was found to improve 
predictive power in addition to pre-treatment alone. 
Conclusions  
Using a novel data integration approach developed as part of this study, a model 
comprising 4 novel biomarkers for accurate and robust prediction of clinical response to 
AIs by two weeks of treatment has been generated and validated. On-going work will 
investigate the applicability to other anti-estrogens, and the adjuvant setting and will 
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1.1. Breast Cancer 
1.1.1. Incidence and Survival 
Breast cancer is a disease which according to Cancer Research UK official statistics 
affects approximately 48,000 woman in the UK each year and in 2010 resulted in over 
11,000 deaths [1]. More woman than ever before in the UK are living with breast cancer 
because of a reduction in mortality over the last 20 years [2] (figure 1). This is due to 
better awareness, the introduction of screening in 1987 and improvements in treatment 
[2, 3].  
 
Figure 1. Female breast cancer in England: incidence and mortality between 1970 
and 2010 (Office of National Statistics). Despite a reduction in mortality, since the 
introduction of screening in 1987 incidence of breast cancer has increased over the last 20 
years. 
1.1.2. Histological Subtypes and Staging 
Breast cancer is a heterogeneous disease both pathologically and genetically [4]. Several 
classification systems have been developed and adopted into clinical practice to 
subdivide breast cancers into groups with similar molecular and histological 




Using histology based on microscopic examination, breast cancer can be broadly 
categorised as either in situ or invasive carcinoma: characterised by invasion through the 
basement membrane. In the case of in situ carcinoma, the majority of such cases are 
classified as ductal (involving the terminal duct lobular unit and the ductal tree) with far 
fewer lobular (limited mainly to the terminal duct lobular unit) cases reported [6] (figure 
2A). The terms ductal and lobular were selected because of the belief that ductal cancers 
arose in ducts and lobular cancers arose in the lobules. Subsequent work showed all 
cancer arises in the terminal duct lobular unit. The nomenclature remains in everyday 
use because ductal and lobular define two groups of cancers with different cellular 
morphology and different clinical behaviours [7]. In situ carcinoma is often regarded as 
‘pre-cancer’ given its non-invasive phenotype. However, in some cases these tumours 
can develop into invasive cancer [8]. Improvements in screening have led to a rise in the 
detection and hence treatment of pre-cancer tumours before they have the opportunity to 
progress.  
Invasive carcinomas are a heterogeneous group of tumours which have been classified 
into 7 histologically distinct subgroups: infiltrating ductal, invasive lobular, 
ductal/lobular, mucinous, tubular, medullary and papillary carcinomas [6]. Of these, 
infiltrating ductal carcinoma (IDC), sometimes designated as ‘no special type’, is the 
most common accounting for 70-80% of all invasive breast tumours [9]. It is 
characterised histologically by invasion of the primary tumour through the basement 
membrane of the duct. IDC is further classified as well-differentiated (grade 1), 
moderately differentiated (grade 2), and poorly differentiated (grade 3) using a system 
adapted from that originally developed by Bloom and Richardson in the 1950s, which 
takes into account nuclear pleomorphism, glandular/tubule formation and mitotic index 
(presence of hyperchromatic and mitotic nuclei) [10-13] (figures 2B and C). It was 
subsequently modified by Ellis and Ellston in 1991 (republished in 2002) [11] and all 
breast cancers are typed and graded according to their system. A staging system known 
as TNM based on tumour size (T), invasion of lymph nodes (N) and presence of 




alternative, numbered staging system comprises 4 stages of breast cancer from I (early 
stage) to IV (advanced stage) and these 4 stages are classified based on similar criteria 
applied to TNM staging [14]. 
 
Figure 2. Light microscopic examination of hematoxylin and eosin (H&E) stained 
formalin fixed paraffin embedded (FFPE) sections of human breast tissue. A: low 
power magnification of ductal carcinoma in situ (DCIS). B&C: medium power magnification 
of invasive infiltrating ductal carcinoma (IDC). B: grade 1 disease with noticeable tubule 
formation. C: grade 3 disease with pleomorphic nuclei and solid nests of tumour with no 
tubule formation. Images were provided courtesy of Jeremy Thomas (Consultant Breast 
Pathologist, Western General Hospital). 
1.1.3. Molecular Subtypes 
The use of molecular markers to further classify carcinomas has been readily accepted as 
standard clinical practice in breast cancer diagnosis. Currently the immunohistochemical 
(IHC) determination of estrogen receptor alpha (ER), progesterone receptor (PR) and 
epidermal growth factor receptor 2 (HER2, ERBB-2) protein levels is used to guide 
treatment and determine which patients are likely to respond to targeted therapies (i.e. 
endocrine therapy for ER
+
 patients and trastuzumab, pertuzumab or lapatinib for HER2
+
 
patients) [15-18]. Currently the Allred score, based on the proportion and intensity of 
positively stained cells, is applied to IHC staining to determine levels of ER and PR 
[19]. HER2 is assessed for over-expression using a scoring system ranging from 0 to 3+, 
where 0 and 1+ are considered negative for over-expression, and 3+ is considered 
positive [20, 21]. Samples that are 2+ have a further test to compare the copies of the 
HER2 gene with the centromere on chromosome 17 by fluorescence in situ hybridisation 




(FISH). If the score exceeds 2.2 then HER2 is regarded as amplified and the cancer is 
classified as HER2
+
. Many IHC 2+ samples have low amplification scores and so are 
classified as HER2
-
 [20-22].  
The advent of high-throughput technologies such as gene expression microarrays has led 
to the identification of distinct intrinsic molecular subtypes which have been confirmed 






; with expression of the basal 



























) [23-27]. Luminal breast cancers are also known to 
express cytokeratins: KRT7, KRT8, KRT18 and KRT19 [28]. More recently, additional 







subtype, similar in molecular profile to the basal-like subtype, was reported which 
appeared to have an epithelial to mesenchymal transition (EMT) phenotype 
characterised by loss of claudins 3/4/7 and E-cadherin but an increase in zinc finger 
protein SNAI2 (SLUG), zinc finger protein SNAI1 (SNAIL), vimentin and zinc finger 







), characterised by high expression of androgen 
receptors (AR
+
), a molecular feature also reported in luminal breast cancers [31]. The 
apocrine subtype consists of those ER
-
 tumours out-with the basal-like group, which are 
reported to be AR
+
. Amplification of HER2 is also a common feature within the 
apocrine subtype [32] (figure 3C).  
A number of researchers have postulated that these molecularly distinct tumour subtypes 
may represent transformation of normal breast stem-like cells with arrest at specific 
stages of development, or alternatively direct transformation of mature cell types into 
less differentiated forms [33, 34]. The proposed model begins with an ER
-
 mammary 
stem cell (MaSC) which maintains itself through self-renewal and differentiates itself 
into committed progenitors. These progenitors essentially give rise to progeny which are 




myoepithelial cells, which surround the luminal epithelium and contact the basement 
membrane [34]. Molecular profiling based on each subpopulation cell type was carried 
out and compared with a human dataset containing representative populations of the 5 
intrinsic subtypes (basal-like, claudin-low, HER2
+
, luminal A and luminal B). The 
findings showed enrichment of the mature luminal cell signature in the luminal A, 
luminal B and HER2
+
 subtypes and enrichment of the MaSC signature (mesenchymal 
signature) in the claudin-low subtype. The basal-like subtype was found to be enriched 
for the luminal progenitor signature, suggesting that basal-like tumours become arrested 
at a specific step in luminal development [33] (figures 3A&B).  
Breast cancer is known to be a heterogeneous disease and much work has been done to 
further classify and define the ER
-
 subset of tumours, beyond intrinsic subtyping, using 
gene expression microarrays. One gene expression study of 587 triple-negative breast 
cancers revealed 6 molecularly distinct subgroups: basal-like 1 (BL1), basal-like 2 
(BL2), immunomodulatory (IM), mesenchymal (M), mesenchymal stem-like (MSL), 
and luminal androgen receptor (LAR). BL1 and 2 subtypes were both characterised by 
high expression of cell cycle and DNA damage response genes with BL2 also showing 
increased expression of growth factor receptor signalling pathways including the 
epidermal growth factor (EGF), nerve growth factor (NGF), c-Met (MET), Wnt/β-
catenin and insulin-like growth factor 1 receptor (IGF1R) pathways. The IM subtype 
was enriched for immune cell signalling pathways (B-cell, natural killer cell (NK), T-
cell and dendritic cell (DC) receptor signalling pathways), cytokine signalling 
(interleukin (IL) 12 and 7 pathways) and core immune signal transduction pathways 
(nuclear factor kappa-light-chain-enhancer of activated B cells (NFκB), tumour necrosis 
factor (TNF), janus kinase/signal transducer and activator of transcription (JAK/STAT) 
pathways). Both M and MSL subtypes were enriched for EMT genes, with the MSL 
subtype also characterised by a decrease in proliferation associated genes and increase in 
stem cell associated genes. Like the apocrine subtype the LAR subtype had increased 
expression of androgen receptors. Comparison of these 6 subtypes with their 




classified tumours were basal-like and the majority tumours in the other subtypes (BL2, 
M, MSL and IM) were a mix of either basal-like, normal-like or HER2
+
. The LAR 
subtype tumours were mostly classified as luminal A, suggesting a luminal origin [35]. 





) was not carried out in this study and may be a better classification 
for the LAR tumours (figure 3D).  
Another study focused on ER
-
 breast cancer used an integrative analysis of three large 





), immune response (IR
+









 subtype was found to over-express HER2 and 
AR and has a molecular profile similar to the apocrine subtype discussed previously. In 
contrast the other 4 subtypes have low HER2 and AR expression. The CC
+
 subtype was 
found to have increased expression of cell cycle and proliferation associated genes 




 subtype which, in addition, was found to highly express immune 
response genes. The IR
+
 subtype was characterised by low expression of cell cycle and 
proliferation associated genes and high expression of immune response genes. The 
ECM
+
 subtype was found to over-express extra-cellular matrix associated genes. 
Comparison of these 5 subtypes with classifications using the intrinsic subtypes revealed 
that the majority of SR
+
 classified tumours were HER2
+







 were basal. The IR
+
 classified tumours were a mix of 
basal and HER2
+
 and the ECM
+
 classified tumours were largely basal and normal-like 
[36] (figure 3E). While these recently described subtypes have brought to light the 
concept of heterogeneity within the ER
-
 breast cancer population and have allowed for 
the identification of tumours with similar molecular profiles, their clinical relevance 








Figure 3. Molecular subtypes of breast cancer. A: Model of the human mammary 
cellular differentiation hierarchy found in normal breast, linked to intrinsic subtypes. B: 
Gradient of enrichment of expression patterns defining mesenchymal and luminal signatures 
linked to intrinsic subtypes. C: Intrinsic breast cancer subtypes. D&E: classifications of ER
-
 
breast cancer, colour coded by association of classification to intrinsic subtypes (red=basal-
like, purple=HER2, blue=luminal A, black=mix of intrinsic subtypes). D: 6 subtypes of triple-
negative breast cancer; BL1=basal-like 1, BL2=basal-like 2, IM=immunomodulatory, 
M=mesenchymal, MSL=mesenchymal stem-like, LAR=luminal androgen receptor [35]. E: 5 
classifications of ER
-
 breast cancer; SR
+









=cell cycle with no immune response, ECR
+
=extra-cellular 
matrix  [36].    
These various molecular subtypes have been identified and validated by several groups 
using microarray-based gene expression analysis and hierarchical clustering. They have 
allowed for the stratification of molecularly distinct diseases, some of which have been 
shown to display highly significant differences in overall survival prediction and 
disease-free survival, with the basal-like and claudin-low subgroups having the worst 
prognosis [24, 25]. Even within the ER
+




more accurate molecular characterisation of the luminal A and B subtypes, improving on 
subtype assignment which was based on subjective IHC status of ER and HER2 alone, 
with a multi-gene molecular profile redefining luminal B as highly proliferative 
compared with luminal A and improving the association of luminal B with poor 
prognosis [24, 25]. Indeed within the luminal population work has been done to further 
characterise tumours so that therapeutic agents and new biomarkers to identify 
molecularly distinct subgroups with poor prognosis groups can be realised. Recently 
quiescin sulfydryl oxidase 1 (QSOX1), an enzyme involved in post-translational 
modifications, was found to be associated with poor prognosis in patients with luminal B 
breast cancer and may represent an important biomarker and target in that population 
[37, 38]. Indeed, another study reported that the transcriptional co-repressor ZNF703 
was a driver, specific to luminal B disease [39]. A recent study proposed that luminal A 
and luminal B (HER2 negative) tumours should be further classified based on genomic 
status relating to diploid/aneuploid and chromosome instability (CIN). Two subgroups 
were identified: diploid/CIN- or aneuploid/CIN+ and the latter was linked to poor 
prognosis in the luminal population [40]. Furthermore, recent work linking copy number 
variation and gene expression to long-term outcome in primary breast tumours has given 
rise to an ER+ subgroup characterised by an 11q13/14 acquired somatic copy number 
aberration (CNA) which has a significantly favourable prognosis compared to a 
subgroup which was devoid of CNAs [41]. Continuing work to further understand the 
ER
+
 population aims to characterise novel molecular subgroups of tumours with poor 
prognosis and identify new biomarkers and targets in a move towards improved, 
personalised treatment.  
1.1.4. Breast Cancer Treatment 
Five main treatment options are currently available for breast cancer: surgery, radiation 
therapy, chemotherapy, hormone therapy and targeted anti-HER2 therapy. In the 
majority of cases optimal clinical management involves surgery combined with one or 
more additional therapies [42]. The optimal treatment strategy is determined by 




and other patient factors such as age, menopausal status and overall health. To aid these 
considerations, standard clinical assessments at diagnosis often include calliper, 
mammographic and 3D ultrasound measurements, and core biopsy of tumour masses 
allowing for histopathological assessment.  
Surgery to remove the tumour remains the most effective treatment for breast cancer and 
consists of either breast conserving surgery (BCS), followed by high-energy x-ray 
radiation therapy, or mastectomy [43-46]. In cases where tumour size exceeds that 
recommended for BCS, chemotherapy or hormone therapy can be given in the 
neoadjuvant setting (before surgery) to reduce tumour size sufficient to allow breast 
conserving surgery (BCS) [47]. 
Chemotherapy involves the cyclical administration of combinations of cytotoxic drugs 
(alkylating agents, anthracyclines, antimetabolites and taxanes) to kill cancer cells. It can 
be used in the adjuvant (after surgery), neoadjuvant or palliative setting [45, 48, 49]. 
Hormone therapy, also referred to as endocrine therapy is a treatment which removes or 
blocks the action of hormones such as estrogen and progesterone which are recognised 
as key molecular drivers in luminal breast cancers. Endocrine therapies are indicated for 
use in both the adjuvant and neoadjuvant settings and in the management of advanced or 
metastatic disease where surgery is not usually a viable option [45, 50]. Targeted anti-
HER2 therapy, refers to giving monoclonal antibodies (such as trastuzumab) or tyrosine 
kinase inhibitors (lapatinib) that target key cellular receptors, such as HER2 which is 
overexpressed in around 15-20% of breast cancers and has an important role in 
tumorigenesis [51, 52]. Targeted anti-HER2 therapies are often combined with 
chemotherapy in HER2
+
 patients (which are mostly ER
-
) and have been shown to reduce 
risk of recurrence and risk of death after 3 years [53]. Other therapies designed to target 
specific pathways believed to be involved in progression and recurrence are currently 
being assessed for efficacy and benefit to survival in breast cancer. These include 
everolimus (RAD001) designed to target the mammalian target of rapamycin (mTOR) 
pathway by blocking the action of the key signalling protein mTOR complex 1 




associated genes particularly in highly-proliferative tumours, indicating that some 
patients with more aggressive tumours may benefit most from this therapy [54]. 
1.1.5. Estrogen Biosynthesis and ER+ Breast Cancer 
The hormone estrogen (17β-estradiol, E2) has been identified as a key molecular 
stimulant in the development of ER
+
 breast cancer, which constitutes around 70-80% of 
all breast cancers [55]. In both pre- and post-menopausal woman estrogen production 
occurs locally in the normal tissues of subcutaneous fat, the breast, muscle tissue and 
bone where it is produced by the enzymatic breakdown of androgens (androstenedione 
and testosterone) by aromatase [55-61]. Indeed, expression of aromatase has been shown 
to occur in fibroblasts within breast cancer tissue [62]. Residual levels of estrogen are 
also commonly found circulating in the blood plasma and are around 20-fold higher in 
post-menopausal women compared with pre-menopausal women despite the loss of 
ovarian estrogen production [57, 58, 63]. In post-menopausal women there is a 
noticeable correlation between risk of breast cancer and levels of circulating estrogen in 
the blood plasma [64]. Aromatase transcription and protein levels have been shown to 
differ between the quadrants of the breast in woman with breast cancer, being 
considerably increased in the quadrant containing the tumour [65, 66]. Evidence 
suggests that this is primarily due to tumour cell released factors such as prostaglandin 
E2 (PGE2) and inflammatory cell released cytokines such as interleukin 6 (IL6), 
interleukin 11 (IL11) and tumour necrosis factor alpha (TNFα), which enhance the 
activity of aromatase in fibroblasts through intracellular cyclic adenosine 
monophosphate (cAMP) signalling and regulation of the aromatase gene (CYP19) via an 
alternative non-standard promoter (promoter II) for the gene [55, 67, 68].  
In hormone-dependent cancers, estrogen taken up from the blood plasma or from local 
production diffuses into the cancer cell and binds ER, in so doing causing the 
dissociation of heat shock proteins from the ER molecule. The ligand-bound molecule 
dimerises, associates with other co-activator or co-repressor proteins and subsequently 
binds to conserved estrogen response element (ERE) sequences within the promoter 




receptor encoded by gene ESR1; it contains two distinct transactivation domains: 
activation function (AF)-1 in the amino-terminal region and AF2 in the carboxy-terminal 
region [70-72]. AF1 is regulated by growth factors acting through the mitogen activated 
protein (MAP) kinase pathway whereas AF2, located in the ligand binding region of ER 
is activated by estrogen [70, 73]. Full agonist activity requires both AF1 and AF2 to be 
active [74]. Studies have shown that ERE bound ER is ubiquitinated and targeted for 
proteosomal degradation suggesting that each ER molecule is destined for only one 
cycle of estrogen signalling [75]. EREs were first identified flanking the regions of 
estrogen-regulated vitelogennin genes in Xenpous lavis and have since been identified in 
the promoter regions of several hundred human genes, with a minimum consensus 
sequence consisting of a 13 base-pair palindromic inverted repeat: 5’-
GGTCAnnnTGACC-3’ (n: any nucleotide) [76-78]. Some EREs have been identified 
which have imperfect palindromic sequences, differing from the consensus sequence by 
one or more nucleotides and are often less responsive to ligand-bound ER than 
consensus sequence EREs [79]. The association of ligand-bound ER with EREs is 
thought to be achieved via two mechanisms: (i) ‘direct binding’ in which the molecule 
directly binds to EREs and associates directly with co-activator/co-repressor molecules 
and the RNA polymerase II transcription initiation complex, or (ii) ‘tethering’ whereby 
the ligand-bound ERα does not bind DNA but rather interacts with another DNA-bound 
transcription factor either stabilising the DNA-binding of that factor, or recruiting 
additional co-factors to the complex [80, 81]. The latter is thought to be the mechanism 
by which ligand-bound ER associates with transcription factor SP1 [80]. Via these 
transcriptional associations estrogen can induce proliferation of cancer cells which over-
express ER (figure 4). It should also be noted that non-ligand-bound ER complexes can 





Figure 4. Mechanism of action of estrogen in ER
+
 breast cancer. Estrogen (E) is 
derived from the enzymatic breakdown of androgens and sequestered into tumour cells 
where it binds ER causing the molecule to displace heat-shock proteins and homodimerise. 
The ligand bound ER dimer subsequently binds to ERE in the promoter region of estrogen 
responsive genes and recruits co-activators which aid in promoting transcription. 
1.1.6. Signalling in ER+ Breast Cancer 
Although the exact mechanisms by which estrogen drives proliferation remain to be 
fully elucidated, a number of potential mechanisms have been proposed [85]. In normal 
human breast tissue, cells which do not express ER proliferate via paracrine signalling, 
whereas in tumours an autocrine action occurs in which ER
+
 cells proliferate [86]. It has 
been reported that estrogen promotes transition through the G1/S phase of cell cycle via 
a number of pathways involving the induction of cyclin-D1 expression by ligand-bound 
ER, mediated by one or more transcription factors including: Jun oncogene (c-Jun), V-
fos FBJ murine osteosarcoma viral oncogene homolog (c-Fos) and activating 




SP1 transcription factor dependent pathway [87-93]. Furthermore, ligand-bound ER has 
also been shown to bind cyclin-D1 and, as a complex, regulate the expression of cyclin-
D1 and other downstream gene targets [91, 94]. Cyclin-D1 subsequently binds and 
activates cyclin-dependent kinase (CDK)-4 and CDK6, which regulate G1/S phase 
transition through the phosphorylation of retinoblastoma 1 (RB1). The latter can no 
longer inhibit E2F/transcription factor DP1 complexes, thus allowing them to activate 
the transcription of S-phase entry genes such as those encoding cyclin-E1 and cyclin-A1 
[87, 88, 95, 96]. Other reports suggest that ligand-bound ER may promote G1/S phase 
transition by induction of V-myc myelocytomatosis viral oncogene homolog (c-MYC) 
which leads to activation of cell division cycle 25 homolog A (CDC25A) and CDK4 
gene transcription [97-99]. Active CDC25A dephosphorylates CDK2 leading to the 
inhibition of RB1 and retinoblastoma-like 2 (p130) and transcriptional activation of 
E2F/DP1 complexes which in turn up-regulates S-phase entry genes [88, 100, 101]. 
Alternatively, it has been proposed that ER could activate G1/S phase transition via 
redistribution and down-regulation of cyclin-dependent kinase inhibitor 1A (p21) and 
cyclin-dependent kinase inhibitor 1B (P27KIP1) thus removing their inhibitory control 
over key cell cycle progression proteins such as CDK2 [101, 102]. It is thought this 
might be achieved by ubiquitin targeting for proteosomal degradation or by nuclear 
export via membrane-bound ER associated with mitogen-activated protein kinase 1 
(ERK2) and exportin 1 (CRM1) [103, 104]. 
1.2. Endocrine Therapy and Resistance to Treatment 
1.2.1.1. Endocrine Therapy    
Endocrine therapy constitutes a major treatment modality in ER
+
 breast cancer and is 
seen as an attractive alternative to chemotherapy which has more associated toxicity 
[105-108]. Indeed, studies have shown it to provide more benefit in the adjuvant setting 
in post-menopausal women with ER
+
 breast cancer than doxorubicin or taxane-
containing chemotherapies [109, 110]. The endocrine system can be manipulated via the 




and/or activity of the key hormone estrogen. Endocrine therapies are considered to be 
cytostatic rather than cytotoxic, leading to reduced proliferation and reduction of growth 
rate [111]. At the simplest molecular level, they achieve this through the arrest of cell 
cycle in G1/S phase [112]. Several types of endocrine therapies exist and are used 
commonly in the treatment of ER
+
 breast cancer in post-menopausal women.  
Tamoxifen (nolvadex) and raloxifene (evista) are examples of selective estrogen 
receptor modulators (SERMs). These function to disrupt the estrogen signalling pathway 
by competitive intra-nuclear binding to ER causing a conformational change to the 
subsequently formed ER dimer involving the shift of helix 12 into an adjacent co-
activator site (AF2), thus blocking the binding of the co-activator, which significantly 
reduces the level of estrogen-regulated gene transcription [74, 113, 114]. However, this 
complex has been shown to exhibit partial estrogen-agonist properties due to the 
remaining activity of AF1 [55, 74]. A newer yet similar class of endocrine therapies 
exist which are known as selective estrogen receptor down-regulators (SERDs) and 
these include fulvestrant (faslodex). Fulvestrant functions to down-regulate ER by 
competitive binding to ER dimers and by causing immobilisation of ER in the nuclear 
matrix which is accompanied by degradation via the ubiquitin-proteasome pathway 
[115]. It has been shown to be more potent than tamoxifen in vitro and does not exhibit 
the partial estrogen-agonist properties, associated with tamoxifen, in murine models. 
This is due to the fact that both AF1 and AF2 activities are supressed, blocking co-factor 
recruitment at the ERE site of estrogen responsive genes [74, 116, 117].  
Another major group of endocrine therapies in routine clinical use are third-generation 
aromatase inhibitors (AIs) which comprise two drug types. Firstly, there are irreversible 
steroidal inhibitors (type 1) including exemestane (aromasin) which are androstenedione 
analogues. Secondly, there are non-steroidal inhibitors (type 2) which include letrozole 
(Femara) and anastrozole (Arimidex) [55, 118-123]. AIs seek to disrupt estrogen 
signalling by either: irreversible and inactivating binding (type 1), or reversible and 
competitive binding (type 2) to the aromatase enzyme; thus significantly reducing local 




in the adjuvant setting letrozole and anastrozole have been shown to be more effective 
than tamoxifen with a significant reduction in the rate of relapse [123, 127, 128]. 
Endocrine therapies can also be used in the treatment of ER
+
 breast cancer in pre-
menopausal women where their use is usually combined with drugs such as goserelin 
(Zoladex) designed to supress ovarian estrogen production [129].  
In post-menopausal women, adjuvant treatment represents the major clinical setting for 
endocrine therapy use where long-term systemic treatment is targeted against micro-
metastatic disease or progression of the primary disease [50]. Indeed several studies 
have reported overwhelming evidence of a high correlation between the adjuvant use of 
endocrine therapy and reduction in the risk of recurrence [130]. Endocrine therapy can 
also have an important role in the neoadjuvant setting where systemic treatment maybe 
indicated for 3 to 4 months prior to surgery in post-menopausal women with large and/or 
technically inoperable tumours. This treatment is intended to shrink the tumour such that 
surgery becomes possible [50, 106]. The Immediate Preoperative Anastrozole or 
Combined with Tamoxifen (IMPACT) study was a phase 3 clinical trial which showed 
that 46% of 124 ER
+
 post-menopausal women initially recommended for mastectomy 
became eligible for BCS following 3 months of neoadjuvant anastrozole [131]. Indeed 
by measuring proliferation levels of malignant cells using the expression of nuclear 
antigen Ki67, studies have shown a reduction in proliferation in approximately 90% of 
ER
+
 primary breast tumours treated with and responsive to AIs, confirming that these 
tumours derive significant proliferative stimulus from estrogen and that this can be 
potently supressed by endocrine therapy [132, 133]. Lastly, endocrine therapy can be 
used in the treatment of advanced or metastatic disease to prolong survival, either as a 
monotherapy or as part of a sequenced treatment regimen with chemotherapy, palliative 









Figure 5. Endocrine Therapy Mode of Action. A: Treatment with aromatase inhibitors 
(AI) which block the conversion of androgens to estrogen by inactivating binding to the 
aromatase enzyme. Non ligand bound ER homodimers can still bind EREs without the 
potential to activate gene expression. B: Treatment with tamoxifen (T) which competes with 
estrogen to bind the ER homodimers. Tamoxifen bound ER has much reduced potential to 
activate gene transcription, however can exhibit partial agonist activity due to the activity of 
AF1 which is not blocked by tamoxifen. C: Treatment with fulvestrant (F) which also 
competes with estrogen to bind ER homodimers. Fulvestrant bound ER has blocked AF1 
and AF2 activity and as a result transcription of estrogen responsive genes is potently 
supressed. Fulvestrant also promotes immobilisation of ER in the nuclear matrix which is 
accompanied by rapid degradation via the ubiquitin-proteasome pathway. 
1.2.2. Resistance to Endocrine Therapy 
Despite the benefits of endocrine therapy in the treatment of ER
+
 breast cancer, 
resistance to treatment eventually occurs in a large number of patients and  represents a 
severe encumbrance to optimal clinical management [50]. Clinically, resistance can 




therapy; following surgery or in rare cases after complete pathological response 
(elimination of all cancer tissue) following a period of drug therapy. Alternatively, in the 
neoadjuvant setting, resistance can be observed as clinical progression of primary 
disease, usually constituting an increase in primary tumour size or disease spread to 
regional nodes or beyond to more distant metastatic sites. Pathological changes such as 
increased tumour grade or increased proliferation are indicators of potential resistance to 
therapy. In the neoadjuvant setting, resistance occurs as either a primary lack of response 
(no change or an increase in tumour size and no evidence of pathological response) early 
in treatment, implying innate resistance, or later following a period of response, 
suggesting acquired resistance [135]. Studies have shown that recurrence on adjuvant 
endocrine therapy occurs in approximately 10-15% of patients with early stage ER
+
 
breast cancer within 5 years [136]. In the neoadjuvant setting 5-10% of patients exhibit 
innate resistance with a further 25-30% developing acquired resistance to treatment 
within 5 years [137, 138]. The majority of patients with advanced or metastatic ER
+
 
disease acquire resistance within 2-3 years of starting endocrine therapy [139].  
1.2.3. Mechanisms of Resistance 
While little is understood about the exact mechanisms underlying clinical response to 
endocrine therapy, even less is known about the mechanisms leading to innate or 
acquired resistance. Several different mechanisms have been described which set the 
basis for continued research aimed at improving the outcome of endocrine treatment. 
1.2.3.1. ER and PR Expression in Tumours with Innate Resistance 
Studies have suggested that innate resistance may be linked to lower levels of ER, which 
might suggest that the drive to proliferation of these cancers is not as highly dependent 
on estrogen as those expressing higher levels of ER. The current use of the Allred score 
for assessing ER levels by IHC staining categorises all tumours with greater than 10% of 
positively stained cells as ER
+
 despite the enormous variation within that group and it 
also does not cope well with intratumoural heterogeneity, with parts of the tumour less 
ER
+




suggests that endocrine therapy alone may be an inappropriate treatment choice for these 
patients particularly if there is heterogeneous ER staining.  
Clinically, the decision to treat with endocrine therapy is primarily based on ER status; 
however, IHC levels of PR are also determined at diagnosis. While the majority of ER
+
 
patients are also PR
+
, a subset is PR
-
, and some studies have linked this genotype with 




 display a poorer response to 




 tumours, and studies 


















 tumours have shown loss of regions containing genes 
associated with tumour suppression and apoptosis in the PR
-
 genotype. Furthermore, 
gains have been identified in regions in PR
-
 tumours which encode genes including: 
mitogen activated protein kinase kinase kinase 3 (MAP3K3), ribosomal protein S6 
kinase beta 1 (RPS6KB1), zinc finger protein 217 (ZNF217). Amplification of these 
genes could lead to activation of the phosphoinositide 3 kinase - protein kinase B-
mammalian target of rapamycin (PI3K-AKT-mTOR), which has been implicated with 
endocrine therapy resistance [143].    
1.2.3.2. PI3K-AKT-mTOR Pathway and Somatic Mutations 
PI3K is activated by growth factor receptor tyrosine kinases (RTKs) and G-protein 
coupled receptors (GPCRs). PI3K phosphorylates phosphatidylinositol 4,5-bisphosphate 
(PIP2) to produce PIP3 which recruits several molecules such as PDK1 and AKT to the 
plasma membrane which, on activation, drive cell cycle progression and survival [144-
146]. The pathway is negatively regulated by PTEN and INPP4B which 
dephosphorylate PIP3 and PIP2 respectively [147, 148]. AKT activates mTORC1 which 
regulates protein synthesis. The PI3K-AKT-mTOR pathway interacts with ER both 
directly and indirectly. AKT can phosphorylate ER which increases estrogen-induced, 
tamoxifen-induced and ligand independent ER transcriptional activity [149, 150]. In 
addition, PI3K promotes c-Jun phosphorylation, which complexes with c-Fos to form 




Studies have also shown that the PI3K pathway can be activated by HER2, the over-
expression of which has been linked to a weaker response to endocrine therapy and poor 
prognosis following adjuvant therapy (see section 1.2.3.7). In this model, activation of 
the PI3K pathway confers resistance to tamoxifen, fulvestrant and deprivation of 
estrogen [149, 154, 155]. Somatic mutations, which represent the most common in ER
+
 
breast cancer, have been described in key members of the PI3M-AKT-mTOR pathway 
including PI3KCA, PIK3CB, AKT1, AKT2, PTEN and INPP4B which have been linked 
to aberrant activation and potential dependence on the pathway [156]. 
1.2.3.3. Genetic Traits Affecting Drug Action 
Some studies looking at tamoxifen have alluded to resistance being linked to inherited 
genetic traits affecting drug metabolism. Some patients carry recessive alleles of a gene 
encoding a dysfunctional isoform of a protein known as cytochrome P450 2D6 
(CYP2D6) which is involved in the conversion of tamoxifen to its active metabolite 
form endoxifen [157, 158]. Around 8% of Caucasian women carry these recessive 
alleles and are likely to respond less well to tamoxifen treatment than women carrying 
wild-type alleles of the gene [158]. Similar findings have been suggested in the study of 
aromatase inhibitors with innate resistance to letrozole being linked to polymorphisms in 
the gene encoding aromatase (CYP19) [159, 160]. Currently the importance of drug 
metabolising enzymes and their genetic variation is thought not to be an important factor 
in endocrine resistance and as such no research in this area has yet reached the clinic. 
1.2.3.4. ER-Independent Signalling 
Other reports suggest that innate resistance may be a feature of ER
+
 tumours in which 
proliferation is regulated by an ER-independent signalling mechanism. Studies have 
shown that acquired resistance can occur in tumours with low levels of ER resulting 
from loss of expression or mutations in its encoding gene (ESR1), suggesting an ER-
independent driving mechanism for proliferation [161, 162]. However, loss of ER is 
only seen in approximately 15-20% of resistant breast cancers and the incidence of 




genotype [163-166]. Alternative mechanisms involve expression of truncated isoforms 
of ER such as ERα36 or other estrogen-related receptors such as estrogen-related 
receptor gamma (ERRγ), both of which have been associated with reduced response to 
tamoxifen. Tamoxifen works by inactivating E2 binding to wild-type ER, resistance in 
the case of ERα36 over-expression could be a feature of lower binding affinity to the 
truncated isoform of the molecule. Studies have shown that expression of ERα36 can be 
induced by bone morphogenetic protein 2 (BMP2), a member of the bone 
morphogenetic protein family of proteins which are recognised as having roles in 
regulation of cell fate and cancer development, suggesting a potential role for this 
molecule in endocrine therapy resistance [167]. Resistance related to ERRγ over-
expression might suggest an important role for this molecule in an alternative estrogen 
signalling pathway [168, 169]. Furthermore, it should be noted that estrogen receptor 
exists as two distinct isoforms: ER (ERα) and ERβ. The exact role of ERβ is not clear, 
however studies have shown that tamoxifen can bind ERβ and that tamoxifen-bound 
ERβ can activate Ap1 regulated genes, possibly by altering the balance of associated co-
activators and co-repressors at the promoter site [170, 171]. Indeed, increased ERβ 
expression has been reported in tamoxifen resistant breast cancers and data from recent 
study suggested that the ratio of ERα to ERβ may be important in predicting response to 
tamoxifen and anstrozole in the neoadjuvant setting [172, 173].  
1.2.3.5. ER Post-translational Modifications 
A number of post-translational modifications of ER have been reported, including 
phosphorylation, methylation and sumoylation which influence its interaction with other 
members of the ER-signalling pathway. It has been suggested that aberrations in the 
post-translational modification of ER could be linked to endocrine resistance [174, 175]. 
ER can be phosphorylated at a number of different sites including serine-118, serine-167 
and threonine-311 within the AF1 binding domain as well as in other domains. 
Phosphorylation and activation of ER at key positions can result from a number of 
pathways including: the MAPK/ERK pathway in response to growth factors such as 




growth factors and the p38-MAPK pathway in response to stress or various cytokines 
[176, 177]. As tamoxifen can still bind partially activated ER, over-expression and 
cross-talk between these pathways regulating ER activation might explain the partial 
agonist capabilities of the drug.  
1.2.3.6. Differential ER Binding 
A recent study looked at genome-wide ER binding events in primary breast tumours of 
patients sensitive and resistant to tamoxifen and revealed that in tamoxifen-resistant 
cancers ER is still recruited to the chromatin and binds regulatory regions in a pattern 
that is unique to resistant tumours [178]. The resistant phenotype may be due to 
selection and expansion of a resistant subpopulation of cells, or alternatively could 
involve the rapid reprogramming of ER binding by forkhead box protein A1 (FOXA1), 
which has a known role in ER-chromatin interactions in response to growth stimuli 
[178-181]. Forkhead motifs and EREs were found to be enriched within the DNA 
regions which showed increased ER binding in tamoxifen-resistant cell lines and in 
primary tumour specimens of patients with a poor clinical outcome, providing further 
evidence for the FOXA1-mediated reprogramming model of ER binding [178]. These 
findings suggest that ER may have an important role to play in tamoxifen resistance by 
binding to a distinct set of regulatory elements giving rise to a unique gene expression 
profile which drives tumour progression and confers resistance to therapy. 
1.2.3.7. Epidermal Growth Factor Receptors 
Resistance to endocrine therapy is common in ER
+
 breast cancers that over-express 
HER2 [182]. Many studies have reported cross-talk between ER and receptor tyrosine 
kinases (RTKs) such as epidermal growth factor receptor 1 (ERBB-1; EGFR/HER1) and 
HER2, which are receptors for epidermal growth factor (EGF) and insulin-like growth 
factor 1 (IGF-1, somatomedin 1) [183, 184]. Over-expression of these receptors suggests 
that tyrosine kinase signalling is driving proliferation and evasion of apoptosis in these 
cancers, representing either a primary mechanism in the case of innate-resistant tumours 




with acquired resistance [154, 185]. Studies have also shown that EGF-signalling can 
lead to an EGF-induced ER with regulatory control, dependent on AP1, over a set of 
genes commonly over-expressed in HER2
+
 breast cancer, which are distinct from those 
regulated by estrogen-induced ER [182]. These data indicate that proliferation may be 
driven by a distinct EGF-dependant mechanism which is independent of estrogen 
signalling. One group has suggested that EGF-induced ER might arise from EGF-
signalling in response to soluble stromal factors including fibronectin and matrix 
metalloproteases, secreted into the tumour microenvironment by fibroblasts, which 
associate with tumour cell membrane-bound β1 integrin thus activating the PI3K/AKT 
pathway and MAPK/ERK pathway leading to ER phosphorylation and activation [186]. 




 breast cancer could benefit 
from endocrine therapy combined with immune therapy targeted at EGF receptors. 
Indeed, this approach has been shown to work in cell line models [128], although studies 
in humans have been disappointing. This mechanism fits well with studies which have 
suggested that ligand bound-ER is associated with repression of ERBB-1 and HER2 
[187]. Depletion of estrogen by endocrine therapy could lead to expression of these 
molecules via loss of activated ER repression. Studies have shown that expression of a 
transcription factor known as paired box gene 2 (PAX2) is associated with reduced 
incidence of endocrine therapy resistance due to its role in ER-mediated repression of 
HER2 [188]. One study reported that the response of cells to tamoxifen is regulated by 
competition between the ER co-activator amplified in breast cancer 1 (AIB-1) and 
PAX2 binding to the cis-regulatory elements in intron 4 of HER2. Indeed, they showed 
that a decrease in expression of PAX2 in tamoxifen resistant cells correlated with an 
increase in HER2 expression. Furthermore immunohistochemical staining of tamoxifen 
treated ER
+
 breast cancer tumours showed that PAX2 expression in the absence of AIB-
1 correlated with recurrence free survival (RFS) and a low rate of HER2 expression. 
Conversely patients which expressed higher levels of PAX2 and AIB-1 had a higher rate 




It should also be noted that the mechanisms behind over-expression of HER2 are 
complex and have been shown to involve genetic and epigenetic modification, as well as 
alterations in upstream regulators such as under-expression of X-linked tumour 
suppressor forkhead box P3 (FOXP3) and transcription factor GATA4 [190, 191].  
1.2.3.8. Breast Cancer Stem Cells 
There is now a large body of evidence suggesting an important role for stem cells in the 
development of breast tissue and that there exist cancer stem cells (CSCs) in tumours 
[192]. In breast cancer these undifferentiated, clonogenic cells are associated with an 
increased invasive and metastatic phenotype, however, their frequency is dependent on 
tumour grade, disease stage and molecular subtype (discussed previously: section 1.1.3) 
[193-197]. Normal breast stem cells are thought to be basal-like and mainly ER
-
. 
Consequently, it is thought that CSC development is not influenced greatly by hormones 
such as estrogen and that these cells may be resistant to endocrine therapy as a result of 
low ER expression, with any partial response attributed to paracrine signalling from 
nearby differentiated ER
+
 tumour cells. Normal breast stem cells are regulated by EGF 
receptor and other growth factor receptor signalling. Some groups have suggested that 
the observed increase in EGF receptor expression in endocrine therapy resistant tumours 
may reflect a greater proportion of CSCs selected by endocrine therapy [192]. 
Furthermore, one study showed that letrozole treated tumours appeared to have an 
expression signature that was more like ‘claudin-low’ tumours and that post-treatment 
tumours were enriched for stem cells compared to pre-treatment samples [198].  
1.2.3.9. Cell Cycle 
Response to endocrine therapy essentially manifests at a molecular level as a G1/S phase 
arrest in cell cycle, a feature which is devoid in resistance cancer cells [112]. The 
resistant phenotype has been linked to amplification and/or over-expression of cyclin-D1 
and cyclin-E1 [199]. Increased expression of cyclin-D1 is associated with activation of 
Cdk4 and Cdk6 and progression to the S-phase of cell cycle. Indeed, studies have linked 




to letrozole resistance [200, 201]. Another study identified a link between over-
expression of cyclin-E2 and resistance to tamoxifen [202]. Studies have also reported 
modifications in other key players associated with the estrogen-dependent regulation of 
cell cycle (discussed previously: section 1.1.6) including C-MYC, RB1, p21 and 
P27KIP1, which have all been linked to endocrine therapy resistance [101, 203, 204]. A 
more recent study has identified that mutations in the gene encoding tumour protein 53 
(TP53) are also linked to resistance to aromatase inhibitors [205]. 
1.2.3.10. Cell Survival and Apoptosis 
Another important feature of endocrine therapy resistance is evasion of apoptosis. While 
the mechanisms remain poorly understood, studies have reported increased expression of 
anti-apoptotic proteins such as B-cell lymphoma 2 (BCL2) and decreased levels of pro-
apoptotic proteins such as BCL2 homologous antagonist killer (BAK), BCL2 interacting 
killer (BIK) and caspase 9 in tamoxifen resistant models [206, 207]. Conversely, some 
studies have shown that loss of BCL2 expression can occur in antiestrogen-resistant cell 
lines and this has been linked to increased sensitivity to chemotherapeutic agents 
including cisplatin [208]. In addition, the PI3K-AKT pathway which is associated with 
cell survival was found to be stimulated by upstream regulators in endocrine resistant 
models (see section 1.2.3.2) [206]. Additionally, NF-κB has been shown to have a role 
in blocking apoptosis through cross-talk with ER and regulation of the baculoviral IAP 
repeat-containing protein 3 (BIRC3) gene [209].  
1.2.3.11. NFκB Signalling and Inflammation 
NFκB plays an important role in processes such as cell survival and proliferation [210]. 
It can promote proliferation through regulation of key cell cycle genes including cyclins 
and CDKs and can mediate growth and survival signals via the PI3K-AKT pathway 
[211, 212]. NFκB has been reported as over-expressed in some endocrine therapy 
resistant breast tumours and many groups have alluded to its role in endocrine therapy 




Some studies have reported cross-talk between ER and NFκB signalling in which 
cooperative binding to transcriptional response elements can lead to specific gene 
expression [219]. Conversely, ER has also been shown to inhibit NFκB via a mechanism 
involving displacement of NFκB co-regulators such as CREB-binding protein (CBP) at 
the site of the NFκB response element [220]. One study suggested the involvement of 
‘tumour growth factor beta (TGFβ) activated kinase 1 / MAPK7-interacting protein 2’ 
(TAB2) in tamoxifen resistance in which a phosphorylated active form of TAB2 exports 
the co-repressor protein ‘nuclear receptor co-repressor 1’ (NCoR) from the nucleus, thus 
translocating it from EREs, resulting in loss of response to tamoxifen [221]. Tab2 has 
also been implicated in the activation of NFκB via the ‘IκB kinase’ (IKK) complex in 
response to ‘interleukin 1’ (IL1) stimulation [222].  
Alterations in the NFκB cascade have also been identified in endocrine therapy resistant 
cells. In tamoxifen resistant cells, expression of the NFκB subunit p50 was increased 
however remained unchanged in fulvestrant resistant cells compared with the sensitive 
cells. Conversely, expression of the p65 subunit was found to be increased in fulvestrant 
resistant cells but remained unchanged in tamoxifen resistant compared with sensitive 
cells. The most abundant form of NFκB is the p50-p65 heterodimer and these findings 
suggest that resistant cells may utilise different strategies for up-regulating the activity 
of this molecule [210]. Furthermore, the phosphorylation levels of p65 at its serine-536 
site were found to be increased in endocrine therapy resistant cells. Phosphorylation at 
this site is necessary for optimal activity of the molecule and was shown to enhance its 
transactivation potential [223].  
Some risk factors identified for breast cancer, including increased age and menopause, 
are associated with increases in indicators of systemic inflammation such as increased 
levels of circulating pro-inflammatory cytokines [224, 225]. Other risk factors such as 
pregnancy and obesity have been linked to the promotion and maintenance of a local 
inflammatory microenvironment in the breast [226]. Tumour associated macrophages 
(TAMs) have been found to comprise up to 50% of a breast tumour mass in some 




correlated with increased angiogenesis as well as reduced relapse-free and overall 
survival [227, 228]. One study in which TAMs were co-cultured with ER
+
 breast cancer 
cells revealed an increase in cancer cell invasiveness compared with cultures with no 
TAMs present. This was reported to involve a mechanism in which an inflammatory 
cytokine known as ‘tumour necrosis factors alpha’ (TNFα), produced by macrophages, 
led to activation of NFκB and ‘c-Jun N-terminal kinase’ (JNK) pathways [229]. Indeed, 
high expression of the macrophage marker ‘cluster of differentiation 68’ (CD68) in 
breast cancer is associated with poor prognosis and lack of response to endocrine 
therapy [230]. Furthermore, increased circulating levels of tumour necrosis factor alpha 
(TNFα) have been associated with advanced tumour stage, lymph node metastasis and 
local invasion [231, 232]. TNFα has been shown to stimulate proliferation in some ER
+
 
cell lines through increased expression of cyclin-D1 by a mechanism dependent on 
NFκB [233, 234].   
Upon TNFα stimulation the p65 NFκB subunit is phosphorylated at serine-536 via the 
IKK complex. Upon IL1 stimulation the PI3K-AKT pathway mediates phosphorylation 
of p65 at serine-536 via an unknown mechanism, although ‘TANK-binding kinase’ 
(TBK), IKK and p38 have all been implicated with IL1-induced p65 phosphorylation at 
serine-536 [235, 236]. TNFα-induced transcriptional activity of NFκB has been found to 
be significantly increased in endocrine therapy resistant cells compared to sensitive 
cells. This is thought to be due to the increased expression of NFκB subunits and 
increased levels of p65 phosphorylation. Interestingly, PR (discussed previously: section 
1.2.3.1), has a known anti-inflammatory role in breast cancer cells and the loss of its 
expression in a subset of endocrine therapy resistant ER
+
 cell lines which over-express 
NFκB has been reported [237, 238].      
1.2.3.12. Hyper-sensitivity to Residual Estrogen   
Hyper-sensitivity to estrogen has also been suggested as a potential mechanism of 
endocrine therapy resistance [55]. Aromatase inhibitors function to dramatically reduce 
estrogen biosynthesis however residual amounts of estrogen remain in tissues [239]. Cell 




hyper-sensitivity to residual estrogen. Reports have suggested that this phenomenon is 
associated with an increase in expression of HER2 and subsequent over-activity of the 
MAPK pathway resulting in changes in the phosphorylation of ER conferring its hyper-
sensitivity to residual estrogen [240, 241]. Other research has indicated that mutations in 
ESR1 may give rise to mutated ER which has increased interactions with the proto-
oncogene tyrosine-protein kinase (SRC) family of co-activators and changes in promoter 
binding dynamics linked to hypersensitivity to estrogen [242].   
1.2.3.13. Epithelial-Mesenchymal Transition 
Epithelial-mesenchymal transition (EMT) is a morphological change which has been 
shown to occur in some epithelial tumours [243, 244]. EMT is associated with a loss of 
differentiation and loss of intracellular adhesion, a feature of an invasive phenotype 
characterising advanced metastatic disease [245-247]. Intracellular adhesion is an 
important feature of tissue architecture maintenance and can limit cell movement and 
proliferation. It is primarily mediated through the adherens junction (AJ) which are 
complexes of calcium-dependent transmembrane cadherin receptors, the cytoplasmic 
domains of which link to the actin cytoskeleton via α-catenin and β-catenin [248]. One 
study reported that development of tamoxifen resistance in cell lines is associated with 
an enhanced motile and invasive phenotype characterised by loss of intracellular 
adhesion and partial EMT. This phenomenon is thought to be brought about by the EGF-
signalling mediated activation of β-catenin and the subsequent increase in expression of 
β-catenin regulated genes known to be involved with tumour progression. Inhibition of 
EGF-signalling in the same cells reduced β-catenin activity and promoted intracellular 
adhesion [249]. This suggests a possible role for EGF-signalling (involving β-catenin) in 
the manifestation of an aggressive phenotype of endocrine therapy resistant tumours. In 
another study, over-expression of the transcription factor zinc finger protein SNAI1 
(Snail) resulted in EMT. In this case ER expression was also lost as a result of Snail 
binding to the promoter region of ESR1 and causing deacetylation of histone H3K9 
[250]. This represents a potential EMT-associated mechanism by which endocrine 





Epigenetic mechanisms including DNA methylation have been shown to be responsible 
for determining and maintaining cell fate and for the stable differentiation of cells [251]. 
An increasing body of evidence is building to suggest an important role for DNA 
methylation in cancer including the silencing of tumour suppressing genes, activation of 
oncogenes and promotion of metastasis [252-254]. More recently, changes in DNA 
methylation have been linked to endocrine therapy resistance [255, 256]. Studies 
comparing endocrine therapy (tamoxifen or fulvestrant) resistant and sensitive cell lines 
have identified a pattern of methylation characterised by promoter hypomethylation in 
the resistant cell line compared with the sensitive [255]. This mechanism of 
hypomethylation was further implicated in a report showing the development of 
tamoxifen resistance in sensitive cell lines treated with a DNA methylation inhibitor (5-
azacytidine) [256]. One study also suggested the hypermethylation of the ERβ gene is 
associated with tamoxifen resistance [257]. In addition, it has been shown that ER itself 
participates in epigenetic control. When ER binds EREs within the genome it recruits 
cofactors involved with epigenetic control including: nuclear receptor corepressor 1 
(NCOR1), NCOR2, steroid receptor coactivator 1 (SRC1) and amplified in breast cancer 
1 (AIB-1) [258, 259]. Tamoxifen resistance has been linked with dysregulation of these 
co-factors suggesting a possible role for epigenetic mechanisms in endocrine resistance. 
Indeed, a recent study suggested a novel concept that prolonged tamoxifen exposure 
could induce epigenetic silencing of a set of estrogen responsive genes with functions 
associated with the negative control of proliferation [260]. 
1.2.3.15. Autophagocytosis 
Autophagocytosis is a cellular catabolic degradation process involving the lysosomal 
machinery whereby aggregated proteins, unfolded or misfolded proteins or damaged 
subcellular organelles are degraded in response to stress or nutrient deprivation in an 
attempt to restore metabolic homeostasis. While the role of autophagocytosis in 
endocrine therapy resistance remains poorly understood, the process is known to be both 




[261, 262]. Some studies have shown that inhibition of autophagocytosis can re-sensitise 
resistance cells to tamoxifen suggesting that it might have a role in resistance in some 
cancers [261]. One study identified a protein known as ‘heat shock protein B beta 8’ 
(HSBP8) as having a role in regulating autophagocytosis in endocrine therapy resistant 
cells [263]. 
1.2.3.16. Heterogeneity of Resistance 
A wide range of distinct mechanisms have been described that have been implicated 
with endocrine therapy resistance in breast cancer these include: lower levels and 
heterogeneity of ER expression; post-translational modifications of ER and differential 
binding of ER; ER-independent signalling including EGF-signalling and NFκB-
signalling; genetic aberrations affecting drug action and control of cellular processed 
such as cell cycle and apoptosis; phenomena such as stem cells, EMT, epigenetics, 
estrogen hyper-sensitivity and autophagocytosis. Together, these findings suggest that 
resistance to therapy is likely to be complex, heterogeneous and may differ between 
primary and acquired resistance and even between endocrine therapy types. Most studies 
have shown that a proportion of patients who become resistant to tamoxifen can respond 
when treatment is switched to an aromatase inhibitor and vice versa, albeit to a lesser 
extent [55]. Groups have highlighted the heterogeneity in gene expression between 
resistant tumours from series of patients all of whom were treated with letrozole 
indicating that even within cancers specifically resistant to certain drugs heterogeneity is 
evident [264].  
Much work remains to be done in order to understand fully and characterise the 
intricacies and interplay of the mechanisms which underlie endocrine resistance in breast 
cancer.  
1.2.4. Combating Resistance 
A number of treatment strategies have been used clinically and assessed in trials to 
counteract endocrine therapy resistance in breast cancer, including alternating or 




simultaneously does not appear of benefit, patients resistant to tamoxifen have been 
shown to respond when treatment was switched to an aromatase inhibitor [55].  
Another approach has involved augmenting standard endocrine therapy with agents 
designed to re-sensitise resistant tumours to endocrine therapy by targeting pathways 
and molecules recognised as drivers of resistance. One such approach has been the 
combination of endocrine therapies with HER2 targeted therapies such as trastuzumab 
and lapatinib, which have shown some promise in endocrine therapy resistant cancers 
which over-express HER2 [268, 269]. A number of studies have also shown that the use 
PI3K-AKT-mTOR pathway targeted therapies such as the mTOR inhibitor everolimus 
and EGFR inhibitor gefitinib can reverse the PI3K-AKT-mTOR mediated resistance to 
endocrine therapy (discussed previously: sections 1.2.3.1/2/5/6/9/10) when used in 
combination with endocrine therapy [268, 270-274]. Indeed, everolimus is now in wide 
use in combination with exemestane (a steroidal aromatase inhibitor) after being shown 
to improve progression-free survival (PFS) in second or third line treatment of patients 
with ER
+
 metastatic breast cancer [156, 275].  
Lab based studies have also yielded some promising results. One cell line study revealed 
that cells resistant to tamoxifen can be re-sensitised to its growth-inhibitory effects by 
targeting and blocking the action of the NFκB pathway [210]. Another group suggested 
that by inhibiting O-6-methylguanine-DNA methyltransferase (MGMT), a DNA repair 
protein they identified as being over-expressed in some tamoxifen resistant cell lines, 
sensitivity to tamoxifen could be restored [276]. Another reported that a CDK2 inhibitor 
could reverse endocrine therapy resistance in tumours over-expressing cyclins-E1 and 
E2 [202].  
A novel approach involved the withdrawal of endocrine therapy. Cell line studies have 
provided evidence for the growth inhibitory effects of withdrawal from endocrine 
therapy, however there is little clinical evidence to support this. One group reported a 
clinical trial which suggested that resistance to endocrine therapy could be minimised by 




A further treatment option was suggested in which low-dose estrogen is intercalated 
with aromatase inhibitors [278]. Indeed, before the development of drugs such as 
tamoxifen, high-dose estrogen represented a major therapy for the treatment of 
hormone-dependent breast cancer. It was thought to work by inducing apoptosis via 
extrinsic Fas/Fas ligand and intrinsic mitochondrial pathways [279]. Another study 
reported that the apoptosis inducing action of estrogen involves endoplasmic reticulum 
stress response and inflammatory response genes [280]. One group demonstrated in 
hormone-dependent xenograft models that loss of response to letrozole was 
accompanied by up-regulation of HER2 and MAPK pathways and down-regulation of 
ER and aromatase activity, which was reversed by replacing aromatase inhibitors with 
low dose estrogen treatment for a short period of time, thus re-sensitising the cells to 
estrogen and hence aromatase inhibition [278]. The major problem with these lab based 
cell line studies is that they take no account of the wide range of cancers seen in clinical 
practice. Their value at best is to provide leads for pathways or mechanisms of resistance 
that might be targeted. 
1.3. Studying Resistance and Predicting Response  
1.3.1. Challenges with Studying Endocrine Therapy Resistance 
Resistance to endocrine therapy has been investigated using a number of different 
approaches which extend from fundamental cell line studies in culture or as xenografts 
in immunosuppressed animals, to clinical adjuvant and neoadjuvant treatment studies 
[50].  
1.3.1.1. Cell Line Studies 
A number of cell line based studies, both as in vitro cultures or as in vivo xenografts 
have been used to investigate endocrine therapy resistance and have involved endocrine 
therapy treated breast cancer cells transfected with the aromatase gene (CYP19) [128, 
281, 282]. Such studies have elucidated some important findings and have advantages 
including the ability to assess dynamic changes with numerous time-points which is not 




including an inability to accurately model the heterogeneity known to be present 
between and within individual primary breast tumours due to their clonal nature. They 
are also unrepresentative of the local tumour microenvironment found in patients, in 
particular they lack stromal and immune components [50]. Cell line models do not 
represent a realistic model to evaluate endocrine resistance as seen in clinical practice, as 
many of the therapies such as aromatase inhibitors cannot be studied. Furthermore, 
many of the mechanisms identified in such cell lines have been found to have no or 
limited clinical utility.  
1.3.1.2. Adjuvant Setting 
Investigations involving adjuvant treatment are limited because the primary tumour has 
been surgically removed and is thus not available for on-treatment molecular analysis. 
Furthermore, measuring the response to treatment relies on monitoring survival and 
disease recurrence. These require long-term follow up with carefully documented study 
outcomes which are difficult to monitor successfully as recurrence may be a result of 
inherent cancer aggressiveness rather than acquired resistance to therapy. Additionally, 
for studies to produce meaningful results the patient sample size must be sufficiently 
large to be statistically valid and data collection on relevant outcomes takes some 
considerable time to acquire [50].  
1.3.1.3. Neoadjuvant Setting 
The neoadjuvant setting presents a number of advantages for investigating the 
characteristics of response and resistance. The primary tumour remains in place during 
treatment and clinical response can be determined by considering changes in tumour 
volume as determined by 3D ultrasound or mammographic measurements. In addition, 
tumours can be biopsied, often at multiple and sequential times, allowing for assessment 
of dynamic changes in gene expression or protein levels as treatment continues. These 
data can be related to clinical response allowing for a dynamic comparison of clinical 




1.3.2. Predicting Response 
There is a clinical need to identify early during treatment those patients who are unlikely 
to gain clinical benefit from endocrine therapy, thus sparing them several months of 
ineffective therapy and unnecessary side-effects. This is of particular relevance in the 
neoadjuvant setting, where the goal is to shrink tumour size such that a cancer becomes 
operable or less extensive surgery becomes possible.   
1.3.2.1. Pathological and Clinical Response 
Following 3 or 4 months of neoadjuvant endocrine therapy, 60-80% of tumours show 
signs of pathological response. This usually includes both a decrease in tumour volume 
and a decrease in cellularity with an increase in fibrosis or formation of fibrous 
connective tissue and in some cases a decrease in histological grade (discussed 
previously: section 1.1.2) [286, 287]. Complete pathological response (CPR) to 
endocrine therapy is rare, but the rate of CPR increases with the duration of treatment 
[288]. It should also be noted that quantitative measurements of partial pathological 
responses rely on subjective assessments without robust formal criteria, and concordance 
between pathologists has been reported to be only in the range of 50-86% [289, 290]. 
Indeed, while the clinical relevance of grade is well characterised, 40-50% of tumours 
are histologically classed as grade 2, and interobserver reproducibility of grade is 
suboptimal, although there has been great efforts to improve reproducibility [291]. A 
number of pathologically responding tumours decrease in size and this constitutes the 
clinically used definition ‘clinically responsive’ [50]. Indeed, clinical and pathological 
response is significantly associated in most tumours [288]. However, it is worth noting 
that around 20% of tumours are discordant in this respect, showing either a clinical 
response (decrease in volume) with no evidence of pathological response, or responding 
pathologically while not changing in size [290, 292].  
These clinical and pathological determinants of response require repeated measurements 
and histological assessments respectively and, while they offer an effective end-point for 




for predicting, early-on-treatment, which tumours are likely to respond or not to 
endocrine therapy [50].    
1.3.2.2. Proliferative Response 
Significant decreases in proliferation after 3 months are seen in approximately 80% of 
ER
+
 tumours in response to endocrine therapy and can be seen as early as 10-14 days 
into treatment. Levels of proliferation are routinely established by measuring expression 
changes of Ki67. Some tumours however display different patterns of Ki67 expression 
such as: an initial decrease followed by recovery to pre-treatment levels, a delayed 
change, and in some cases there is little change over the three months of treatment [292]. 
Ki67, discovered in 1991, is a nuclear non-histone protein which was reported to be 
absent from quiescent cells and universally expressed in proliferating tissues. Based on 
these characteristics, Ki67 became established as a marker of proliferation. However, 
work carried out since then showed that expression of Ki67 varies in intensity 
throughout cell cycle which could impact the identification of proliferating cells [293]. 
Indeed some studies have shown that the expression of Ki67 in the G1 phase of cell 
cycle can be minimal [294, 295]. That said, expression of Ki67 has been shown to 
correlate positively with other markers of proliferation such as proliferating nuclear 
antigen and minichromosome maintenance protein 2 (MCM2) [296, 297]. While the 
association between Ki67 and response to chemotherapy has been demonstrated [298, 
299], no significant association has been reported with neoadjuvant endocrine therapy 
[300-302]. Indeed, while an early proliferative response is positively and significantly 
correlated with both clinical and pathological response (sensitivity) to endocrine therapy, 
discordancy occurs in a number of cases rendering it a poor predictor of which patients 
(specificity) are likely to be resistant to endocrine therapy [292, 303].    
1.3.2.3. Molecular Response Markers 
The most commonly used predictive molecular marker for endocrine therapy is ER. It 
has a strong negative predictive value with ER
-
 tumours hardly ever responding to 
endocrine therapy and around 50-70% of ER
+




around 30-50% of ER
+
 patients will exhibit innate or acquired resistance to endocrine 
therapy (discussed previously: see section 1.2.2) [135]. Another molecular marker with 
predictive value is PR. This molecule is regarded as a classical marker of estrogenic 
activity and is reduced in 70-80% of cases treated with endocrine therapy [288, 292]. 
However, loss of PR expression can occur independently of clinical and pathological 
response [292, 304]. Indeed, studies have shown increased response rates in PR
+
 
tumours compared with PR
-
 tumours; however response to endocrine therapy can occur 
in both [304-306]. Similar results were found with other classical markers of estrogenic 
activity including pS2 [304]. Additionally, it has been shown that ER
+
 tumours over-
expressing HER2 are less likely to respond to endocrine therapy; however the number of 
such cases is small and they do not account for all resistant cases [307, 308].  
The use of single molecular markers to predict response is far from adequate given their 
poor correlation with clinical and pathological response [309, 310]. Even expression of 
ER, clinically the most widely used molecular marker, has only around 50-70% 
accuracy in endocrine therapy response prediction in ER
+
 cases. 
1.3.2.4. Multigene Signatures 
1.3.2.4.1. Gene Expression Profiling 
The advent of high-throughput gene expression profiling technologies, such as gene 
expression microarrays, applied to translational research has revolutionised the way 
breast cancer is perceived; highlighting the importance of heterogeneity and the fact that 
distinct subtypes of the disease exist which can affect the same anatomical site [311]. 
Indeed much work has focused on developing multigene signatures using high-
throughput gene expression microarray technology, which have primarily been used for 
molecular classification; thereby confirming the importance of key disease drivers such 
as ER and HER2 signalling (discussed previously: section 1.1.3), and for prognosis 
[311-313]. A number of prognostic studies in breast cancer to date have focused on 
identifying subsets of patients with such a good prognosis, where the absolute benefit is 




chemotherapy [314]. Two of the most advanced prognostic signatures designed for this 
purpose and available for clinical use are Mammaprint® and Oncotype DX®, both 
developed to estimate recurrence risk in node-negative early breast cancer [230, 315, 
316].  
1.3.2.4.2. Commercial Profiling: Prognostic Assays 
The 70-gene Mammaprint® test uses fresh tissue and microarray technology to evaluate 
expression of genes associated with proliferation, invasion, metastasis, tumour stroma 




 cancers [316]. The test was given Food and Drug 
Administration (FDA) approval in 2008 to be used as a prognostic test (indicating risk of 
relapse within 5 years) for breast cancer patients greater than 61 years of age with node 
negative stage 1 or 2 tumours greater than 5cm in size. Those patients with bad 
prognosis are recommended for chemotherapy and endocrine therapy combined adjuvant 
treatment, whereas those with good prognosis are recommended to receive only adjuvant 
endocrine therapy [311]. It should be noted that this test is of limited clinical use in ER
-
 
breast cancer with only 0-4% of such patients predicted to have a good prognosis [317-
321]. An independent validation of the Mammaprint® signature demonstrated that 
prognostic accuracy is highly time-dependent and may be more suitable as a predictor of 
early relapse [316, 320]. Furthermore, no clinical validation studies of the 
Mammaprint® signature have been performed in randomised trial populations [322-
324].    
The 21-gene Oncotype DX® test uses ‘formalin fixed paraffin embedded’ (FFPE) tissue 
with quantitative real-time PCR (qRT-PCR) to measure expression of 16 genes 
associated with proliferation, estrogen regulation, HER2 and invasion in hormone 
receptor positive cancers, as well as 5 reference genes [230, 315, 325]. The test outcome 
is presented as a Recurrence Score (RS) ranging from 0-100 to predict the risk of 10 
year distant recurrence. In clinical use the RS is subdivided into three groups: low (<18), 
intermediate (18-31) and high (>31), and several publications have shown that ER
+
 
breast cancer patients with low RS have a low risk of recurrence and derive little benefit 




According to the National Comprehensive Cancer Network (NCCN) guidelines for 
breast cancer treatment, patients with low RS score should be treated with endocrine 
therapy alone, while patients with high RS score should receive a combination of 
endocrine therapy and chemotherapy. However, one issue with the Oncotype DX® test 
is that the optimum clinical management strategy for patients with intermediate RS 
scores remains at present unclear [311].     
More recently, a molecular diagnostic test known as MapQuant DX
TM 
was launched to 
accurately measure tumour grade, risk of metastasis, predict response to chemotherapy 
and indicate proliferation. This test utilises microarray technology and measures 
expression of the ‘Genomic Grade Index’ (GGI), a published 97 gene signature [330-
333]. When applied to an independent validation cohort the GGI had strong association 
with histological grade, although 9% of grade 1 tumours were classified as having high 
GGI and 14% of grade 3 tumours were classified as having low GGI. However, GGI 
was found to be more strongly associated with relapse free survival than histological 
assessment of grade. Furthermore, GGI was able to stratify histological grade 2 cancers 
into prognostically significant high or low grade groups. In independent validation 
studies GGI has also shown to be independently prognostic of outcome (risk of 
recurrence) in tamoxifen treated patients. Tumours with high GGI profiles were also 
reported to respond well to neoadjuvant chemotherapy despite having a significantly 
worse outcome compared with low GGI tumours [330]. The MapQuant DX
TM
 test was 
recently converted to an 8 gene assay (PCR-GGI) based on quantitative real-time PCR 
(qRT-PCR) measurements [334]. While the evidence for genomic grading is compelling, 
independent validation of the MapQuant DX
TM
 and PCR-GGI systems has not yet been 
documented. Furthermore, their ability to discriminate between high and low grade in 
ER
-
 tumours is limited [335, 336].   
Theros® is a qRT-PCR based assay designed for lymph node negative ER
+
 breast cancer 
treated with surgery alone reported to assess risk of recurrence and benefit from 
endocrine therapy. The test measures the ratio of expression of homeobox gene Hox-






 tamoxifen treated patients with a high risk of recurrence and predict 
outcome in ER
+
 patients, either adjuvant systemic therapy naïve or tamoxifen treated. 
However, its ability to predict benefit from neoadjuvant hormone therapy or from 
chemotherapy remains to be seen [337, 338]. Furthermore, the test has been shown to 
have limited power in lymph node positive disease [339]. It should also be noted that 
neither the MapQuant DX
TM
/PCR-GGI nor Theros® tests have been included in the 
NCCN guidelines for breast cancer treatment [311]. 
1.3.2.4.3. Prognostic Signature Research 
Several other gene signatures, not yet adopted as commercially available tests, have also 
been reported in an attempt to refine tumour classification and improve prognostication.  
The ‘invasiveness gene signature’ (IGS) is based on the hypothesis that tumours are 
arranged in cellular hierarchy, initiated and maintained by a small population of cancer 
stem cells with self-renewing potential which express antigen CD44 and are low or 
negative for signal transducer CD24 [340, 341]. The signature consists of 186 genes 
associated with heightened risk of death and metastasis in different types of cancers; 
however, in breast cancer it was only significant for ER
+
 grade 2 disease [342]. It is also 
noteworthy that the study was underpowered, with the signature being derived from only 
5 metastatic pleural effusions. Furthermore, it is questionable whether the gene 
expression profile of a rare subgroup of cancer stem cells (accounting for only 0.6-5% of 
tumour breast cells) can be detected in samples which are largely tumour bulk 
(composed mostly of non-tumorigenic cells) [311, 340].  
One group compared the expression profiles of stroma from the tumour bed (connective 
framework of tissue surrounding tumorigenic cells) of 53 breast cancers and stroma 
from normal tissue, identifying a list of 200 most variable genes between the two 
groups. They derived a 26 gene ‘stroma-derived prognostic predictor,’ which was found 
to be independently predictive of outcome, highlighting the importance of the stromal 




of the ‘stroma-derived prognostic predictor’ in the clinical setting are yet to be validated 
[311, 343]. 
The ‘sensitivity to endocrine therapy’ (SET) index comprised a signature of 165 genes 
which were co-expressed with ESR1 in 437 patients (unrelated to treatment or outcome). 
The association of the signature with distant relapse risk was evaluated in 5 independent 
validation cohorts: 2 cohorts (n=225 and 298) of patients who received adjuvant 
endocrine therapy, a cohort who received adjuvant chemotherapy followed by endocrine 
therapy (n=122) and two cohorts who received no adjuvant systemic therapy (n=208 and 
133). The SET index was found to be significantly associated with distant relapse and 
death risk in endocrine therapy and chemotherapy plus endocrine therapy treated 
cohorts, but not in systemic therapy naïve cohorts. While this signature has been 
extensively validated in independent cohorts and been shown to predict survival benefit, 
there is as yet no evidence suggesting accurate prediction of response to therapy or 
inherent prognosis [344]. 
A recent test known as EndoPredict (EP), based on gene expression has been validated 




 breast cancer 
treated with adjuvant endocrine therapy. The test uses RNA levels of a panel of 8 genes 
(plus 3 reference genes), as determined from RT-PCR of FFPE tissue, which are used to 
calculate an EP score. EP score and nodal status together with HER2 status are 
combined to give a comprehensive risk score: EPclin. Using the EPclin score, 58%-68% 
of women from two large phase III trials classified as having high/intermediate risk of 
recurrence (according to clinical guidelines) were predicted to be low risk. The rate of 
occurrence of distant metastases in this group was found to be only 5%. Further 
validation work has shown reproducible performance of the assay and negligible inter-
laboratory variation. The authors suggest that use of the EPclin score may reduce the 
indications for chemotherapy in ER
+
 post-menopausal women with a limited number of 
clinical risk factors [345-348]. While this test show promises in identifying subgroups of 




perform current clinical guidelines, there is once again no evidence, as yet, to suggest 
that the test can predict response to therapy or inherent prognosis. 
1.3.2.4.4. Lessons from Prognostic Signature Research 
Numerous prognostic signatures have been proposed beyond those already discussed 
including signatures assessing: amplification of cyclin-D1, inactivation of p53, 
activation of PI3K pathway, MAPK cascade and prediction of invasion [342, 349-353]. 
Most prognostic signatures have significant agreement in their prediction of outcome 
and identification of similar groups of patients despite the fact that the overlap of 
individual gene lists is negligible [335, 336, 354-360]. Meta-analysis of different 
prognostic signatures, looking at genes, pathways and networks revealed that 
classification of patients into good or bad prognosis groups relies heavily on expression 
of proliferation genes. Indeed some signatures were found to perform better when only 
proliferation associated genes were used to predict prognosis [336]. Furthermore, this 
analysis confirmed that the prognostic power of most signatures, particularly the four 
commercially available assays (Mammaprint®, Oncotype DX®, MapQuant DX
TM
 and 




 subgroup of breast cancers, providing more 
evidence for proliferation as the key determinant of prognosis in this subgroup [335, 
336]. The study and use of prognostic signatures has revealed important characteristics 
of breast cancer including the fact that ER
+
 disease comprises a spectrum of cancers 
which range from low proliferation with good outcome to highly proliferative cancers 
with poor outcome. Whereas ER
-
 tumours largely comprise distinct entities, driven by 
distinct molecular aberrations, whose prognosis may not be determinable using 
proliferation gene based signatures [328, 361, 362]. Indeed, recent studies have 
suggested the importance of immune response genes in the prediction of outcome in ER
-
 
breast cancer [36, 363, 364]. 
1.3.2.4.5. Predicting Response to Endocrine Therapy 
Unlike prognostic signatures which relate gene expression to outcome (risk of relapse), 




particular therapy [311]. Such research is aimed at determining the optimal systemic 
therapeutic regimen and the magnitude of benefit associated with it for individual 
patients, in a move towards individualised therapy [311, 354].   
A number of predictive multigene signatures have been reported which directly relate 
gene expression to the clinical and pathological response to endocrine therapy in ER
+
 
patients. The majority of which have not yet been validated for clinical use. One of the 
first developed for endocrine therapy was a study to predict clinical response to 
tamoxifen in patients with recurrent disease (local/regional relapse or distant metastasis). 
Gene expression profiles of primary tumour samples from 112 patients who later 
recurred and received tamoxifen were derived. Of the 112 patients, 52 responded with an 
objective decrease in size of recurrent mass and 60 had progressive disease. A 44-gene 
signature was derived, which included genes associated with estrogenic regulation, 
apoptosis, extracellular matrix remodelling and immune response. The signature was 
reported to predict endocrine therapy outcome and time to progression in ER
+
 patients 
with recurrent disease. In independent validation the gene signature was shown to 
predict response to tamoxifen in 77% of patients, outperforming the commonly used ER 
marker which predicts response in 50-60% of metastatic patients [365]. However, it 
should be noted that this signature has not yet been shown to be of significant predictive 
value in patients with early stage disease.  
One of the first gene expression studies focused on response to aromatase inhibitors was 
published in 2007 by Mackay et al [366] and reported response to letrozole and 
anastrozole during short pre-operative (14 days) treatment using sequential biopsies 
from 34 patients. The study revealed that short term estrogen deprivation by aromatase 
inhibitors led to profound changes in transcriptomic profile, including genes associated 
with proliferation and estrogen signalling. While many of the changed genes reported 
had been previously identified in cell line studies, many additional estrogen responsive 
genes were identified in this study. Importantly the study revealed complex changes in 
matrix remodelling and stromal interactions which cannot be easily studied in cell lines. 




on estrogen (GIDE), a measure of the number of genes with at least a 2-fold change on 
treatment. The GIDE was found to be significantly associated with on-treatment changes 
in Ki67 and to pre-treatment levels of HER2 [366]. While time-course studies in cell 
lines have revealed much about the response to estrogen deprivation, cell lines are not 
representative of the tumour microenvironment and may not be an optimal model for 
investigating endocrine therapy resistance (discussed previously: section 1.3.1.1). This 
pilot study was one of the first to use multiple biopsies from the same patient, allowing 
for an assessment of changes in gene expression rather than static expression levels at a 
given time point. By comparing on-treatment with pre-treatment in the same patient, this 
valuable approach has allowed for identification of key genes which are consistently 
changed over a number of patients as a direct result of a given therapy. While the design 
of this study is novel and may have potential for determining key predictive genes 
associated with sensitivity or resistance to endocrine therapy, several limitations are 
apparent. Firstly, the study is underpowered with only 34 patients, and no independent 
validation was performed to confirm the findings. Furthermore, given that the study was 
based on only 14 days of treatment prior to surgery, clinical response could not be 
directly evaluated, as changes in tumour size take longer than 14 days to manifest 
(discussed previously: section 1.3.2.1). Instead, changes in immunohistochemical Ki67 
were used as a surrogate for clinical response, which despite correlation with both 
clinical and pathological response, has been shown to be a suboptimal predictor of 
response due to discordancy in some patients (discussed previously: section 1.3.2.2). As 
a result, there is currently no conclusive evidence demonstrating the predictive capacity 
of this signature.  
In 2007, Miller et al [284] published a similar study designed to investigate changes in 
gene expression associated with short-term neoadjuvant letrozole therapy also using pre-
treatment and on-treatment (14 days) biopsies from the same patient. From gene 
expression profiling of 58 patients, 143 genes were identified which were consistently 
changed between pre-treatment and 14 days biopsies. Using the most significantly and 




hierarchical clustering, reinforcing the concept of heterogeneity of response [284]. 
However, the clinical significance of the molecular subgroups remains to be seen. The 
molecular changes observed in both Mackay et al [366] and Miller et al [284] studies 
were largely consistent, with aromatase inhibitor treatment leading to supressed 
expression of genes associated with proliferation and estrogenic signalling, and 
increased expression of genes involved with stromal remodelling, cell adhesion and 
immune response [50]. Importantly, these changes were identifiable within two weeks of 
treatment; long before clinical changes and pathological changes in morphology could 
be seen (discussed previously: section 1.3.2.1), raising the potential for determining 
early-on-treatment which patients are likely to respond and adapting therapeutic 
protocols in resistant patients. 
In 2008, Harvell et al [367, 368] published one of the first gene expression signatures 
reported to discriminate between tumours clinically responsive and non-responsive to 
endocrine therapy which used clinical response after extended therapy (4 months) as the 
end-point criteria. They published a 50 gene signature which was later refined to a 25 
gene signature based on pre-treatment gene expression levels. However, the signature 
was based on expression profiles from only 6 patients: 3 responsive and 3 non-
responsive rendering the study significantly underpowered. In addition, no independent 
validation of their findings was carried out.  
In 2009, Miller et al [124] published the largest study of its type at the time of 
publication in which they presented a gene expression signature reported to discriminate 
between tumours clinically responsive and non-responsive to aromatase inhibitors. 
Findings were based on the same microarray gene expression dataset used in their 2007 
publication [284]. Neoadjuvant clinical response to letrozole in the 58 patients was 
evaluated by changes in 3D ultrasound measurements taken over a 3 month treatment 
period (immediately prior to surgery), giving rise to 37 responding tumours and 15 
showing lack of response. Gene expression analysis revealed 205 co-variables 
consistently differentially expressed between clinically responding and resistant 




were differentially expressed in pre-treatment samples, 45 were differentially expressed 
in 14-days samples and 91 were significantly different when considering expression 
changes between pre-treatment and 14-day samples. Hierarchical clustering based on the 
205 genes separated clinically responding and resistant tumours into two distinct groups. 
The most predictive genes were found to be associated with protein biosynthesis, in 
particular of ribosomal proteins. Interestingly, changes in proliferation associated genes 
and estrogenic signalling genes were found to occur in both clinically responding and 
non-responding cases [124]. The major limitation of this study is the lack of validation 
of predictive capacity in an independent cohort of patients which as yet has not been 
reported. In addition, the assessment of clinical response (at least 50% reduction in 
tumour volume by 3 months) was an arbitrary threshold and does not allow for a 
satisfactory and clear differentiation between clinically responsive and resistant tumours, 
e.g. a tumour with a reduction of 51% would be classed as clinically responding whereas 
a tumour with a 50% reduction would be resistant.    
1.3.3. Considerations when Developing Predictive Gene Signatures 
1.3.3.1. Sample Size and Patient Heterogeneity 
A number of multigene signatures have been reported to predict subgroups of ER
+
 
patients unlikely to respond to endocrine therapy. However, many of these studies are 
underpowered, with findings based on relatively small numbers of patients in the 
training set and as a result may not be representative of the population [369]. When 
considering gene signatures derived from a single time point, such as before treatment, 
this problem may be confounded by patient heterogeneity (variables such as age, BMI, 
tumour size, tumour grade, tumour histological subtype, lymph node involvement, 
metastasis, additional medical conditions or drug regimens and inherent genetic 
differences). By considering consistent changes in gene expression between sequential 
biopsies (before and after/during treatment) from the same patient in a pairwise fashion, 
the issues of patient heterogeneity can be somewhat minimised and significantly 




for statistical validity it is desirable to recruit the largest number and most representative 
patients as possible.  
1.3.3.2. Microarray Bias 
The predictive capacity of many reported signatures is often not reproducible in external 
datasets [313]. This can be in part be due to the small unrepresentative sample size in the 
original training set; however, it can also be related to issues of microarray bias. Several 
studies have alluded to microarray bias as a major contributory factor affecting the 
reproducibility of microarray data derived results [313, 369, 370]. Bias can occur at all 
stages of microarray experiments from patient selection and sample processing to choice 
of microarray platform. Bias of this nature can lead to results becoming dataset-specific. 
Some studies have reported methods which can lead to a reduction in microarray bias 
which have been shown to significantly improve reproducibility [369, 370].  
1.3.3.3. Independent Validation 
A major limitation of published predictive gene signatures is a lack of independent 
validation, proving that findings are real, that they are strongly associated with clinical 
outcome and out-perform or improve upon current clinically used predictors of response. 
Successful validation is an essential first step if any new predictive signatures are to be 
endorsed in the clinic to improve patient care [312]. Furthermore, most predictive 
signatures are derived from microarray data, which should be considered a surrogate for 
gene expression, implying a further need for validation of results in external independent 
datasets and by alternative methods for measuring gene expression such as qRT-PCR. 
Independent validation is often carried out using publically available external datasets 
which may or may not be similar in design to the pilot study. Important factors for 
consideration when selecting an appropriate validation study for endocrine therapy 
response might include: the patient cohort (age range, BMI range, menopausal status), 
disease features of the cohort (tumour size, spread to nodes, metastasis, ER/PR/HER2 
status), treatment (drug, length of treatment window) and assessment criteria used for 




such as gene expression profiling of multiple biopsies taken from the same patients over 
a period of treatment, are promising and may yield important information, a lack of 
similar external experimental datasets with which to validate findings is likely.  
1.3.3.4. Response Criteria 
Predictive multigene signatures for neoadjuvant response to therapy are designed by 
comparing differences in gene expression, or differences in changed gene expression, 
between tumours defined as responsive or non-responsive. The predictive capacity of 
such signatures is highly dependent on the criteria used for response assessment. Such 
criteria include clinical, pathological and molecular assessment of response (discussed 
previously: sections 1.3.2.1 to 1.3.2.3) and, while these show reasonable concordance, 
they do not agree for every case. Therefore, if the aim of a neoadjuvant predictive 
signature is based primarily on the clinical need to reduce tumour size sufficiently to 
allow surgery if the cancer was inoperable or breast conservation if operable only by 
mastectomy then it would seem logical to use clinical response assessment (as 
determined by changes in periodic 3D ultrasound over the treatment period) as the 
primary end point [50]. However, pathological and proliferative responses do represent 
useful secondary end points. Although it should be noted that using proliferation as an 
end point might lead only to identification of proliferation associated genes, which have 
been indicated as being poor predictors of clinical response to aromatase inhibitors 
[124]. If clinical response (changes in tumour size or volume) is to be used as the main 
end point then attention must be given to the cut-offs applied for each response group. 
Rather than applying a single arbitrary cut-off where all tumours above a certain value 
are classed as resistant and all below this value are responsive, it may be beneficial to 
design a predictive signature based on 2 well characterised groups of tumours that 
respond well or not at all. For example, tumours which reduce by a least 70% by 3 
months would be classed as responsive, while tumours which increase or decrease by no 
more than 50% by 3 months would be classed as non-responsive, all tumours in-between 
(intermediate clinical response) could be excluded from the development of a predictive 




that has greater power to differentiate between responsive and non-responsive tumours. 
It may also be able to stratify subsequently the intermediate clinical response group into 
clinically relevant responsive or non-responsive subgroups, ultimately identifying which 
individual patients are likely to benefit from alternative or combination therapy.  
1.3.3.5. Heterogeneity in the Resistant Patients 
Previous studies have alluded to heterogeneity within the clinically resistant group 
despite a similar clinical response to treatment [264]. However, predictive multi-gene 
signatures for endocrine therapy in ER
+
 patients to-date have failed to take this 
heterogeneity into account, instead considering all clinically resistant cases as belonging 
to the same molecular group. For this reason, predictive capability is likely to be dataset-
specific, with reproducibility highly dependent on the frequency and distribution of 
distinct molecular subtypes within validation datasets compared with the training set. 
The exploration and characterisation of distinct molecular subgroups within the 
clinically resistant patients may be an important consideration in the development of 
signatures with greater predictive accuracy and reproducibility. Indeed, it should be 
noted that the accurate elucidation of distinct molecular subtypes will doubtless require a 
large sample number; once again reinforcing the importance of this factor in the 
experimental design. 
1.3.3.6. Clinical Application of a Predictive Signature 
The application of gene expression technology in the field of breast cancer research has 
yielded much important information and has vastly improved understanding of the 
disease at a molecular level [313]. However, there are a number of important 
considerations to address before it can be readily applied in a clinical setting to aid 
diagnostic and treatment decisions [312]. Foremost, a predictive signature must 
demonstrate clear clinical benefit for patients. Furthermore, it must be shown, ideally 
with prospective independent validation, to out-perform or improve upon currently used 
parameters for guiding clinical decisions. In addition, thought must be given to the 




from expensive high-throughput commercial or custom microarray platforms to low cost 
lower-throughput qRT-PCR assays. While most predictive signature are developed from 
microarray data, there may be potential to convert resultant signatures to lower cost 
technologies such as qRT-PCR as was the case with Oncotype DX® and MapQuant 
DX
TM 
[230, 315, 325, 328]. Another benefit of qRT-PCR is that the assay can be 
effectively performed on formalin-fixed paraffin embedded (FFPE) tissue with greater 
ease than with microarray technology. Importantly, FFPE tissue is far easier to collect, 
store and work with than fresh frozen tissue. A number of factors can affect the choice 
of technology. Firstly, costs can be prohibitive and studies must be conducted to assess 
the cost-to-benefit ratio [312]. Secondly, the number of genes included in the assay is a 
point for consideration, as large numbers of genes may preclude the application of 
lower-throughput technologies such as qRT-PCR. There is also a known issue with 
reproducibility; microarray bias (discussed previously: section 1.3.3.2) can significantly 
impact the reproducibility of results and can manifest from differing technical variables 
(platforms, RNA extraction, processing and hybridisation techniques) used across 
different sites [369]. It may be possible to minimise bias by instigating a strict common 
protocol for implementation of a predictive assay at different sites; however, commercial 
enterprises including Oncotype DX® and Mammaprint® address the issue by only 
offering their assay at one controlled site using the same validated technology and 
delivered by the same technicians. 
1.4. Aims and Approaches 
There is a clinical need to identify, before or early-on-treatment, subgroups of patients 
who are or will acquire resistance to endocrine therapy, avoiding months of ineffective 
therapy or disease progression and ultimately improve patient care. The primary aim of 
this study is to identify novel predictive biomarkers of clinical response to endocrine 
therapy in ER rich primary breast tumours, improving upon currently used clinical and 
pathological determinants of response and out-performing previously reported predictive 




exist within the clinically non-responsive population in order to improve predictive 
power and reproducibility [264].  
This study will involve the generation of a new whole genome expression microarray 
dataset, representing the largest of its type, profiling multiple tumour biopsies taken 
from each of 35 patients before, after 14 days and again after 3 months (before surgery) 
of continuous neoadjuvant letrozole therapy. The primary end point of the experiment 
will be clinical response as defined by dynamic changes in 3D ultrasound volume 
measurements taken from each patient periodically over the 3 months of therapy. 
Pathological response will also be assessed for each patient. 
For the purpose of predictive marker investigation, cut-offs for tumour volume 
reduction/increase (clinical response) will be assigned so as to create two clearly 
separated groups of consistently responsive and non-responsive tumours, excluding 
those tumours with intermediate and transient response profiles. It is hypothesised that 
the resultant signature of predictive biomarkers, based on the well characterised 
response groups, may have heightened predictive power and reproducibility.  
While selecting strict cut-offs for clinical response seems a logical step to improve 
discovery of robustly predictive markers, it will inevitably limit the sample size of the 
dataset lowering statistical significance, especially in the number of non-responsive 
cases which are usually less frequent than clinically responsive cases [138]. Indeed, this 
is confounded by the fact that the availability of matched pre- and on-treatment samples 
from patients with complete clinical follow-up is limited. To address this issue by 
increasing sample size, this study will also involve the development and validation of 
novel raw intensity full genome microarray data integration approaches, which have 
value out-with this project as a useful bioinformatic tool. However specific to this study, 
it will allow for the successful integration of the new microarray dataset (this study) with 
a previously published dataset with the same design [124], thereby generating the largest 
dataset of its type. This part of the study will involve an investigation into the nature of 




between different microarray experiments and which will need to be sufficiently 
minimised for successful integration of the data [369, 370]. In this case, the issue of 
microarray bias is confounded by the fact that both datasets were derived from different 
microarray technologies/platforms, which has previously been described as an 
insurmountable problem [371]. If successful, a pipeline for the integration of microarray 
data from different platforms will be developed and validated then applied to investigate 
endocrine therapy resistance in ER
+
 breast cancer.  
There is a clinical need to predict response as early as possible. If a predictive signature 
is to out-perform current clinical or pathological determinants of response, it must 
accurately predict response before the clinical or pathological changes manifest or 
become evaluable. For that reason, the developed signature of predictive biomarkers, 
derived from the integrated data, will be based on: pre-treatment, 14 days on-treatment 
and changes between these two time-points only. Investigations will be carried out to 
determine which time-point or combination of time-points will give rise to the signature 
with the greatest predictive power. Previous studies have alluded to ‘change by 14 days’ 
as being most predictive, however, this has never been conclusively confirmed and if 
found to be the case may inform the clinical need for a 14-day biopsy [50]. 
The developed signature of predictive markers will be validated in an independent 
external microarray dataset, profiling multiple tumour biopsies taken from each of 44 
patients before and after 14 days of continuous neoadjuvant anastrozole. Clinical 
response in this dataset was assessed from repeated tumour measurements taken 







2. Direct Integration of Intensity-level Data from 
Affymetrix and Illumina Microarrays improves 
Statistical Power for Robust Reanalysis 
2.1. Acknowledgements and Contributions 
I would like to acknowledge the contribution made to this chapter by Robert Kitchen 
PhD, who carried out the nested analysis of variance described in the materials and 
methods (section 2.3.3), the results of which are displayed in figure 11 (section 2.4.1), 
which he produced for this study. 
2.2. Introduction 
2.2.1. Combining Datasets for Meta- or Re-analysis 
In the clinical sciences, systematic review of multiple attempts to answer a specific 
research question is a valuable tool to synthesise high-quality empirical evidence in 
order to determine a consensus view. Such reviews or meta-analysis have greater 
statistical power to identify true effects from insignificant artefacts and, as such, are 
capable of identifying subtle effects that might be missed or deemed insignificant in 
smaller datasets. In the context of gene-expression analyses, meta-analysis of results 
from microarray studies has great potential, but also presents significant challenges due 
to differences in the platforms and analysis approaches employed in each study [369, 
370, 374-376]. Direct integration of probe-level expression data from multiple studies is 
potentially even more powerful, but is further complicated due to differences in the 
conditions under which each dataset was generated, such as the amplification or 
labelling method, the scanner used or even just the date on which the samples were 
processed. A recent comprehensive review found that the aims of different microarray 
meta-analysis studies were quite distinct, with the majority combining p-values, effect 
size or ranked analysis, with only 27% (51 studies) seeking to directly merge the data 
[374]. Previous work has demonstrated that non-trivial systematic bias or ‘batch effects’ 




arising from variation at multiple stages in the experimental workflow; from patient 
selection and sample acquisition to laboratory processing and subsequent analysis of 
derived data (figure 6). However, such systematic bias can largely be removed from 
each with appropriate batch correction methods [370, 376, 377].  
 
Figure 6. Overview of a microarray experiment workflow. Biological and technical 
variation can occur at several stages, contributing to systematic bias. QC: quality control. 
Adapted from Sims et al (2009)[313].  
2.2.2. Dataset Size and Statistic Power 
Gene expression profiling has been applied to many areas of translational cancer 
research, including identification of new drug-targets, monitoring response to treatment, 
revealing mechanisms of resistance, and predicting prognosis [313]. Although the 
majority of microarray datasets are now made publicly available, many studies are 
limited in size and therefore cannot accurately reflect the general population, as they 
lack statistical power [164, 378]. Collection of clinical material often remains the rate-
limiting step, particularly with ‘window-of-opportunity’ studies that utilise matched 
before- and after-intervention samples from the same patient [54, 124, 377, 379, 380] 
(see section 1.3.3.1). Due to the reduced patient-patient variation, these studies can be 
highly effective for identifying consistent gene-expression changes, such as the effects 




The extensive patient- and tissue-diversity inherent in molecular studies of cancer, 
which often contribute to underpowered studies [378] and confounding [381], mean that 
it is currently not necessarily critical (or appropriate) to measure gene-expression at the 
greatest resolution or specificity now offered by exon-arrays and RNA-sequencing.  
Rather, it may be of greater utility to maximise the number of existing biologically 
independent observations by combining the growing numbers of datasets in the public 
repositories, than simply generating another small independent dataset with limited 
statistical power [313]. 
2.2.3. Directly Integrating Affymetrix and Illumina Data 
Previous comparisons of expression measurements derived from Affymetrix and 
Illumina platforms have reported, ‘generally consistent’ [382], ‘very high agreement’ 
[383] or ‘correspondence across platforms was high’ [384]. However, these studies are 
often based on titrated or technical replicates rather than clinical samples and have not 
sought to integrate the data directly. Cross-platform analysis of microarray data has 
previously been shown to be possible and worthwhile, although this has normally been 
performed using transformed relative values [385], rather than by the direct integration 
of intensity-level data. Comparisons of relative values from two-colour microarray data 
has been shown to lead to fold change compression [384]. 
The Affymetrix and Illumina microarray platforms differ fundamentally in their design. 
Of particular note are the major differences in probe selection, design and physical 
attachment to the array or chip [383]. Affymetrix GeneChips are fabricated by in situ 
synthesis of 25-mer oligonucleotide probes, several of which span the entire length of a 
single gene and together make up a ‘probeset’ each of which provides an intensity 
reading for the gene (figure 7). Along with each probe, the Affymetrix GeneChip also 
includes one-base mismatch probes designed to act as controls for non-specific 
hybridisation [383, 386]. Illumina Beadarrays comprise single longer 50-mer 
oligonucleotide probes which are attached to micro-beads and spotted onto glass-slide 
arrays using a random self-assembly mechanism. Unlike the Affymetrix GeneChip, the 




however, in contrast to the latter, each oligonucleotide is represented in the order of 30 
times on each array, providing an internal technical replication, not found on Affymetrix 
GeneChips [383, 387]. Furthermore Affymetrix GeneChips exist as single microarrays 
on one chip (for a single sample) which are processed independently, whereas Illumina 
Beadarrays comprise several (6, 8 or 12) microarrays on one glass-slide and thus 
hybridisation and scanning can be performed simultaneously [383]. Considering these 
fundamental differences in the design, it is not clear whether data derived from 
Affymetrix and Illumina microarrays can or should be compared directly.  
 
Figure 7. Schematic representation of the differences in probe design between 
Affymetrix GeneChips and Illumina Beadarrays. A: Affymetrix GeneChips are comprised 
of multiple 25-mer probes which span the coding regions of each gene. B: Illumina 
Beadarrays utilise 50-mer probes and the majority of genes are represented by a single 
probe.  
The findings reported in this study demonstrate that it is possible to directly combine 
appropriate datasets at the intensity level to improve statistical power. Inter-platform 
bias can be sufficiently reduced to expose previously obscured biological variation and 
furthermore, data correction does not amplify meaningless noise in the results. Despite 
intrinsic differences between these technologies, suitably similar studies can be directly 
integrated for robust and meaningful meta-analysis, and to that end a validated workflow 





Figure 8. Workflow for direct integration of Illumina and Affymetrix intensity level 
gene expression data. The same/similar processing steps were used wherever possible. 
Green: Affymetrix data processing and blue:  Illumina data processing. The number of 
probes/genes remaining after each pre-processing step are shown in rounded rectangles.  
2.3. Materials and Methods 
2.3.1. Data Generation 
2.3.1.1. Affymetrix Dataset 
Affymetrix gene expression data was generated from primary breast tumour core 
biopsies before, 10-14 days after and approximately 3 months following neoadjuvant 
Letrozole treatment as part of a previously described clinical study [124, 284]. The 
research was carried out in compliance with the Helsinki Declaration, with all patients 
giving informed consent to be included in the study which had been approved by the 
local ethics committee (LREC; 2001/8/80 and 2001/8/81 and 06/S1103/65 – see 




described [284], before hybridisation to HGU-133A GeneChips (Affymetrix) according 
to the standard protocol.  
2.3.1.2. Illumina Dataset (Affymetrix Subset) 
RNA from a subset of 18 samples (pre-treatment, 10-14 days and 3 month samples from 
6 patients defined as clinical responders to treatment) used in the aforementioned study 
[124, 284] was then amplified using the WT-Ovation FFPE System Version 2 (NuGEN), 
purified using the Qiaquick PCR Purification Kit (Qiagen), biotinylated using the IL 
Encore Biotin Module (NuGEN), purified using minElute Reaction Cleanup Kit 
(Qiagen) and quantified using a Bioanalyser 2100 with RNA 6000 Nano Kit (Agilent). 
cRNA was then hybridised to Human HT-12v3 expression Beadarrays (Illumina, 
Cambridge, United Kingdom) according to the standard protocol for NuGEN amplified 
samples.  
2.3.1.3. New Illumina Dataset 
A new Illumina gene expression dataset was also generated from primary breast tumour 
core biopsies before, 10-14 days after and approximately 3 months following 
neoadjuvant Letrozole treatment. RNA was extracted using the miRNeasy Mini Kit with 
RNAse Free DNAse treatment (Qiagen). RNA was then amplified, labelled, purified, 
quantified and hybridised as described above for the Illumina (Affymetrix Subset). 
2.3.2. Published MAQC and Breast Cancer Datasets 
Methods for the MAQC Illumina Human-6 Expression BeadChip (v1) and Affymetrix 
U133 Plus 2.0 array hybridisations are provided in the original study [384]. The data 
was retrieved from NCBI GEO accession GSE5350. Publicly available primary breast 
cancer datasets [388, 389] were downloaded datasets from NCBI GEO and 
ArrayExpress. Breast cancer subtypes were assigned using three signatures from Sørlie 




2.3.3. Data Processing and Analysis 
All data were processed using the R/Bioconductor software and packages [392]. A 
custom Chip Definition File (CDF) file [393] was used to map the Affymetrix data to 
Ensembl gene annotations and RMA implemented by the affy package used for 
normalisation. Illumina probe profiles were quantile normalised using the lumi package 
and mapped to Ensembl gene sequences using a composite list comprising mappings 
from reMOAT [394], Ensembl BioMart [395] and a custom BLAST sequence search of 
the online Ensembl gene database where there was agreement between at least two of 
the resources (details of resources used are provided in figure 8). Where multiple 
Illumina probes represented an Ensembl gene the mean expression level was calculated. 
Prior to reannotation the data were filtered using Illumina or Affymetrix probe detection 
P-values, removing probes that were undetected (p>0.05 in the total minus 3 samples). 
The number of probes/genes remaining after each pre-processing step are shown in 
figure 8. R-scripts for data pre-processing are given in supplementary section 6.1)  
A number of batch-correction and cross-platform normalisation methods were evaluated, 
including mean-centering [369], ComBat [396], Distance Weighted Discrimination 
[397] and Cross-platform Normalisation (XPN) [398] (XPN and other batch correction 
methods can be implemented through ArrayMining Online [399] or via the 
inSilicoMerging R package) in order to determine the most effective method for 
reducing the bias imposed by the different platforms. Principal component analysis and 
hierarchical clustering analysis was performed using Cluster [400]. Significance analysis 
of Microarrays (SAM) [401] pairwise differential gene expression analysis was 
performed using the siggenes package (R/Bioconductor). 
A linear additive model was applied to log-scale expression data to estimate the 
variances in the MAQC dataset. The variation introduced at a given level propagates 
additively throughout subsequent levels, allowing these variance contributions to be 
modelled. The total variance for a given gene was assumed to be the aggregate of 
individual contributions from the inter-sample, -platform, -laboratory, and -replicate 




from log-normal distributions and, as all factors meet in unique combinations, a nested 
variance model is individually applied to each gene such that the model of the measured 
expression, Xijkl, of each probe is defined as Xijkl = μ + Ai + Bij + Cijk + Dijkl + ϵijkl. (i=1,… 
,s; j=1,…,t; k=1,…,u; l=1,…,v) where μ is the geometric-mean expression of the gene 
from the given sample-type, Ai is the effect attributed to the ith sample, Bij is the random 
effect of the jth platform, Cijk is the random effect of the kth lab, Dijkl is the random 
effect of the lth replicate hybridisation, and ϵij is the residual measurement error. Finally, 
s is the total number of samples, t is the number of platforms on which the samples were 
assessed, u is the number of labs processing the arrays, and v is the number of replicate 
samples in the corresponding platform processed in each lab. The variance of any given 










; these components represent the inter-











 is performed independently for each gene as stated 
in Snedecor and Cochran (1989) [402]. Models of this kind are formally defined in 
Neter, Wasserman and Kutner (1985) [403] and Oberg and Mahoney (2007) [404] and 
have previously been used to optimise gene-expression experimental design [405, 406]. 
All variance estimates were performed using a REML procedure implemented in the 
nlme package in R [407, 408]. 
2.4. Results 
2.4.1. Direct Cross-platform Integration of MAQC Data 
The Microarray Quality Control (MAQC) consortium [384] investigated the 
reproducibility of microarray-derived gene expression measurements by assessing 
performance across platforms, chips, and processing sites using a titration of Universal 
Human Reference RNA (UHRR) and Human Brain Reference RNA (UBRR). The  
complete MAQC Affymetrix and Illumina datasets were combined by re-annotating 
probes on each platform in terms of their Ensembl gene targets (discussed previously: 
see section 2.2.3 and figure 8). As expected, sample A (100% UHRR) replicates from 




25% HBRR) replicates than the other samples. This was also the case for sample B 
(100% HBRR) and D (25% UHRR, 75% HBRR) replicates, reflecting their relative 
biological similarity (figure 9). Without adjustment, correlations between the same 
samples (A, B, C, or D) processed on different platforms were much lower (R=0.70-
0.77) than the same samples processed only on the Illumina Beadarrays (R=0.98-1.00) 
or Affymetrix GeneChips (R=0.99-1.00) (figures 9 and 10).  
 
Figure 9. Boxplots showing the Pearson correlation coefficients within and between 
labs before and after correction by three different methods. X-axis: comparison of 
samples: A = 100% UHRR, B = 100% HBRR, C = 75% UHRR + 25% HBRR, D = 25% 
UHRR + 75% HBRR. Y-axis: UC = uncorrected, MC = mean-centering, DWD = Distance 







Figure 10. Affymetrix and Illumina data from the MAQC project can be directly 
integrated. Pairwise Pearson correlation heatmaps demonstrate cross platform bias and the 
effects of three correction methods: mean-centering, Distance Weighted Discrimination 
(DWD) and an Empirical Bayes method (ComBat). R values range from low correlation (red) 
to high correlation (white) through shades of orange and yellow reflecting the overall 
similarity of expression profiles based on biological and platform-specific variation. The 
shades of purple to pink indicate the samples (A = 100% UHRR, B = 100% HBRR, C = 75% 
UHRR + 25% HBRR, D = 25% UHRR + 75% HBRR). Samples are ordered by replicate and 






Adjusting for the platform differences using the mean-centring method [369] provided 
only a marginal improvement compared to uncorrected data, whilst the Distance 
Weighted Discrimination (DWD) method [397] suppressed not only the platform-
specific bias, but also legitimate biological variability between samples (figures 9 and 
10). The greatest improvement was observed following correction by ComBat, a method 
that exploits variance moderation during data adjustment [396]. Similar correlations 
were found both across and within platforms, suggesting that whilst removing the 
platform bias, the ComBat method retains legitimate biological variation between the 
biologically distinct samples (figures 9 and 10). Another promising method, Cross-
platform Normalisation (XPN) [398], could not be evaluated with these data due to the 
small number of independent biological replicates.   
In addition to correlating expression values, variance estimates for each of the 15,781 
Ensembl genes probed by the two platforms at the inter-sample, inter-platform, inter-
laboratory, and inter-chip levels were calculated using a nested analysis of variance 
described in section 2.3.3 (figure 11). As expected, and in agreement with the correlation 
analysis, the difference between the platforms was responsible for the majority of the 
overall variance in uncorrected (58%), quantile-normalised (47%), and mean-centered 
(44%) expression data. Inter-platform variance was significantly reduced by both DWD 
and ComBat, to 15% and 7% of the total, respectively. Consistent with the correlation 
analysis, the DWD method also substantially reduced inter-sample variance, which is 
likely to obscure genuine biological differences between the samples (figure 11). 
Conversely, the ComBat method slightly increased inter-sample variance, potentially 





Figure 11. Cross-platform correction minimises technical variation whilst maintaining 
biological variation and differential expression. UC = uncorrected, MC = mean-
centering, DWD = Distance Weighted Discrimination, CB = Empirical Bayes method 
(ComBat). This figure was produced by Robert Kitchen PhD. 
To examine the effects of cross-platform integration on the identification of genes 
differentially expressed between UHRR and HBRR, Affymetrix and Illumina data were 
both analysed separately and as a combined dataset. Differential expression was 
assessed using the Significance Analysis of Microarrays (SAM) method [401]. Analysis 
of the 60 combined Affymetrix plus Illumina HBRR and UHRR samples together, 
resulted in lower false discovery rates and a greater number of statistically significant 




and 15 ‘B’) samples were analysed separately. There were also many more overlapping 
genes in the combined analysis and either of the platforms following cross-platform 
correction, when identifying the top 1000 differentially expressed genes (as described 
previously [369]), again with ComBat performing best (figure 13). The overlap of 
differentially expressed genes identified by samples processed on either of the two 
platforms independently (15 ‘A’ and 15 ‘B’ samples) was also much more consistent 
following ComBat, than DWD or mean-centering correction (figure 14). Taken together, 
these results indicate that combining data across the two platforms increases specificity 
and reduces the number of predicted false positives, suggesting improved statistical 
power. 
 
Figure 12. Plot showing the relationship between the false discovery rate and the 
number of genes identified. Comparing UHRR (A) with HBRR (B) using either 15 
Affymetrix or 15 Illumina replicates or both together. MC = mean-centering, DWD = Distance 






Figure 13. Venn diagrams demonstrate the overlap between the 1000 most 
differentially expressed genes between the MAQC UHRR and HBRR (A and B 
samples).  The SAM method was used to identify the most differentially expressed genes 
with either Affymetrix (green) or Illumina (blue) alone, or Affymetrix and Illumina together 
(purple).   
 
Figure 14. Venn diagrams showing the overlaps between the 1000 most significant 
differentially expressed genes. The SAM method was used to identify the most 
differentially expressed genes (each comparison is 15 ‘A’ samples versus 15 ‘B’ samples). 
Green = Affymetrix comparisons, blue = Illumina comparisons, teal = Affymetrix versus 





2.4.2. Increasing Statistical Power through Integration of Clinical 
Datasets  
2.4.2.1. Matched Clinical Samples Common to both Platforms 
In order to evaluate the feasibility of directly comparing intensity level gene expression 
of clinical samples processed separately on the two platforms, a new dataset of Illumina 
Beadarray data was generated from RNA derived from breast tumour samples that were 
assessed as part of a larger published study using Affymetrix GeneChips [124, 284, 409] 
(figure 15). These samples comprised matched pre-treatment, 10-14 day, and 3 month 
primary breast tumours from 6 patients with a clinical response to neoadjuvant 
Letrozole.  
 
Figure 15. Matched clinical samples processed on Affymetrix and Illumina platforms. 
Core biopsies of primary breast cancer tumours were taken at pre-treatment, 10-14 days on 
treatment and again after 3 months from each of 6 patients (18 samples) undergoing 
neoadjuvant letrozole treatment. All samples were processed and hybridised to both 
Affymetrix GeneChips and Illumina Beadarrays for comparison.  
As with the MAQC data, pairwise Pearson correlations of samples processed on the two 
platforms were significantly increased following correction with the ComBat method, 




biologically independent samples (figures 16 & 17). A fourth method, cross platform 
normalisation (XPN) [398] generated similar results to ComBat, although Pearson 
correlations for the majority of matched samples across both platforms were marginally 
higher (figures 17 and 18). In addition, a greater number of pairs of Affymetrix and 













Figure 16. Affymetrix and Illumina data from clinical datasets can be directly 
integrated. Pairwise Pearson correlation heatmaps from 18 matched clinical breast cancer 
samples from 6 patients demonstrate cross platform bias and the effects of four correction 
methods: mean-centering, Distance Weighted Discrimination (DWD), an Empirical Bayes 
method (ComBat) and cross platform normalisation (XPN). R values range from low 
correlation (red) to high correlation (white) through shades of orange and yellow reflecting 
the overall similarity of expression profiles based upon biological and platform-specific 
variation. The inner diamond represents the matched samples from the two platforms. Each 
patient is numbered with an ID (48, 69, 87, 119, 120 and 133) and each sample is also 
numbered pre-treatment (-1), 10-14 days (-2) and 3 months (-3) post treatment. Uncorrected 
data is NOT shown (to show it on the same colour scale as the other plots would not clearly 






Figure 17. Comparison of Pearson correlation coefficients across different correction 
methods. A: Boxplots showing the range of Pearson correlation coefficients between 18 
matched samples (including pre-treatment, 10-14 days and 3 months from 6 patients) for 
different correction methods. B: Affymetrix dataset and C: Illumina dataset boxplots showing 
the range of Pearson correlation coefficients between all possible sample combinations for 
different correction methods. MC = mean-centering, DWD = Distance Weighted 







Figure 18. Hierarchical clustering of samples based on Pearson correlation after 
either ComBat or XPN correction. Colour denotes samples from the same patient, the 
suffixes on patient ID’s (48, 69, 87, 119, 120 and 133) denote as follows: ‘.1’ = pre-
treatment, ‘.2’ = 10-14-days, ‘.3’ = 3 months, ‘.Illum’ = Illumina Beadarray data, ‘.Affy’ = 
Affymetrix GeneChip data. 
2.4.2.2. Integrating Independent Clinical Datasets 
The cross-platform dataset was expanded with 48 new Illumina pre-treatment and 
matched 3 month samples from 24 independent patients to give a total of 60 Illumina 
samples to compare with 60 pre-treatment and 3 months Affymetrix samples from the 
original dataset. All patients and tumours had similar characteristics and were shown to 
clinically respond to 3 months of neoadjuvant Letrozole treatment, with tumour 
ultrasound measurements showing a stable volume reduction of 70% over the 3 month 
period. The twelve pre-treatment and 3 month samples common to both microarrays 





Figure 19. Integration of partially overlapping Affymetrix and Illumina datasets. The 
Affymetrix dataset (original study) was generated in two separate batches, the first in 2003 
and the second in 2004. The 2010 Illumina dataset comprises 12 (discounting 10-14 day 
samples) of the 18 matched samples (patient IDs: 48, 69, 87, 119, 120 and 133) common to 
both datasets (discussed previously: see section 2.3.2.1). The new Illumina dataset 
comprises an additional 48 samples from 24 independent patients and 4 replicates from the 
overlapping 12 matched samples (pre-treatment and 3 months from patients 69 and 133) 
common to both platforms (discussed previously: see section 2.3.2.1).   
Independent assessment of the Affymetrix and Illumina datasets in this study identified 
the need to correct for batch effects within the platforms (prior to integration) due to 
variation in date of sample processing, consistent with previous studies [369, 370, 376]. 
Before correction samples (based on expression of all genes after filtering) were found 
to cluster together by date of processing rather than by biological similarity and 
differences (based on expression of all genes after filtering). Batch correction was 
performed on each dataset independently using ComBat as described previously [369, 
370, 376, 377, 396]. Following correction samples clustered more heterogeneously with 
no identifiable batch effects in multi-dimensional scaling (MDS) analysis. In addition 
the Illumina datasets included replicate matched samples, common to both datasets 
(2010 and 2011). Before correction identical samples from different processing batches 
had no identifiable association with each other, the result of masking by the batch effect. 
After correction, matched samples were found to cluster strongly with each other 
indicating that the batch effect bias had been reduced while maintaining true biological 





Figure 20. Multidimensional scaling to identify batch effects within datasets. A: 
Affymetrix and B: Illumina 3D multi-dimensional scaling (MDS) plots of all samples based on 
all genes (after filtering; discussed previously: see section 2.2.3) before (left) and after (right) 
ComBat batch correction. All plots are scaled on 3 dimensions, plots after correction are 
tilted to better display the association of paired samples. Before correction samples on both 
platforms separate into clusters based on the date they were processed. Following 
correction artificial bias has been reduced and the clustering of samples is more 
heterogeneous. After correction of the Illumina datasets, pairs of matched replicate samples 
common to both datasets cluster with each other. Affymetrix (A): blue circles = 2003 
samples, orange circles = 2004 samples. Illumina (B):  blue circles = 2010 samples, orange 
circles = 2011 samples. Red/black/purple/green circles = represent pairs of identical 
matched samples common to both 2010 and 2011 Illumina datasets.  
Following intra-platform batch correction, Affymetrix and Illumina datasets were 
integrated, retaining only Ensembl gene ID’s present in both datasets (discussed 




changes between pre-treatment and 3 month samples across the two platforms results in 
reasonable concordance (R=0.68). However, following XPN correction there is a 
dramatic improvement in the correlation of fold changes (R=0.99) demonstrating that 
XPN has greatly reduced the variation between both platforms while maintaining a 
sufficient range of highly-concordant fold changes to account for biological variability. 
Importantly, the analysis of fold changes showed that XPN correction did not affect the 
magnitude of fold changes (figure 21).  
 
Figure 21. Comparison of Affymetrix and Illumina fold changes between pre-
treatment and 3 month samples before and after XPN correction. Scatterplot 
demonstrating the pre-treatment to 3 month fold changes between the Affymetrix and 
Illumina datasets before (light colours) and after XPN correction (dark colours). Light colours 
were applied to data points reflecting their position within the quadrants of the plot (Q1-Q4). 
Dark colours were applied to XPN corrected data points based on the same data points 
original quadrant location prior to correction: ie after correction (dark purple) the data points 
in quadrant 3 (Q3) were located in the same quadrant as before correction (light purple). 
Multidimensional scaling (MDS) demonstrated that the samples common to the 
Affymetrix and Illumina datasets cluster together and that intra- and inter-platform batch 
effects have been minimised (figure 22). Prior to XPN correction, samples from the 




pre-treatment samples from the same patient cluster closely together as do the 3 month 
samples from the same patient. XPN correction significantly reduces the bias between 
samples from different platforms, but the pre-treatment and 3 month samples from the 
same patients still cluster independently, indicating that the true biological differences 
(due to treatment) are maintained.  
 
Figure 22. Comparison of cross-platform matched samples by multidimensional 
scaling before and after XPN correction. Multidimensional scaling (MDS) plots before 
(uncorrected) and after XPN correction demonstrating the relationship between overlapping 
samples. Circles = pre-treatment, squares = 3 months post treatment with Letrozole, open 
symbols = Affymetrix, filled symbols = Illumina, triangles = matched Illumina replicate 
samples, different colours represent different patients. 
The standard deviation across genes for all pre-treatment or 3 month samples was higher 
in Affymetrix than Illumina, but was dramatically increased after combining the data. 
Correction with either ComBat or XPN reduced variation to a level similar to that seen 
in either dataset independently; further suggesting that gene-wise cross-platform bias is 
reduced, while true biological variation is maintained (figure 23). When all samples of 
the combined XPN-corrected dataset were clustered by a published list of genes 
identified as most changed in response to neoadjuvant endocrine therapy [124, 409] the 





Figure 23. Analysis of inter- and intra-platform variance before and after ComBat and 
XPN correction. Boxplots of standard deviation for each gene across all samples from the 
same subgroup (pre-treatment and 3 months) for Affymetrix and Illumina datasets 










Figure 24. Hierarchical clustering and heatmap based on published list of genes 
identified as most changed between pre-treatment and 3 month samples in patients 
treated with neoadjuvant Letrozole. Colour bar indicates the platform the sample was 
processed on with Affymetrix in green and Illumina in blue. 
Increasing sample number by integration of the Affymetrix and Illumina datasets 
resulted in the identification of a greater number of significantly differentially expressed 
genes using pairwise SAM (i.e. the consistency of pre-treatment and 3 month samples 





Figure 25. Effect of cross-platform integration and correction on differential gene 
expression analysis. Plot shows the relationship between the estimated false discovery 
rate relative to the number of significant differentially expressed genes identified using SAM 
analysis of Affymetrix and Illumina datasets independently and when combined both before 
and after XPN correction.  
Interestingly, correction of the combined data by XPN showed only minor improvement 
compared with uncorrected data in a pairwise SAM analysis with a 93.8% overlap of 
genes (figure 26A). However, when a non-pairwise SAM method was used (i.e. two 
unmatched groups: (i) all pre-treatment samples and (ii) all 3 month samples), XPN 
correction of the integrated data was essential (figures 26B and C). There was an 
impressive 90% overlap of common differentially expressed genes following XPN 
correction when comparing the pre-treatment samples from one platform with the 3 
month samples from the other. By contrast, the overlap between pre-treatment and 3 
month groups in each dataset (Affymetrix or Illumina) independently was only 42.4% 




versus Illumina 3 month samples (and vice versa) with the XPN-corrected equivalent 
resulted in a very poor overlap (12.1%), indicating the importance of XPN correction for 
robust differential gene expression of cross-platform integrated datasets. 
 
Figure 26. Venn diagrams showing the overlaps between the 1000 most significant 
differentially expressed genes. A: pairwise SAM analysis and B&C: non–pairwise SAM 
analysis with Affymetrix (green), Illumina (blue) and combined (teal). 
2.4.3. Published Affymetrix and Illumina Datasets can be Successfully 
Integrated 
Two publicly available non-subtype specific primary breast cancer datasets of 
comparable size and composition (Naderi et al. [389]  n=153 on Illumina HumanWG6 
v1 and Desmedt et al. [388] n=198 on Affymetrix HGU133A) were assigned to 
molecular subtypes using centroids from the intrinsic gene signatures of Sørlie et al. 
(2003) [25], Parker et al. [27], and Hu et al. [390]. This was performed on each dataset 
independently and then both datasets were combined, both before and after XPN 
correction. Clustering the integrated data before correction resulted in two distinct 




(figure 27). Following XPN correction the integrated data clustered based on true 
biological differences, with two clear clusters representing the basal/ERBB2 intrinsic 
subtype and the luminal subtype for each of the intrinsic centroids (figure 27). 
Assignment of molecular subtype was highly consistent (Sørlie: 96.6%, Hu: 94.9% and 
Parker: 96.6%) between uncorrected and XPN-corrected datasets, further suggesting that 










Figure 27. Comparison of primary breast tumour gene expression profiles generated 
on Affymetrix and Illumina platforms. The Naderi et al. [389] study used Illumina WG6v1 
BeadChips, whilst the Desmedt et al. dataset [388] was generated with Affymetrix HG-
U133A arrays. A: Before cross-platform correction. B: After XPN correction. Hierarchical 
clustering of tumours is based upon the 500 most variable genes (thumbnails show all 
genes).  i) Subtypes were assigned by three methods Sorlie et al. (2003) [25], Parker et al. 
[27] and Hu et al. [390]. Red = basal, purple = ERBB2, blue = luminal A, light blue = luminal 
B, green = normal-like. Clusters of genes associated with the subtypes are highlighted as 





Once again, increasing sample number through integrating datasets results in a greater 
number of significantly differentially expressed genes, between the Sørlie et al. basal 
and luminal A or the more subtle comparison of luminal A and luminal B subtype 
samples, at a given FDR (figure 28). Uncorrected integrated data performs poorly in 
comparison to the integrated data after XPN correction or indeed to either dataset 
independently.   
 
Figure 28. Plots showing the relationship between false discovery rate against the 
number of significant differentially expressed genes identified across a range values 
of delta using SAM analysis. Analysis was carried out in Affymetrix (Desmedt) and Illumina 
(Naderi) datasets independently and when combined both before and after XPN correction 
to identify genes differentially expressed between the basal and luminal A (A) or luminal A 
and luminal B subtypes (B). 
2.5. Discussion 
The biggest obstacles to the direct comparison of data obtained from different 
microarray platforms are differences in the sequence and the number of probes that 
target each transcript. Many studies simply use the most highly or variably expressed 
probe to represent a gene, despite evidence that some probes hybridise to multiple genes 
and others have out-dated or incorrect annotation [393, 410-413]. Limiting integration of 




measurements simply based upon the official gene symbol would severely restrict our 
ability to evaluate whether data from different platforms can be directly integrated. For 
this reason, probes were re-annotated in this study using alternative CDFs [393] for 
Affymetrix and a validated composite look-up list for Illumina [394] (discussed 
previously:  section 2.2.3). 
The microarray quality control (MAQC) project declared that expression values 
generated on different platforms cannot be directly compared because unique labelling 
methods and probe sequences will result in variable signals for probes that hybridize to 
the same target [384]. However, in the interests of making the best use of published data 
on valuable clinical material, this study was designed to assess whether it would be 
reasonable to integrate Affymetrix and Illumina data in the interests of improving 
statistical power and unearthing true biological findings. It has previously been shown 
that robust classifiers developed using data generated from one platform can accurately 
predict the phenotype of samples assessed on a different platform [414]. This study 
demonstrates that it is possible to combine Affymetrix and Illumina gene expression 
data for meaningful integrative reanalysis. Previous work has shown that for either 
platform alone (intra-platform), integration of microarray data should only be performed 
with appropriately similar datasets [369, 370, 376], although exactly where the similarity 
threshold lies is an important consideration that is still to be determined. 
This study revealed that the Distance Weighted Discrimination (DWD) method [397], 
(which has been used for cross-platform normalisation and cited by more than 50 
published studies), may be unreliable in terms of its ability to remove technical noise 
and preserve biological variability. Perhaps this method is best suited to transformed 
data such as that generated by two-colour cDNA studies. Relatively strict filter-
thresholds were used in the current analyses, including conservative detection p-values 
to limit the analysis to clearly expressed genes as a previous meta-analysis approach 
found low or intermediate expressing genes to have poorer inter-platform reproducibility 
than highly expressed genes [381]. Another recently published comparison of cross-




concordance [415]. Like this study, this focused on direct adjustment approaches, where 
the major batch effect (platform used) is clearly identifiable rather than surrogate 
variable analysis (SVA) approaches [416, 417], which look at latent or unknown 
variables, such as when samples are processed on different days, in different groups or 
by different people. Direct integration approaches are only appropriate for small 
numbers of highly similar datasets specifically selected to answer clearly defined 
questions, as opposed to recent global survey-based approaches used to identify 
common tissues or expression profiles across all available datasets [418-420]. Whilst 
integrating data across platforms increases the number of samples, it also has an impact 
on the number of genes represented. Genes may be ‘lost’ at the reannotation stage if not 
present on both arrays. Therefore integration is a trade-off between increased sample 
numbers and decreased gene number. Sample numbers are perhaps the biggest factor in 
the reliability of microarray studies. Ein-Dor et al. suggested that thousands of samples 
are needed to generate a robust gene list for predicting outcome in cancer [378]. The 
overlap of differentially expressed genes between single and integrated Affymetrix and 
Illumina datasets was found to be high, although it should be remembered that it has 
previously been demonstrated that greater biological reliability is seen between studies 
at the pathway, rather than individual gene level  [313].  
2.6. Conclusion 
This study sought to evaluate whether it is reasonable to combine appropriate 
Affymetrix and Illumina datasets for reanalysis. Despite fundamental differences in the 
technology, data from these platforms can legitimately be combined at the normalised 
and corrected intensity, rather than the fold change level for robust reanalysis, with 
improved statistical power than the original datasets alone. A validated workflow for 
integration of Affymetrix and Illumina gene expression data has been presented and 
cross-platform normalisation (XPN) has been evaluated as the most appropriate 
correction method to date for the purpose of reducing inter-platform bias allowing for 




3. Understanding and Predicting Response to 
Endocrine Therapy Early in Breast Cancer 
Treatment 
3.1. Acknowledgments and Contributions 
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performed all 3D ultrasound sonography. I would like to acknowledge the contribution 
made by Anita Dunbier PhD, who carried out the independent validation analysis 
(section 3.5.4.6). 
3.2. Introduction 
Third-generation aromatase inhibitors such as letrozole and anastrozole have an 
established role in the treatment of estrogen receptor alpha positive (ER
+
) 
postmenopausal breast cancer [118, 121-123, 421]. The endocrine effect of these drugs 
involves specific inhibition of the aromatase enzyme thereby reducing endogenously 
synthesised estrogen [55, 126, 422, 423]. In hormone sensitive breast cancers estrogen 
deprivation can lead to cell death, reduced proliferation and reduced tumour progression 
[424]. However, not all patients respond, with response rates only 50-70% in the 
neoadjuvant setting and lower in advanced disease [124, 304, 425]. Therefore, there is a 
clinical need to identify early-on-treatment biomarkers which predict for response/non-
response to endocrine therapy and which outperforming currently used parameters for 
response assessment, in a move towards improved and stratified treatments and 
ultimately better patient care. 
This study involved the generation of a new whole genome gene expression microarray 
dataset profiling 34 patients with primary breast cancer treated neoadjuvantly with 
letrozole. Tumour specimens were collected at pre-treatment, 14 days and again at 3 




existing published dataset [124] of similar design in order to increase sample numbers 
and improve statistical power (see section 2) and resulted in generating the largest 
microarray study of its type comprising a unique series of 89 ER
+
 letrozole treated breast 
cancer patients with dynamic gene expression profiles. Clinical response was determined 
for each patient using repeated 3D ultrasound measurements taken throughout the 
treatment window (figure 29). 
This work has led to the development of a classifier of response to endocrine therapy in 
the neoadjuvant setting. The optimal model was based on the expression of 4 genes 
which could classify response in the letrozole dataset with 96% accuracy. The model 
was validated in the anastrozole-only arm of an independent clinical trial and found to 
predict response with 91% accuracy, outperforming previously reported predictive 










Figure 29. Experimental design. Post-menopausal women with ER
+
 primary breast 
tumours treated with continuous neoadjuvant letrozole over approximately 3 months were 
recruited to the study. Tissue biopsies were taken from the primary tumour at pre-treatment, 
14 days and again at approximately 3 months (usually a surgical specimen). RNA was 
extracted from tissue specimens and used for gene expression microarray analysis. 
Dynamic clinical response was determined by 3D ultrasound sonography performed by a 
single operator (JMD) periodically throughout the treatment window.   
3.3. Materials and Methods 
3.3.1. Patients 
The study population comprised postmenopausal women presenting to the Edinburgh 
Breast Unit (Western General Hospital) with large primary histologically confirmed 
invasive breast cancer, immunohistochemically determined to be ER
+
. A consecutive 
series of 235 patients were recruited between 2004 and 2011 as part of an on-going 




the tumour was multifocal or of a certain histological type (mucinous, tubular or 
lobular), (ii) if the pathologist determined low tumour cellularity or less than 40% 
malignancy in the pre-treatment biopsy, (iii) if extraction failed to yield sufficient RNA 
to be suitable for further study, (iv) if follow-up records for clinical assessment of 
response were unavailable or incomplete, or (iv) if the drug was changed from letrozole 
to another agent during the treatment window due to an adverse drug reaction. Of the 70 
patients who met these criteria, 36 had 3 or more tumour biopsies available for each 
(comprising pre-treatment, 14 day and approximately 3 month biopsies) and were 
selected for microarray analysis. All patients gave informed consent to be included in 
the study which had been approved by the local ethics committee (LREC; 2001/8/80, 
2001/8/81 and 06/S1103/65 – see supplementary section 6.4 and 6.5). Patients were 
treated with a neoadjuvant protocol in which letrozole (Femara, 2.5mg; Novartis Pharma 
AG, Basel, Switzerland) was given daily for approximately 3 months. Microarray 
analysis was performed on the 36 patients and analysable results were obtained from 34 
patients. Failures were either due to inadequate amplification of total RNA or if the 
number of probes detected with expression levels above the background (defined by 
negative control probes) with a P-value less than 0.05 was less than 9000.  
3.3.2. Response Assessment 
Clinical response was determined using dynamic changes in tumour volumes assessed 
by repeated measurements taken over the treatment period. Measurements were usually 
taken around day 45 and again at 3 months and several patients had additional 
measurements taken throughout the 3 month treatment period. Assessment was based on 
ultrasound measurements performed by a single sonographer (JMD) (figure 29). 
Response classifications were determined as described in section 3.4.2.  
Pathological response was determined by a pathologist from haematoxylin and eosin 





3.3.3. Tumour Samples 
Tumour biopsies were taken with a 14-guage needle: before, approximately 14 days 
after, and approximately 3 months after commencement of continuous letrozole 
treatment as described previously [426]. Samples were snap-frozen in liquid nitrogen 
and frozen sections were taken, H&E stained and the cellularity and percentage presence 
of cancerous tissue within each specimen was assessed by a pathologist. 
3.3.4. RNA Processing and Microarray Hybridisation 
Biopsies were homogenised and RNA was extracted using the miRNeasy Mini Kit with 
RNAse Free DNAse treatment (Qiagen). RNA quantity and quality was verified on a 
Bioanalyser 2100 with RNA 6000 Nano Kit (Agilent) and Nanodrop 2000c (Thermo 
Scientific). RNA was reverse transcribed and amplified using the WT-Ovation FFPE 
System Version 2 (NuGEN), purified using the Qiaquick PCR Purification Kit (Qiagen), 
biotinylated using the IL Encore Biotin Module (NuGEN), purified using minElute 
Reaction Cleanup Kit (Qiagen) and quantified once again using the Nanodrop 2000c 
(Thermo Scientific). Labelled cDNA was then hybridised to Human HT-12v4 whole-
genome expression Beadarrays (Illumina) according to the standard protocol for NuGEN 
amplified samples. Samples in the same response group were assigned random positions 
across all the Beadarrays with samples from the same patient on the same array. 
Beadarrays were hybridised and processed in 5 batches and each batch included a 
replicate Universal Human Reference RNA (UHRR) control sample in order to assess 
the need for batch effect correction [369, 370, 376]. The Human HT-12v4 whole-
genome expression Beadarray covers more than 48000 transcript probes and its 





3.3.5. Published Datasets 
3.3.5.1. Affymetrix Dataset: Letrozole 
Affymetrix gene expression data was generated from primary breast tumour tissue 
biopsies taken before, approximately 14 days after and again approximately 3 months 
after commencement of continuous neoadjuvant letrozole treatment in 58 patients (data 
was available online from 55 patients) as part of a previously described clinical study 
[124, 284]. Patients were selected from a consecutive series recruited between 2001 and 
2003 as part of the aforementioned letrozole clinical audit (see section 3.3.1).  RNA was 
extracted, amplified and labelled as previously described [124] before hybridisation to 
HGU-133A GeneChips (Affymetrix) according to the standard protocol. 
3.3.5.2. Illumina Dataset: Anastrozole 
Illumina gene expression data was generated from primary breast tumour tissue biopsies 
from 44 patients before, and after 2 weeks of continuous anastrozole treatment in the 
anastrozole-only arm of a multicentre neoadjuvant clinical trial [373]. This study 
received approval from an institutional review board at each site and was conducted in 
accordance with the 1964 Declaration of Helsinki and International Conference on 
Harmonization/Good Clinical Practice guidelines. Written informed consent was 
obtained from each patient before participation. RNA was extracted, amplified and 
labelled as previously described [372], before hybridising to HumanWG-6 v2 
Expression BeadChips (Illumina) according to the standard protocol. Tumour volume 
measurements were taken at pre-treatment, 8 weeks and again at 16 weeks and clinical 
response assessment was determined using the modified UICC/WHO assessment criteria 
as described previously [372, 373, 427]. Briefly, clinical response was determined by 
objective status and based on comparison of pre- with on- treatment (16 week) 
measurements taken as the sum of products of perpendicular diameters of measurable 
lesions. Measurements were collected using physical examination, calliper, ultrasound 
or magnetic resonance imaging (MRI); the same method was always used for follow-up 




complete disappearance of all measurable and evaluable disease. A partial response (PR) 
was a decrease under pre-treatment of greater than or equal to 50% and progressive 
disease was an increase of 50% above pre-treatment. Stable disease/no response (SD) 
did not qualify for CR, PR or progressive disease.    
3.3.6. Data Processing and Analysis 
All data was processed using the R/Bioconductor software and packages [392], and the 
TM4 Microarray software suite (MeV) [428, 429] unless otherwise stated. Data 
generated on the Illumina microarray platform (this study, samples from 34 patients) and 
data generated on the Affymetrix platform (published dataset [124, 284], samples from 
55 patients) were each independently pre-processed and re-annotated to Ensembl gene 
identifiers, then combined and batch corrected (see section 2). UHRR control samples 
were removed from the Illumina dataset prior to pre-processing. Briefly, Illumina probe 
profiles were quantile normalised using the lumi package (R/Bioconductor) and mapped 
to Ensembl gene sequences using a composite list comprising mappings from reMOAT 
[430], Ensembl BioMart [395] and a custom BLAST sequence search of the online 
Ensembl gene database where there was agreement between at least two of the 
resources. Where multiple Illumina probes represented an Ensembl gene, the mean 
expression level was calculated. A custom Chip Definition File (CDF) [393] was used to 
map the Affymetrix data to Ensembl gene annotations and RMA implemented by the 
affy package (R/Bioconductor) was used for normalisation. The datasets were then 
filtered using Illumina or Affymetrix probe detection P-values, removing probes that 
were undetected (P>0.05 in the total minus 3 samples). Both datasets were then 
combined and batch-corrected with cross-platform normalisation (XPN; ArrayMining) 
[398, 399] to reduce platform associated bias (see section 2). Replicate samples included 
in both datasets were used to confirm the success of integration as described in section 
3.4.1. The combined, corrected Affymetrix and Illumina dataset (89 patients; 267 
samples) was used for all further analysis (figure 30). These datasets were considered 
suitable for integration as both studies were designed with a similar experimental focus 




clinical parameters (see section 3.4.1). R-scripts for data pre-processing are given in 
supplementary section 6.1)  
Differential gene expression analysis was performed using Rank Product (RP) (MeV; 
TM4 Microarray Software Suite) [428, 429]. Pathway enrichment and functional gene 
ontology analysis was performed in DAVID Bioinformatics Resources 6.7 [431-433]. 
Multivariate analysis and regression and classification analysis was carried out using 
Random Forest (RF) (see section 3.3.6.1) [434] and Classification and Regression Trees 
(CART) (see section 3.3.6.2) [435, 436] (Salford Predictive Miner, Salford Systems, San 
Diego, USA) (figure 30). Predictive signatures were assessed using centroid 
classification and logistic regression (glm package: R/Bioconductor). Gene expression 
heatmaps were generated in MeV using Euclidean distance with complete linkage 
following gene mean-centering performed in Cluster 3.0 [400]. Multidimensional 
scaling was performed in R with scaling plots generated in JMP10 (JMP Software, 
USA). All statistical analyses were carried out in Prism 6 (Graphpad Software, 
California, USA). 
3.3.6.1. Random Forest (RF) 
Random Forest (RF) [434] analysis was used to reduce a large list of differentially 
expressed genes between responsive and non-responsive tumours to a relatively small 
number comprising the most important factors. RF is a form of dynamically construed 
nearest neighbour classifier capable of considering interaction effects among variables. 
It was used to grow a forest of 5000 classification trees each derived from a randomly 
boot-strapped sample of the original dataset and partially randomly selected predictor 
variables. Separate models were then combined in an ensemble via a voting or averaging 
process generating a list of variables ranked based on the contribution of each variable to 
model accuracy. Measures of contribution to accuracy are defined by the Gini score, 
which cumulates and standardises a measure of improvement (split of responsive and 




3.3.6.2. Classification and Regression Trees (CART) 
Classification and regression trees (CART) [435, 436] were used to develop decision 
tree based models to predict response to endocrine therapy. CART models are examples 
of binary recursive partitioning; binary as parent nodes are always split into exactly 2 
child nodes and recursive as the process is repeated by considering each child node as a 
parent. CART models use exhaustive searches and computer-intensive testing 
techniques to identify a set of logical variables which can robustly separate 
heterogeneous data into homogenous segments. CART models are non-parametric, 
assuming neither a linear nor continuous non-linear relationship between variables and 
classifiers. CART models begin by attempting to divide the entire dataset into two 
segments using one variable. In the process every eligible variable is examined for 
splitting power resulting in partitioning of the data using the best performing predictor. 
Splitting of the data continues at each node resulting in growth of a maximal tree (a tree 
which cannot be grown any further) and which can subsequently be pruned. An error 
rate is defined for the maximal tree and for each sub-tree based on the misclassification 
rate derived from random internal testing.  
In this study, 73 samples were included in the training set, 54 classified as responsive 
and 19 as non-responsive. Continuous expression variables from 200 genes were used as 
potential candidates for classification. One disadvantage of CART models is that trees 
can be unstable and as a result small changes in the data can result in generating very 
different trees. This is largely due to the fact that if a particular split changes all 
subsequent splits, which follow after it in the tree, also change. To address this, cross 
validation was carried out in which the test dataset (n=73) was randomly split into 10 
sections, each with a similar distribution of response outcomes. One of the subsets was 
reserved for testing while the other 10 are combined and used as the test set for model 
building. The process was then repeated 10 times with a different subset of the data 





Figure 30. Flowchart of data pre-processing, integration, analysis and validation. Pre-
treatment, 14 day and 3 month gene expression data from 89 patients (combined dataset; 
teal) receiving neoadjuvant letrozole was derived by integrating a new gene expression 
study (Illumina: dark blue) with a previous study [124] (Affymetrix; dark green). Clinical 
response was determined by changes in tumour volume and patients were characterised as 
responsive (green) or non-responsive (red). Rank product differential gene expression 
analysis and multivariate techniques (RF and CART) and functional analysis were used to 
build a model to predict response to therapy. The model was independently validated in a 







Immunohistochemical staining of FFPE tissue for Ki67 was performed on a subset of 
samples derived from the Miller et al dataset as part of a previous study [292]. Staining 
and scoring was performed as described previously [292]. 
3.3.7.2. CD45 Staining 
Immunohistochemical staining of FFPE tissue with a mouse monoclonal antibody to 
CD45 (Cell Signalling Technology Inc.) diluted x100 was performed. Antigen retrieval 
was carried out using 0.1M sodium citrate/0.1M citric acid pH6 and detection using the 
EnVision
TM
 kit (Dako, Agilent Technologies) with 1 hour incubation as per the 
manufacturer’s standard protocol. Sections were counterstained using haematoxylin. 
Scoring was carried out using subjective assessment of two independent scorers as 
described in section 3.4.4.3.    
3.4. Results 
3.4.1. Integration of Microarray Data 
In order to increase sample number, particularly of non-responsive tumours which were 
limited in the sample population, data generated on the Illumina microarray platform 
(this study, samples from 34 patients) and data generated on the Affymetrix platform 
(published dataset [124, 284], samples from 55 patients) were integrated as discussed 
previously in sections 2 and 3.3.4. These datasets were considered suitable for 
integration as both studies have a very similar experimental design including: time-
course, drug protocol, response assessment method and tissue sampling schedule. 
Furthermore, both studies have a similar composition in terms of patient/sample 
numbers and clinical parameters and indeed statistical analysis using logistic regression 
(LR) yielded no significant differences (figure 31). Criteria to describe distinct patterns 
of clinical response based on dynamic tumour volume changes were defined as 




pattern groups: (i) ‘quick stable’ response, (ii) ‘slow’ response, (iii) ‘non-response’, (iv) 
‘intermediate’ response, (v) ‘acquired response’ and (vi) ‘acquired non-response’, based 
on strict criteria (see section 3.4.2.1). The proportions of the 6 response groups, in 
particular the 3 major groups (i-iii), were found to be comparable in both datasets (figure 
32), providing further justification for the suitability of these datasets for integration.  
 
Figure 31. Table comparing the composition of Affymetrix and Illumina datasets. 
Affymetrix (dark green) and Illumina (dark blue) datasets were compared in respect of 
composition of clinical and pathological variables. Logistic regression analysis was 






Figure 32. Comparison of proportions of clinical response patterns in Affymetrix and 
Illumina datasets. The combined dataset comprised 62% of samples from the Affymetrix 
dataset and 38% from the Illumina dataset (centre). Affymetrix (dark green; left) and Illumina 
(dark blue; right) datasets were compared in respect of proportions of each clinical response 
pattern: ‘quick stable’ (green), ‘slow’ (light green), ‘non-response’ (red), ‘intermediate’ 
(yellow), ‘acquired response’ (purple) and ‘acquired non-response’ (blue). 
Prior to cross-platform integration, batch effects in the Affymetrix data due to sample 
processing data were minimised using ComBat [396] as discussed previously in section 
2.4.2.2 and figure 20. The Illumina data was processed in 5 batches with a Universal 
Human Reference RNA (UHRR) control sample included in each batch to assess inter-
batch variation as in a previous study [370]. An additional replicate UHRR sample was 








Figure 33. Analysis of inter- and intra-batch variation in the Illumina dataset. A: 
distribution of replicate UHRR control samples in Illumina dataset processing batches. B: 
heatmap of Pearson correlations between replicate UHRR samples. R values range from 
low correlation (orange) to high correlation (white) through shades of yellow reflecting the 
overall similarity of expression profiles. C: comparison of variance (standard deviation) 
between inter-batch samples (UHRR1, 2, 3, 4 and 6) and intra-batch samples (UHRR4 and 
5). ** = P<0.01.    
Analysis of the UHRR samples revealed that Pearson correlations between intra-batch 
samples (R=0.99) were marginally higher than inter-batch correlations (R=0.95-0.97) 
(figure 33B) and the variance between inter-batch UHRR samples was significantly 
higher (P<0.01) than between intra-batch samples (figure 33C). To correct the marginal 
batch effect the Illumina data was ComBat [396] corrected to reduce inter-batch 
variation.  
The pre-processed Affymetrix and Illumina datasets were then integrated and XPN [398] 
corrected to reduce platform-related bias (figure 34). Samples (pre-treatment, 14 day and 
3 month) from 6 patients originally included in the Affymetrix dataset were also 
included as replicates in the Illumina dataset. Pearson correlation analysis based on the 




success of integration (figure 35). The corrected combined dataset was used for all 
further analysis. 
 
Figure 34. Integration and XPN correction of Affymetrix and Illumina datasets. 3D 
multidimensional scaling (MDS) plot of all samples from the Affymetrix dataset (dark green) 
and Illumina dataset (dark blue) based on all genes, before (left and right) and after (centre) 
XPN correction. 
 
Figure 35. Hierarchical clustering of matched samples based on Pearson correlation 
after XPN correction. Colour denotes samples from the same patient (as per the patient ID 
legend), the suffixes on patient ID’s (48, 69, 87, 119, 120 and 133) denote as follows: ‘.1’ = 
pre-treatment, ‘.2’ = 10-14-days, ‘.3’ = 3 months, ‘.Illum’ = Illumina Beadarray data, ‘.Affy’ = 





3.4.2. Clinical and Pathological Assessment of Response 
Clinical response was determined using dynamic changes in tumour volumes assessed 
by repeated measurements taken over the treatment period. Assessment was based on 
ultrasound measurements performed by a single sonographer (JMD). Patterns of clinical 
response were found to be varied and transient in a number of cases. To address this, 
criteria to describe distinct patterns of clinical response were defined and these were 
later used as the basis to determine overall clinical response or non-response and to 
select samples for predictive model development (figure 36). 
3.4.2.1. Patterns of Clinical Response 
Patterns of clinical response were determined using strict criteria (all percentage 
reductions relate to changes relative to the pre-treatment measurement). The three major 
patterns which characterise 82% of tumours in the combined dataset were defined as: (i) 
‘quick stable’ response: a volume reduction of at least 50% by day 45 and at least 70% 
by 3 months, (ii) ‘slow’ response: a volume reduction between 0 and 50% by day 45 and 
at least 70% by 3 months, (iii) ‘non-responder’: increase in tumour volume or a partial 
reduction that never exceeds 50% (figure 36). 
Three additional clinical response patterns were defined which characterise a small 
proportion of tumours (18% of the combined dataset) which have a transient or medial 
response to therapy: (iv) ‘intermediate’ response: a partial response by day 45 and 
continued partial response or no further change by 3 months, tumours reduce by at least 
50% but not more than 70%, (v) ‘acquired response’: an increase above initial tumour 
volume  by day 45 then a rapid reduction of at least 70% of initial volume by 3 months, 
(vi) ‘acquired non-response’: a decrease in tumour volume of at least 50% by day 45 





Figure 36. Patterns of clinical response to neoadjuvant letrozole therapy. A: line graph 
of relative (%) changes in tumour volume assessed periodically over the treatment period. 
Each line represents one patient. B: Pie chart showing proportions of each clinical response 
pattern in the combined dataset. A&B: colours denote different clinical response patterns as 
follows: ‘quick stable’ (green), ‘slow’ (light green), ‘non-response’ (red), ‘intermediate’ 
(yellow), ‘acquired response’ (purple) and ‘acquired non-response’ (blue).C: For clarity the 
major clinical response patterns: ‘quick stable’ (green), ‘slow’ (light green), ‘non-response’ 





3.4.2.2. Determination of Overall Clinical Response 
Overall response was used as the primary endpoint in this study and refers to the clinical 
characterisation of response after approximately 3 months of therapy, where in the 
neoadjuvant setting results can impact significantly on future clinical treatment decisions 
including the most appropriate surgery to perform. Tumours which respond well to 
endocrine therapy with significant reduction in volume are better candidates for less 
invasive breast conserving surgeries. The heterogeneous nature of response as 
demonstrated by the response pattern groups (see section 3.4.2.1), in particular the 
‘slow’ response group which respond as well as the ‘quick stable’ responders by 3 
months but which fail to respond as quickly, (figure 36) precludes early measurements 
or early changes in volume from being accurate indications of overall response. 
Therefore, in-keeping with currently used clinical parameters, overall response in this 
study was characterised by tumour volume changes at 3 months with the following cut-
offs: ‘responsive’: tumour volume is less than or equal to 30% of initial volume, and 
‘non-responsive’: tumour volume is greater than 50% of initial volume. Assigning these 
criteria gave a ‘responsive’ group comprising all tumours with ‘quick stable’ response 
and ‘slow’ response patterns, and a ‘non-responsive’ group consisting of the tumours 
with ‘non-response’ patterns (figure 37).  
For the purposes of identifying early predictive molecular biomarkers of overall 
response, tumours with ‘intermediate’ response patterns (which comprise 10% of the 
combined dataset) were excluded, as tumour volume changes by 3 months are 
ambiguous, falling out with the predefined criteria for either ‘responsive’ or ‘non-
responsive’ tumours. Additionally tumours with ‘acquired response/non-response’ 
patterns, which account for 8% of the dataset, were also excluded. Dramatic changes in 
clinical response of these atypical tumours are ‘acquired’ late in treatment suggesting 
molecular changes which occur out with the window of early molecular response 
biomarker determination (figure 37). However, response status in these excluded 





Figure 37. Association between overall response and clinical response patterns. 
Tumours classified as ‘responsive’ comprise all those with ‘quick stable’ and ‘slow’ response 
patterns and those classified as ‘non-responsive’ comprise all those with ‘non-response’ 
patterns. Tumours with ‘intermediate’ or ‘acquired response/non-response’ patterns were 
excluded. 
In the dataset used for later independent validation analysis (see section 3.4.4.7), in 
which 44 patients were treated with neoadjuvant anastrozole [373], clinical response was 
determined using the modified UICC/WHO criteria applied to tumour measurements 
after 16 weeks of continuous therapy (see section 3.3.5.2). To ensure consistency of 
response, classification patients in the combined dataset (this study) were also assessed 
for clinical response using the modified UICC/WHO criteria applied to 3 month tumour 
volume measurements. All patients determined to have a complete response (CR) or 
partial response (PR) using the modified UICC/WHO criteria were classified as 
responsive using the overall response criteria used in this study. All patients with stable 
disease (SD) or progressive disease using the modified UICC/WHO criteria were 
classified as non-responsive in this study (figure 38). Based on these findings, patients in 
the validation dataset with clinical responses classified as CR or PR were taken as 








Figure 38. Association between response criteria used in this study and the modified 
UICC/WHO criteria. Patients in this study were assessed for clinical response, based on 3D 
ultrasound measurements performed after 3 months of therapy, using both the overall 
response criteria (this study) and the modified UICC/WHO criteria. Responsive = green, 
non-responsive = red.  
3.4.2.3. Clinical Features of Response 
Clinicopathological data were collected for every patient including TNM staging, 
tumour grade, and tumour volume at diagnosis and immunohistochemical determination 
of ER and HER2 status and were assessed for prediction of overall response outcome by 
logistic regression (LR) (figure 39). Of the clinicopathological variables tested, HER2 
positivity was found to be significantly associated with non-response to therapy 
(P=0.006). However, in the non-responsive tumours HER2 over-expression occurs in 
only 42% and even within the HER2 positive population only 50% of tumours are non-
responsive. Other variables were not found to have a statistically significant association 





Figure 39. Table showing association of clinicopathological data with clinical 
response. Clinicopathological data comprising TNM staging, grade at diagnosis, initial 
tumour volume and range of volumes across the response groups and immunohistochemical 
scoring of HER2 and ER were collected for every patient. Logistic regression analysis was 
performed to assess prediction of overall clinical response; P = P-values.  
3.4.2.4. Pathological Response 
With the objective of neoadjuvant endocrine therapy to shrink tumour size such that 
breast conserving surgery becomes possible, clinical response was taken as the primary 
endpoint. However, pathological response was also determined at pre-treatment, day 14 
and 3 months for each patient by a pathologist (JT) (figure 40A). Pathological response 
was assessed by changes in tumour grade as determined by microscopic examination of 
acinar/tubule formation, nuclear atypia/pleomorphism and presence of mitotic cells. 




response, defined as no remaining tumour, occurred in only 5 of 73 patients by 3 
months. A partial response was defined as either a decrease by more than 20% in tumour 
cellularity, improvement of grade or both and progression was characterised by an 
increase in tumour cellularity of greater than 20%, increased grade or both. Pathological 
response at 3 months is given in figure 40B. In terms of tumour cellularity, partial 
response to therapy occurs in the majority (65%) of clinically responding tumours and in 
approximately one third (39%) of non-responsive tumours. However, approximately half 
(53%) of the non-responsive tumours do not show any significant changes in cellularity. 
The majority of tumours do not change in grade by 3 months (58% of responsive and 
58% of non-responsive) however a greater proportion of responsive tumours decrease in 
grade compared with non-responsive tumours (31% and 11% respectively). Conversely, 
a greater proportion of non-responsive tumours progress with an increase in tumour 
grade compared with the responsive tumours (32% and 4% respectively).  
Pathological response was also determined at day 14 for each patient (figure 41A). In 
terms of tumour cellularity, 41% of responsive tumours were classified as having a 
partial response while another 41% were found not to have changed. In the non-
responsive tumours, 47% were classified as having a partial response and 37% were 
found not to have changed. In terms of changes in tumour grade by day 14, the majority 
74% of responsive and 89% of non-responsive tumours did not change. As an indication 
of overall response, early (day 14) pathological changes were not found to be 





Figure 40. Association of pathological response with clinical response after 3 
months of therapy. A: Table comparing pathological response, in respect of changes in 
tumour cellularity and changes in tumour grade, with overall clinical response. B: Pie charts 
showing proportion of pathological response classifications associated with clinically 
responsive (left) and non-responsive (right) tumours in respect of changes in tumour 
cellularity (top) and changes in tumour grade (bottom). Pathological response classifications 
are as follows: complete and partial response (green), no change (grey), progression (red) 






Figure 41. Association of pathological response with clinical response after 14 days 
of therapy. A: Pie charts showing proportion of pathological response classifications 
associated with clinically responsive (left) and non-responsive (right) tumours in respect of 
changes in tumour cellularity (top) and changes in tumour grade (bottom). Pathological 
response classifications are as follows: complete and partial response (green), no change 
(grey), progression (red) and unknown (black). B: results of logistic regression (LR) analysis 
to assess prediction of overall clinical response using early pathological changes. 
3.4.2.5. Breast Cancer Molecular Subtypes and Response 
All tumours were profiled using the intrinsic subtype classifications proposed by Sørlie 
et al [25] applied to pre-treatment expression (figure 42). Of 73 tumours, 82% were 
found to be classified as luminal A and the remaining 18% as luminal B. Within the 
luminal B tumours the majority (62%) were non-responsive. However, within the non-
responsive population, luminal B only accounts for 42% of tumours with the majority 





Figure 42. Association of luminal B molecular subtype with clinical response. Left: pie 
chart showing the proportion of tumours classified as luminal A (dark blue) and luminal B 
(light blue) using the Sørlie intrinsic subtype classifications applied to pre-treatment 
expression. Right: pie chart showing the proportion of luminal B tumours belonging to each 
of three clinical response patterns: ‘quick stable’ (green), ‘slow’ (light green) and ‘non-
response’ (red).  
3.4.3. Molecular Profile of Quick Stable Response 
Within the ‘quick stable’ response subgroup, pairwise Rank Product (RP) differential 
gene expression analysis (FDR=0.01) was used to identify the most changed genes 
which characterise a good clinical response to therapy. The analysis gave rise to 551 
consistent early changed genes between pre-treatment and day 14 (figure 44) and 1063 
consistent overall changes between pre-treatment and 3 months (figure 43). Pathway 
enrichment and biological process gene ontology analysis was carried out separately for 
down-regulated and up-regulated genes in DAVID Bioinformatics Resources 6.7. 
Functional analysis revealed genes down-regulated after 3 months of therapy were 
enriched for processes including proliferation, glycolysis and oxidative phosphorylation. 
Genes found to be up-regulated at 3 months were enriched for processes including 
extracellular matrix (ECM) or stromal remodelling (including cellular adhesion and 
angiogenesis) and inflammatory immune response. Common to both up and down-
regulated gene lists, were genes with biological process annotations enriched for cell 
signalling (G-protein complex receptor signalling and small GTPase mediated signal 




transcriptional cofactor activity) and protein processing (protein folding, amino acid 
metabolism, phosphorylation, glycosylation and acetylation). Several of the genes (78 of 
the 551 early changed genes and 162 of the 1063 overall changed genes) had unknown 
biological function. Another set with unknown biological function was annotated as 
‘metal ion binding’ reflecting their known molecular function.   
 
Figure 43. Functional analysis of significantly differentially expressed genes between 
pre-treatment and 3 months in the ‘quick stable’ response group. Pie charts showing 
genes down-regulated (top) and up-regulated (bottom) at 3 months grouped by functional 
association. Each gene was assigned to only one group which was the most significantly 
enriched functional process or pathway. Large pie charts (left) comprise functional groups 
represented by at least 15 genes, minor functional groups are shown in small pie charts 







Figure 44. Functional analysis of significantly differentially expressed genes between 
pre-treatment and 14 days in the ‘quick stable’ response group. Pie charts showing 
genes down-regulated (top) and up-regulated (bottom) at 14 days grouped by functional 
association. Each gene was assigned to only one group which was the most significantly 
enriched functional process or pathway. Large pie charts (left) comprise functional groups 
represented by at least 15 genes, minor functional groups are shown in small pie charts 
(right). Colours assigned to each functional group are consistent throughout all figures in this 
study.  
3.4.3.1. Down-regulated Genes and Processes 
Proliferation associated genes including those involved in the regulation of cell cycle 
such as cyclins (CCNA2, CCNB1, CCND1 and CCNE2), cyclin-dependent kinases 
(CDK1, CDK2 and CDK3) and cell-division cycle genes (CDC7, CDC20, CDC23 and 
CDC25C) were significantly down-regulated at 3 months. In addition, genes involved 




MCM3, MCM4, MCM5, MCM6 and MCM7) and replication factor genes (RFC2, 
RFC3, RFC4 and RFC5) were also significantly down-regulated at 3 months. Other 
proliferation associated genes found to be down-regulated at 3 months were involved 
with the M-phase of mitosis including formation of the centromere-kinetochore complex 
(CENPF, CENPI, CENPN and CENPQ) and formation of mitotic spindle (ASPM, 
AURKA, TPX2 and SAC3D1).   
Genes involved with glycolysis (GAPDH and PDHB) and several involved with the 
mitochondrial generation of energy through oxidative phosphorylation were also found 
to be significantly down-regulated following 3 months of therapy. The latter includes 
genes encoding major protein complexes involved in the electron transport chain such as 
cytochrome c oxidase (COX6C and COX7A2), ATP synthase (ATP5E and ATP5EP2) 
and NADH dehydrogenase ubiquinone (NDUFA4, NDUFA7, NDUFA8, NDUFB2, 
NDUFB5 and NDUFB7).  
3.4.3.2. Up-regulated Genes and Processes 
Genes significantly up-regulated by 3 months were enriched for immune processes 
which might suggest an inflammatory response to treatment (discussed later: see section 
3.4.4.3). Up-regulated genes in this category included those encoding lysosomal acid 
hydrolases such as proteases (cathepsins: CTSA, CTSB, CTSG, CTSK, CTSL1, CTSS 
and CTSZ), glycosidases (HEXB and FUCA1) and lipases (LIPA and ACP5), genes 
encoding the major histocompatibility complex type two (HLA-DMB, HLA-DOB, 
HLA-DPA1, HLA-DPA2 and HLA-DRA) and genes involved in the complement and 
coagulation cascade (C1S, C7, VWF, CFD, CFH and CFI). Additionally, genes 
encoding inflammatory chemokines including C-X-C motif and C-C motif ligands were 
significantly up-regulated by 3 months suggesting a possible chemokine mediated 
recruitment of immune cells and induction of inflammatory response.  
Genes associated with ECM/stromal remodelling, adhesion and angiogenesis were also 
significantly up-regulated at 3 months. These include genes involved in fibrosis and 




biglycan (BGN), collagens (COL1, COL2, COL3, COL5, COL6, COL14, COL15, 
COL16 and COL21 family of collagen genes) and laminins (LAMA, LAMB and LAMC 
family of laminin genes) and genes involved in cellular and matrix adhesion (CD36, 
ANXA9, CLDN5, CLDN8, FBLN2, FBLN5, THBS2 and THBS3). 
3.4.3.3. Comparison of ‘Quick Stable’ and ‘Slow’ Response Gene 
Changes 
A comparison of early and overall consistent gene changes derived from pairwise RP 
(FDR=0.01) analysis in ‘quick stable’ response and ‘slow’ response tumours revealed 
significant overlap in both early and overall changed genes (figure 45). However, a 
greater proportion of genes were significantly up or down-regulated in the ‘quick stable 
response’ tumours both at day 14, consistent with the early dramatic changes in volume 
seen in these tumours, and at 3 months compared with the ‘slow response’ tumours. 
Given the clear differences in early clinical response between these two groups of 
responsive tumours (see section 3.4.2.1), robust prediction of overall response and non-
response is likely to rely on identifying molecular biomarkers which have consistent 
early expression or early changed expression across the ‘quick stable’ and ‘slow’ 






Figure 45. Comparison of early and overall gene expression changes in ‘quick stable’ 
and ‘slow’ response tumours. Venn diagrams comparing early changes (by day 14: top) 
and overall changes (by 3 months: bottom) in differentially expressed genes both down-
regulated (left) and up-regulated (right) in ‘quick stable’ (green) and ‘slow’ (light green) 
response tumours.  
3.4.4. Predicting Response to Therapy 
3.4.4.1. Early and Late Gene Changes in Major Functional Groups 
The major functional groups identified as significantly up or down-regulated within the 
‘quick stable’ response tumours were analysed further to identify gene groups that 
change early in treatment (by day 14). Changes were assessed in both responsive and 
non-responsive tumours to identify unique patterns of change and differences in 
expression levels associated with response (figure 46). Hypothetically, genes and 
processes which change early in treatment and/or have early expression profiles 
differentially associated with clinical response represent promising candidates for early 




Proliferation associated genes were found to be significantly down-regulated in both 
‘quick stable’ and ‘slow’ response tumours with changes occurring as early as day 14. 
Consistent early down-regulated genes include the cyclins (CCNA2, CCNB1 and 
CCND1), the mini chromosome maintenance genes (MCM2, MCM4 and MCM6) and 
the mitotic spindle associated genes (ASPM and AURKA). Within the non-responsive 
tumours proliferation associated genes were found to be down-regulated in some 
patients, however to a significantly lesser extent than in responding tumours with several 
tumours showing no change by day 14 or 3 months (figure 46). The full list of 
proliferation genes is given in supplementary section 6.3. 
Glycolysis and oxidative phosphorylation associated genes were found to be 
significantly and consistently down-regulated by 3 months in both ‘quick stable’ and 
‘slow’ response tumours. Some tumours were found to change as early as day 14 
however early changes were not consistent across all responsive tumours, with several 
tumours maintaining high expression levels of these genes at day 14. Within the non-
responsive tumours, expression levels and associated changes were found to be more 
heterogeneous with some tumours having low expression of these genes at pre-treatment 
and increased expression at day 14 and 3 months while others had down-regulated 
expression consistent with the responsive tumours (figure 46). 
Genes involved with the immune/inflammatory response and ECM/stromal remodelling 
were found to be significantly co-expressed, with the same tumours having similar 
expression levels and consistent patterns of changed expression across all differentially 
expressed genes in these functional categories, suggesting that these biological processes 
are linked. In the responsive tumours, significant up-regulation of these genes occurs by 
3 months in the majority of tumours while only some tumours have increased expression 
by day 14. Within the non-responsive tumours expression of these genes remained 
consistently low at day 14 and at 3 months with only a minority of tumours having 





Figure 46. Heatmaps showing changes in gene expression over time in major 
functional groups. Expression of genes involved in four major function groups: 
proliferation/cell cycle/DNA replication (green), glycolysis and oxidative phosphorylation 
(red), immune/inflammatory response (yellow) and EMC/stromal remodelling and adhesion 
and angiogenesis (brown) identified as differentially down-regulated (top) or up-regulated 
(bottom) between pre-treatment and day 14 in ‘quick stable’ response tumours. Samples are 
in numerical order of patient ID for each time point shown (pre-treatment, day 14 and 3 
month) above each heatmap block. Log2 expression levels have been gene mean centred 
across all response groups shown, A: ‘quick stable’ (green; left), B: ‘slow’ (light green; 
centre) and C: ‘non-response’ (red; right) tumours. In the heatmaps, colours represent 
relative differences in expression with red denoting higher expression and green lower 
expression.   
3.4.4.2. Proliferation and Response to Therapy 
Further analysis of the proliferation associated gene set (n=60, the full list of 
proliferation genes is given in supplementary section 6.3.) revealed strong associations 
with response after 14 days of treatment (figure 47B). While expression of proliferation 
genes at pre-treatment was poorly associated with response, high expression at day 14 
was found to be reasonably correlated, with the majority of non-responsive tumours 




and ‘slow’ (P=0.0053) response tumours (figures 47A). However, while the latter is true 
for most of the responsive tumours, some maintained high expression levels of 
proliferation genes, similar to the non-responsive tumours, at day 14. Of these the 
majority belong to the ‘slow’ response group which, early in treatment, have been shown 
(see section 3.4.2.1) to behave clinically like the non-responsive tumours. In addition, 
analysis of fold changes (change in proliferation gene expression between pre-treatment 
and day 14) also revealed poor associations with response (figure 47C). Together, these 
findings suggest that while proliferation associated genes may comprise an important 
part of a predictive model of response, proliferation alone is not robustly predictive of 
response, in particular in distinguishing between ‘slow’ response and non-responsive 
tumours early in treatment. Furthermore, changes in early gene expression and 
expression levels at pre-treatment may not be as predictive as day 14 expression levels.  
Immunohistochemically-assessed expression of the proliferation marker Ki67 was 
carried out at pre-treatment, 14 days and 3 months for samples in the Affymetrix part of 
the combined dataset as part of a previous study [292]. Interestingly, expression of Ki67 
was not found to be significantly different between responsive and non-responsive 








Figure 47. Association between proliferation and clinical response. A&B: heatmaps 
and boxplots showing expression and mean expression respectively of 60 proliferation 
genes identified as significantly down-regulated in the ‘quick stable’ response tumours at 
pre-treatment (A) and 14 days (B). In heatmaps samples were ordered from low (left) to high 
(right) based on mean expression. Coloured bars above heatmaps correspond to colours in 
boxplots and represent clinical response patterns: ‘quick stable’ (green), ‘slow’, (light green) 
and ‘non-response’ (red). In the heatmaps log2 expression was gene mean centered across 
all samples and heatmap colours represent relative differences in expression with red 
denoting higher expression and green lower expression. C: heatmap and boxplot showing 
change in expression (fold change) of proliferation genes by day 14. In the heatmap colours 
represent log2 fold changes: red = increased expression, black = no change and green = 
decreased expression. (Continued on page 128) D: line graph and boxplots for each time 
point of immunohistochemically determined scores for Ki67 over time with assessments 
made at pre-treatment, 14 days and 3 months. In the line graph each line represents a 
single patient. Line and boxplot colours denote clinical response patterns: ‘quick stable’ 
(green), ‘slow’ (light green) and ‘non-response’ (red). A-D: stars above boxplots denote 
statistical significance: **** = P<0.0001, *** = P<0.001, * = P<0.05. All possible statistical 
comparisons were conducted between groups; only statistically significant differences are 
represented in plots. 
3.4.4.3. Inflammation, Stromal Remodelling and Response to Therapy 
Multidimensional scaling (MDS) was used to model associations between responsive 
and non-responsive tumours at pre-treatment, day 14 and 3 months based on the 551 
early (by day 14) most changed genes in ‘quick stable’ response tumours from pairwise 
RP (FDR=0.01) analysis (figure 48). Clustering of responsive and non-responsive 
tumours based on all 551 genes was heterogeneous at pre-treatment and day 14, however 
by 3 months a cluster comprising only responsive tumours and enriched for ‘quick 
stable’ response tumours was clearly identifiable (figure 48). Tumours in the responsive-
only cluster were those with the most changed gene expression profile between pre-
treatment and 3 months. RP analysis (FDR=0.01) and pathway enrichment and 
biological process gene ontology analysis at 3 months revealed that tumours in this 
cluster were significantly enriched for high expression of immune/inflammatory 




providing further evidence that these processed are linked. These results indicate that a 
local immune/inflammatory response and ECM/stromal remodelling occurs in some 
tumours and is significantly associated with a positive response to therapy, however, 
such a response is not dependent on up-regulation of these processes. Conversely, non-
responsive tumours were not found to be up-regulated in respect of these processes. 
Despite the strong association with a positive response to therapy, these processes have 
been shown to be significantly up-regulated in only some responsive tumours by 3-
months and only in a small subset of those as early as day 14. However, identification of 
individual genes involved which are consistently up-regulated early in treatment may be 
possible and these may represent promising candidate markers for discriminating 
between subsets of responsive and non-responsive tumours. 
 
Figure 48. Modelling of association between responsive and non-responsive tumours 
over time reveals an immune/ECM enriched responsive cluster at 3 months. Left: 3D 
MDS plot (2D scaling coordinated with third dimension as time) of all tumours at each time 
point based on the 551 most differentially expressed genes between pre-treatment and 14 
days in ‘quick stable’ response tumours. Right: 2D MDS plot of all tumours at 3 months. 
Tumours belonging to the immune/ECM enriched cluster are shown beneath the blue plane 
and enrichment of functional groups are represented by the gradient-coloured triangles (dark 
= high expression, light = low expression). Both: each sphere represents a single sample at 
a given time point, spheres are coloured based on clinical response pattern: ‘quick stable’ 





Inflammatory activity can be readily assessed in histological specimens by staining for 
leukocyte infiltration using the leukocyte common antigen: CD45. This molecule is a 
type 1 transmembrane protein tyrosine phosphatase which is commonly expressed on the 
cell surface of mature haematopoietic lineage cells with the exclusion of platelets and 
mature erythrocytes [437]. Presence of leukocyte infiltration was determined by 
examination of CD45 stained specimens for each patient at pre-treatment and 3 months. 
Assessments were made using semi-quantitative subjective criteria in which a score 
between 0 and 3+ was assigned based on intensity and proportion of stained cells (figure 
49A). Leukocytes were found to be present either ‘diffusely’, homogeneously 
distributed throughout the specimen, as heterogeneous ‘aggregates’ or a combination of 
both (figure 49A). Analysis of results revealed that the majority of responsive tumours 
had no leukocyte infiltration at pre-treatment, including the subset of responsive tumours 
with significantly increased 3 month expression of immune/inflammatory and ECM 
related genes (figures 49B, D and E). However, 10 of the 19 non-responsive tumours 
were found to have leukocyte infiltration at pre-treatment suggesting a possible link 
between the presence of immune/inflammatory cells and non-response to therapy in 
some tumours (figures 49B and E). Interestingly, logistic regression (LR) analysis 
revealed a strong association P=0.007 between leukocyte infiltration and non-response at 
pre-treatment compared to the responsive group: comprising all ‘quick stable’ and 
‘slow’ response tumours (figure 49B). Analysis to compare the presence of leukocyte 
infiltration with proliferation was carried out and the presence of immune/inflammatory 
cells at pre-treatment was found to be associated with higher expression of proliferation 
genes at day 14 (figure 49C). The majority of both responsive and non-responsive 
tumours were found to have no leukocyte infiltration at 3 months. Interestingly, the 
presence of leukocytes in the subset of responsive tumours with increased expression of 
immune/inflammatory and ECM related genes at 3 months was found in only 11 of 25 
tumours suggesting that immune related cells were not responsible for increased 





Figure 49. Association between leukocyte infiltration and clinical/proliferative 
response to therapy. A: tissue sections of pre-treatment and 3 month samples were 
stained for CD45 and scored between 0 and a maximum of 3+ using semi-quantitative 
subjective criteria. Leukocytes were ‘diffusely’ distributed through the tissue (top), 
‘aggregated’ (bottom) or a combination of both. B: bar chart showing IHC score proportions 
for leukocyte infiltration across ‘quick stable’, ‘slow’ and ‘non-response’ groups. Colours in 
bars of graph refer to IHC score for leukocyte infiltration as per the legend.  C: heatmap 
showing the association between leukocyte infiltration and expression of the 60 most 
significantly down-regulated proliferation-associated genes by day 14 in ‘quick stable’ 
response tumours across all tumours. Log2 expression was mean centre and ordered from 
low (left) to high (right) based on mean expression. Colours in the heatmap range from 
green to red through black and refer to relative expression, red = higher expression and 





Coloured bars above the heatmap represent clinical response patterns: ‘quick stable’ 
(green), ‘slow’, (light green) and ‘non-response’ (red) and IHC scores for leukocyte infiltration 
as per the key. D: 2D MDS plot of all tumours at 3 months from figure 48.Tumours belonging 
to the immune enriched cluster are shown beneath the blue plane and enrichment of the 
immune functional group is represented by the gradient-coloured triangle (yellow = high 
expression, black = low expression). Each sphere represents a single sample at 3 months, 
spheres are coloured based on clinical response pattern: ‘quick stable’ (green), ‘slow’ (light 
green) and ‘non-response’ (red). E&F: scores for pre-treatment (E) and 3 months (F) were 
pooled and graphed as a percentage of the total tumours assessed in the group. Groups 
used were: ‘responsive’ (green) or ‘non-responsive’ (red). Responsive tumours were further 
split into those with either high (yellow) or low (black) immune/inflammatory related gene 
expression at 3 months, as per figure 49D. Colours in bars of graph refer to IHC score for 
leukocyte infiltration as per the legend.  
3.4.4.4. Differential Gene Expression between Responsive and Non-
responsive Tumours 
Rank product analysis (FDR 0.01) was also used to identify significantly differentially 
expressed genes between responsive and non-responsive tumours at pre-treatment 
(n=353) and day 14 (n=369). Pathway enrichment and biological process gene ontology 
analysis was then used to determine enriched groups of functionally related genes. At 
pre-treatment and day 14 non-responsive tumours were found to express higher levels of 
proliferation associated genes compared with responsive tumours (figure 50). Given the 
strong association between proliferation and response (see section 3.4.4.2) these early 
differentially expressed genes represent likely candidates for predictive response marker 
exploration within this functional group. Responsive tumours were found to expresses 
higher levels of genes at pre-treatment associated with immune/inflammatory response 
and also at day 14, coupled with higher expression of ECM/stromal remodelling 
associated genes. Given the strong association between up-regulation of these functional 
groups at 3 months and positive response (see section 3.4.4.3), early differentially 
expressed genes involved in these processes may represent early markers of a positive 
response in some tumours. Other differentially expressed genes between responsive and 




signalling, transcription, protein processing, metabolism and metal ion binding. A 
number of genes also have unknown biological function. In addition, a proportion of the 
genes were designated as belonging to ‘minor biological processes’ indicating that they 
were assigned a functional processes annotation which was enriched in the gene list by 
only 10 genes or less. 
 
Figure 50. Functional groups of genes differentially expressed between responsive 
and non-responsive tumours at pre-treatment and 14 days. RP analysis was carried out 
to identify significantly differentially expressed genes between responsive and non-
responsive tumours at pre-treatment (top) and 14 days (bottom). Each gene was assigned to 
only one group which was the most significantly enriched functional process or pathway. 
Functional groups shown were represented by at least 15 genes. ‘Minor biological 
processes’ comprise processes represented by less than 15 genes are shown as one group 






3.4.4.5. A Gene Expression Model for Early Prediction of Response  
Lists of genes differentially expressed in the ‘quick stable’ response tumours and 
between responsive and non-responsive tumours at pre-treatment and at 14 days were 
pooled together (n=771) and filtered, removing genes with unknown function or genes 
designated as ‘metal ion binding’, giving 573 genes. A list of variables comprising pre-
treatment, 14 day expression and delta (change in expression between pre-treatment and 
14 days) were included for each of the 573 genes and used for random forest (RF) 
analysis. This multivariate procedure was used to identify the 200 most informative 
variables differentiating between responsive and non-responsive tumours. Of these, 82 
were pre-treatment variables, 82 were day 14 variables and 36 were delta variables. The 
200 most informative variables comprised 131 distinct genes (the full gene list is 
provided in supplementary section 6.3). Pathway enrichment and biological process 
gene ontology analysis of these genes was carried out and revealed significant 
enrichment for proliferation and immune/inflammatory associated genes as well as 
genes involved with transcription and metabolism. Other biological processes found to 
be enriched to a lesser extent include apoptosis, protein processing, cellular signalling 
and ECM/stromal remodelling (figure 51).  
 
Figure 51. Functional enrichment of the 131 most informative genes differentiating 
between responsive and non-responsive tumours. RF was used to identify the 200 most 
informative variables, comprising 131 distinct genes, differentiating between responsive and 
non-responsive tumours. Each gene was assigned to only one group which was the most 
significantly enriched functional process or pathway. Colours assigned to each functional 





The 200 most informative variables were then used as the input for classification and 
regression tree (CART) modelling. The optimal model generated had 8 terminal nodes 
and was subsequently pruned to reduce the error rate (figure 52).  
 
Figure 52. Plot showing the association between error rate and the number of 
terminal nodes in the CART model. The CART algorithm begins by attempting to divide 
the entire dataset into two segments using one variable, in the process every eligible 
variable is examined for splitting power resulting in partitioning of the data using the best 
performing predictor. Splitting of the data at each node continues resulting in growth of a 
maximal tree (a tree which cannot be grown any further). An error rate is defined for the 
maximal tree and for each sub-tree based on the misclassification rate derived from random 
internal testing. The maximal tree was pruned from 8 terminal nodes to 7 in order to reduce 
the error rate.  
The final model (figures 53-55) comprised 7 terminal nodes using expression values 
from 4 genes (figure 53): pre-treatment expression of the immune related gene IL6ST 
(GP130) and the apoptosis induction related gene NGFRAP1 (BEX3); and day 14 
expression of 2 proliferation associated genes: ASPM (mitotic spindle associated) and 
MCM4 (DNA replication associated). The CART model calculates expression value cut-
offs or splitters for each node (figure 54D). These determine the path taken by individual 
subjects through the classification tree. Subjects propagate down to terminal nodes 





Figure 53. Table showing details of the 4 genes used in the CART model. The CART 
model uses pre-treatment expression of 2 genes: the immune related gene GP130 and the 
apoptosis related gene BEX3, and day 14 expression of two proliferation associated genes: 
ASPM and MCM4.  
The 4 gene model uses pre-treatment expression of GP130 as a primary splitter which 
has prediction accuracy itself of 85% (figure 54A). Tumours with low expression of 
GP130 are strongly associated with non-response and are further classified by day 14 
expression of ASPM and pre-treatment expression of BEX3. Conversely, tumours with 
high expression of GP130 are strongly associated with positive response and are further 
classified by day 14 expression of MCM4 and ASPM and pre-treatment expression of 
BEX3. After primary node splitting, node 2 (ASPM) represents the primary predictive 
terminal node for non-response, accurately identifying 53% of the non-responsive 
tumours (figure 54B), whereas, node 3 (MCM4) represents the primary predictive 
terminal node for positive response, accurately identifying 78% of responsive tumours 
(figure 54B). Overall, the model was found to have 96% accuracy, 89% sensitivity, 98% 
specificity, a positive predictive value (PPV) of 89%, a negative predictive value (NPV) 
of 96% and an area under the receiver operating characteristic AUC (ROC) curve of 
0.96 units
2
 in the test set (letrozole data), only failing to predict response accurately in 3 





Figure 54. The 4 gene CART model. A: decision tree diagram showing the hierarchical 
structure of the model and relationship between the constituent components. Each node is 
uniquely numbered 1 to 6 (blue numbers) and represents the expression of a single gene at 
pre-treatment (PT) or 14 days (D14). From each node the path through the model is 
determined by a CART algorithm calculated splitter value based on log2 expression of the 
given gene. For each node the branch to the right indicates an expression level above the 
model defined splitter value for the given gene and the branch to the left indicates an 
expression level below the splitter value (as per the legend). The primary splitter is GP130 
which has prediction accuracy itself of 85%; expression levels below the GP130 splitter 
value (left branch) are associated with non-response (red dotted-line box) and expression 
levels above the splitter (right branch) are associated with good response (green dotted-line 
box). Terminal nodes are represented by their association with a particular response group: 
responsive (green ‘R’) and non-responsive (red ‘NR’). B: pie charts showing the proportion 
of responsive (green) and non-responsive (red) patients correctly classified at each node in 
the decision tree. Node numbers correspond to blue node numbers on the decision tree 
diagram (A). C: classification test statistics calculated for the 4 gene CART model using the 
training set (letrozole data): accuracy, sensitivity, specificity, PPV, NPV and AUC (ROC). D: 









Figure 55. The 4 gene CART model (full decision tree). Full decision tree diagram 
showing the hierarchical structure of the model and relationship between the constituent 
components. Each node is numbered, parent nodes are outlined in blue and terminal nodes 
in red. Each node shows the number of cases and proportion therein of responsive (class 1; 
green) and non-responsive (class 2; red) patients partitioned by each splitter at each node. 
Splitter values are given for each node next to Ensembl gene IDs representing the 4 genes 
in the model suffixed with ‘BL’ for baseline/pre-treatment expression or ‘D14’ for 14 day 
expression. 
Further analysis of the 4 gene CART model using the gene expression profiles of each 
tumour showed that higher GP130 expression at pre-treatment is strongly associated 
with a positive response to therapy. In addition, higher day 14 expression of proliferation 
associated genes ASPM and MCM4 is strongly associated with non-response and higher 
pre-treatment expression of the apoptosis induction gene BEX3 is associated with a 










Figure 56. Distribution of expression variables and association with partitioning in 
the 4 gene CART model. Scatter diagrams showing the distribution of log2 expression for 
each of the four genes in respect of the responsive (green) and non-responsive (red) 
patients partitioned at each node in the model. Each graph represents a node in the model. 
Splitter values are shown for each gene (dotted-lines) and brackets denote branches in the 
model. Only patients within a given bracket are partitioned at the next node which in the 
model indicated by the direction of the bracket. Terminal nodes have no brackets. PT=pre-
treatment expression and D14= 14 day expression.  
Mean gene expression profiles for each of the 4 genes were compared in responsive 
(‘quick stable’ and ‘slow’ response tumours independently) and non-responsive tumours 




profiles of ‘quick stable’ and ‘slow’ response tumours were found to be very similar 
with no significant differences in expression at any of the three time points for all 4 
genes. Mean expression of GP130 and BEX3 was found to be higher across the time 
points in responsive tumours compared with non-responsive whereas the converse was 
true for the proliferation associated genes: ASPM and MCM4. Individual analysis at 
each of the time points revealed that GP130 has significantly lower expression at pre-
treatment, day 14 and 3 months in non-responsive tumours compared with ‘quick stable’ 
response tumours (P=0.009, 0.001 and 0.0005 respectively) and ‘slow’ response tumours 
(P=0.0447, 0.0124 and 0.0719 respectively). Differences at pre-treatment in expression 
of ASPM between non-responsive tumours and both subsets of responsive tumours were 
not significant. Differences at day 14 and 3 months were significant between non-
responsive and ‘quick stable’ tumours (P=0.081 and 0.008 respectively) however 
comparisons between non-responsive and ‘slow’ tumours failed to reach significance. 
Differences in expression of MCM4 between non-responsive and responsive tumours 
were only significant at 14 days (P<0.0001 for both). BEX3 expression was significantly 
different between non-responsive and ‘quick stable’ response tumours at pre-treatment, 
14-days and at 3 months (P=0.0029, 0.0217 and 0.001 respectively). Comparison of 
expression between non-responsive and ‘slow’ response tumours was only significant at 







Figure 57. Mean gene expression profiles over time in responsive and non-
responsive tumours. Mean log2 gene expression values were calculated for each of the 4 
genes at each time-point: pre-treatment (0), day 14 (14) and 3 months (90) for all patients in 
each response pattern subgroup: ‘quick stable’ (green), ‘slow’ (light green) and ‘non-
response’ (red). Error bars denote standard error of the mean.  
The 4 gene CART model was able to classify all tumours, including those with 
‘intermediate’ response patterns (previously excluded: see section 3.4.2.1), as either:  
‘responsive’ characterised by a dramatic reduction in tumour volume by 3 months of 
therapy or ‘non-responsive’ characterised by significantly less or no change in tumour 
volume over 3 months (figure 58A). Progression free survival (PFS) was analysed for all 
tumours, based on model predicted classifications. A progression event was defined by 
any or all of the following criteria: increase in tumour volume greater than or equal to 
20% above previous ultrasound measurement. Kaplan-Meier survival analysis (figure 




the model as ‘responsive’ compared with those classified as ‘non-responsive’ 
(P<0.0001).The logrank hazard ratio was calculated to be 0.196 (95% CI: 0.037 to 
0.286), taking the reciprocal (1/0.196 = 5.516) suggests that the estimated hazard 
(disease progression event) function is around 5.5 times more for patients classified as 
non-responsive by the model.     
 
Figure 58. Predicted clinical response profiles and progression free survival. A: line 
graph of relative (%) changes in tumour volume assessed periodically over the treatment 
period. Each line represents one patient. Colours indicated predicted overall clinical 
response: responsive (green), non-responsive (red). B: curve showing Kaplan-Meier 
progression free survival analysis based on response classifications predicted using the 4 
gene CART model.    
3.4.4.6. Acquired Response/Non-response 
The 4 gene CART model was applied to assess response in tumours with transient 
patterns of clinical response defined as ‘acquired response’ or ‘acquired non-response’, 
which had previously been excluded from the analysis (see sections 3.4.2.1 and 3.4.2.2). 
Interestingly, the model predicts all but one of the tumours to be non-responsive. The 
responsive tumour was classified as an early non-responder and despite have increasing 
in tumour volume by 30% above pre-treatment at day 50, by 3 months of therapy had a 
complete clinical and pathological response with disappearance of all identifiable 




rather than those with acquired response. The remaining ‘acquired response’ tumours 
may be inherently non-responsive to endocrine therapy and potentially undergo late 
molecular changes, out with the 14 day window for prediction, which result in eventual 
clinical response. The tumours with patterns of clinical response defined as ‘acquired 
non-response’ are characterised by a reduction in tumour volume from pre-treatment by 
around day 45 followed by a dramatic increase in volume by 3 months. Based on overall 
clinical response (response by 3 months) these tumours are accurately identified as non-
responsive using the 4 gene CART model potentially suggesting that despite an early 
clinical response to therapy, the molecular profiles of these tumours at pre-treatment and 
14 days are characteristic and predictive of overall non-response to therapy (figure 59).          
 
Figure 59. Profile and prediction of tumours with ‘acquire response/non-response’. 
A&B: line graphs of tumours with ‘acquired response/non-response’ patterns of clinical 
response showing relative (%) changes in tumour volume assessed periodically over the 
treatment period. Each line represents one patient. A: coloured by clinical response pattern: 
‘acquired response’ (purple) and ‘acquired non-response’ (blue). B: coloured by predicted 
overall clinical response using the 4 gene CART model: responsive (green) and non-
responsive (red).  
3.4.4.7. Independent Validation of Predictive Model 
In order to independently validate the model, data was derived from the anastrozole-only 
arm of an independent clinical study in which patients (n=44) with primary breast cancer 




taken at pre-treatment and 14 days and response was assessed by changes in tumour 
volume using the modified UICC/WHO criteria. For the purposes of validation, patients 
IDs were coded for blind prediction with clinical response data held by an independent 
collaborator.  
As the CART model is based on model-calculated expression cut-off values of the 4 
genes it was necessary to XPN correct the training (letrozole data) and test set 
(anastrozole data) to remove batch and platform effects between the datasets (see 
sections 2 and 3.4.1) (figure 60).  
 
Figure 60. Integration and XPN correction of letrozole and anastrozole datasets. 3D 
multidimensional scaling (MDS) plot of all samples from the letrozole dataset (Affymetrix and 
Illumina combined dataset; this study) (yellow) and anastrozole dataset (blue) based on all 
genes, before (left and right) and after (centre) XPN correction. 
The XPN-corrected letrozole training set was then used to re-compute expression cut-off 
values (splitters) for each of the genes which were then applied to predict response in the 
anastrozole test set. Prediction in the letrozole training set maintained 96% accuracy 
following XPN-correction. Each tumour in the anastrozole test set was classified as 
either responsive or non-responsive using the 4 gene CART model and results were sent 
to the collaborators who reported the prediction accuracy of the model to be 91%, 




tumours (80%) (figure 61A). Sensitivity and specificity of the model in the test dataset 
were calculated to be 80% and 97% respectively and PPV and NPV were found to be 
92% and 90% respectively (figure 61B). Interestingly, prediction accuracy based on 
expression of GP130 alone was found to be 82%. 
 
Figure 61. Table of 4 gene CART model prediction results in training and test 
datasets. A: total prediction accuracy and accuracy within both response groups: 
responsive (green) and non-responsive (red) were determined within the training dataset 
(letrozole; yellow) and the test dataset (anastrozole: blue). B: classification test statistics 
calculated for the 4 gene CART model using the test data (anastrozole data): accuracy, 
sensitivity, specificity, PPV and NPV. 
Gene expression profiles for each of the 4 genes were also compared in all clinically 
responsive and non-responsive tumours at time-points relevant to the 4 gene CART 
model in the anastrozole test dataset (figure 62). Results were similar to those found in 
the letrozole training dataset with pre-treatment expression of GP130 and BEX3 found 
to be significantly higher in responsive tumours compared with non-responsive tumours 
(P=0.0029 and 0.029 respectively). In addition, day 14 expression of ASPM and MCM4 
was found to be significantly higher in non-responsive compared with responsive 
tumours (P=0.0154 and 0.0092 respectively), consistent with the findings from the 






Figure 62. Comparing expression of the 4 CART model genes between responsive 
and non-responsive tumours in the anastrozole test set at relevant time points. 
Boxplots comparing log2 gene expression of the 4 genes at either pre-treatment (GP130 
and BEX3) or 14 days (ASPM and MCM4) between clinically responsive (green) or non-
responsive (red) tumours.* = P<0.05, * = P<0.01.  
3.4.4.8. The Clinical Need for a 14 Day Biopsy 
The 4 gene CART model is dependent on expression of 2 genes at pre-treatment and 2 
genes at 14 days and therefore as well as the routinely performed pre-treatment biopsy 
also requires a 14 day biopsy to be performed. Clinically, a predictive model based 
solely on pre-treatment gene expression would be preferable, dispensing with the need 
for this second biopsy, if suitably high prediction accuracy could be achieved. To assess 
this, 82 pre-treatment variables derived from the random forest list of the 200 most 
informative variables differentiation between pre-treatment and 14 days were used as 
input to CART. The optimal CART model had 6 terminal nodes comprising pre-
treatment expression of 3 genes (figure 63). As with the 4 gene CART model (see 




the immune cell signalling associated gene LAX1 and the HPRT1 gene which plays an 
essential role in purine metabolism via the purine salvage pathway where it catalyses 
conversion of hypoxanthine and guanine to inosine monophosphate and guanosine 
monophosphate respectively [438].  
 
Figure 63. The 3 gene pre-treatment only CART model. A: decision tree diagram 
showing the hierarchical structure of the model and relationship between the constituent 
components. Each node represents the expression of a single gene at pre-treatment. From 
each node the path through the model is determined by a CART algorithm calculated splitter 
value based on log2 expression of the given gene. For each node the branch to the right 
indicates an expression level above the model defined splitter value for the given gene and 
the branch to the left indicates an expression level below the splitter value (as per the 
legend). Terminal nodes are represented by their association with a particular response 
group: responsive (green ‘R’) and non-responsive (red ‘NR’). B: Table showing details and 
functional association of the 3 genes used in the pre-treatment only CART model. 
Predication accuracy with the 3 gene pre-treatment CART model was 93% in the 
training set (letrozole data) however was shown to perform less well (84% accuracy)  
than the 4 gene pre-treatment and 14-day CART model (91% accuracy) in the test set 




lower in both training (76%) and test (63%) datasets compared with the pre-treatment 
and 14 day model (PPV = 89% and 92% respectively).  
 
Figure 64. Table of prediction results for 3 gene pre-treatment only CART model in 
training and test datasets. Total prediction accuracy and accuracy within both response 
groups: responsive (green) and non-responsive (red) were determined within the training 
dataset (letrozole; yellow) and the test dataset (anastrozole: blue). B&C: classification test 
statistics calculated for the pre-treatment only model in training (B) and test (C) datasets: 
accuracy, sensitivity, specificity, PPV, NPV and AUC (ROC). 
3.4.4.9. Improving on Previous Models 
A study by Harvell et al in 2008 published a gene expression signature comprising 50 
genes [368], later refined to 25 pre-treatment genes [367], derived from gene expression 
microarray analysis of pre- and on-treatment samples from 6 patients treated 
neoadjuvantly with either: exemestane or exemestane plus tamoxifen for 4 months. Of 
the 6 patients, 3 were defined as responsive and 3 as non-responsive based on clinical 
response assessed by physical exam, mammography, ultrasound or MRI. Clinical 
response categories used were: complete response (disappearance of all detectable 
disease), partial response (longest dimension decrease by ≥ 30%), marginal response 
(longest dimension decreased by 20-29%), stable disease (no significant change in 
tumour size) and progressive disease (increase in tumour volume ≥ 20%). In their study 




those with stable or progressive disease were defined as ‘non-responsive’. In the 
combined letrozole dataset (this study), 20 of the genes in the 25 gene signature (figure 
65) were represented. Pearson correlation analysis was carried out between the 20 pre-
treatment genes and centroids in which the expression of each gene was defined as either 
-1 (lower expression) or 1 (higher expression) based on the association between 
expression and clinical response reported in the original study (figures 65B and C). 
Samples from the current study were then ranked in order of Pearson correlation to the 
most highly correlated centroid (responsive or non-responsive). The analysis revealed 
poor association between expression pattern of the 20 genes and clinical response.  













Figure 65. Assessment of a previously reported predictive signature by Harvell et al 
(2008). A-C: heatmap of the combined letrozole dataset (this study) showing expression of 
20 genes from a 25 gene signature identified as being predictive of clinical response to 
neoadjuvant endocrine therapy in a published study [367]. Samples were ranked by highest 
Pearson correlation to either responsive (left to right; as per green triangle under heatmap) 
or non-responsive (right to left; as per red triangle under heatmap) centroids (C). C: genes in 
centroids were assigned either -1 (green; lower expression) or 1 (red; higher expression) 
based on the association between expression and clinical response in the original study (B). 
A: coloured bars above the heatmap represent clinical response patterns: ‘quick stable’ 
(green), ‘slow’, (light green) and ‘non-response’ (red). Log2 expression was gene mean 
centered across all samples and heatmap colours represent relative differences in 
expression with red denoting higher expression and green lower expression. B: heatmap 
adapted from Harvell et al (2008) [367] showing the association between relative expression 
of the 20 genes and clinical response. Colours range from red to green through yellow with 
red denoting higher expression and green denoting lower expression. 
The most closely related to the current study was conducted by Miller et al [124] in 
2009. They published a gene expression signature reported to differentiate between 
responsive and non-responsive tumours comprising 205 variables: 69 pre-treatment, 45 
day 14 and 91 change be day 14 variables. In the original study the signature was 
derived from the Affymetrix-only part of our combined letrozole dataset and therefore 
could not be independently tested in this combined dataset. Instead it was tested in the 
Illumina-only part of the dataset. Testing was carried out using logistic regression (LR) 




responsive and non-responsive patients based on expression profiles of the 205 variables 
in the Affymetrix-only part of the letrozole data, as in the original study. The predictive 
accuracy of the 205 expression variable signature was found to be 91% with CC and 
100% with LR analysis in the original training set (Affymetrix data) but only 53% with 
CC and 43% with LR analysis when applied to the Illumina-only part of the dataset 
(figure 66).  
 
Figure 66. Validation of a previously reported predictive signature by Miller et al 
(2009) based on expression of 205 variables. A: table of prediction results using the 205 
variable model in training (Affymetrix; dark green) and test (Illumina; dark blue) datasets. 
Total prediction accuracy and accuracy within both response groups: responsive (green) and 
non-responsive (red) were determined from CC validation and LR analysis. B: logistic 
regression modelling of the relationship between responsive (green) and non-responsive 
(red) samples and probability of non-response (constrained between 0.0 and 1.0) for the 






In hormone sensitive breast cancer, aromatase inhibitors such as letrozole and 
anastrozole have an established therapeutic role, particularly in post-menopausal women 
[118, 121-123, 421]. However, a number of patients respond less well to therapy and 
therefore, in a move towards better patient care and treatment, there is an important 
clinical need to identify early-on-treatment biomarkers which predict for response/non-
response to endocrine therapy and which outperform currently used parameters for 
response assessment and are translational with the potential for routine clinical use.  
3.5.1. Currently Used Measures and Biomarkers of Response 
3.5.1.1. ER as a Biomarker 
The most widely used biomarker to determine suitability of hormone therapy in breast 
cancer is estrogen receptor alpha (ER). However, within the ER
+
 population response 
rates to anti-estrogen therapies are only 50-70% in the neoadjuvant setting and lower in 
advanced disease [124, 304, 425]. As a result, there is a need to elucidate biomarkers 
which have the power to accurately identify those patients within the ER-positive 
population who will respond less well to endocrine therapy.  
3.5.1.2. Early Clinical Response 
Analysis of clinical response based on dynamic changes in 3D ultrasound measurements 
over the treatment period revealed heterogeneous patterns of response. Within the 
population of patients who responded well to therapy there were two subgroups; the first 
defined as ‘quick stable’ response patients were characterised by significantly reduced 
tumour volumes by around day 45 of treatment and continued positive response 
thereafter. The second responsive group denoted as ‘slow’ response patients responded 
as well as the ‘quick stable’ patients by 3 months of therapy with significant reductions 
in tumour volume. However, by around day 45 they showed little change akin to the 
subgroup of ‘non-response’ patients. The latter group was characterised by little or no 




similarity in clinical response between the ‘non-response’ and ‘slow’ response tumours 
by day 45 precludes clinical response, based on early changes in tumour volume or size, 
from being an accurate predictor of overall response to therapy. Three additional 
subgroups were defined to characterise distinct patterns of clinical response. The 
‘intermediate’ response subgroup clearly gained some benefit from the therapy however 
tumour volume reductions were not as dramatic as with the ‘quick stable’ and ‘slow’ 
response tumours. The ‘acquired response/non-response’ tumours represented only a 
small proportion of the patients in the study and these were characterised by sudden and 
dramatic changes or reversals in response which occur late in treatment and involve 
molecular changes that occur out-with the window of early molecular marker detection. 
For the objective of designing a molecular classifier of response only ‘quick stable’ and 
‘slow’ response tumours (collectively referred to as the ‘responsive’ tumours) and the 
‘non-responsive’ tumours were used, thus creating two distinct well-separated groups, 
each with clearly defined clinical response criteria. 
3.5.1.3. Early Pathological Response 
Pathological response by 14 days was found to be poorly associated with clinical 
response. Approximately half of both the clinically responsive and non-responsive 
tumours have a reduction in tumour cellularity by 14 days while the remaining half of 
both groups either do not change or have an increase in cellularity. In terms of changes 
in grade, the majority of both responsive and non-responsive patients do not change by 
14 days. Indeed, logistic regression analysis shows that neither changes in tumour 
cellularity nor grade were found to be significantly predictive of clinical response. 
Together these findings suggest that early pathological changes are poor indictors of 
overall clinical response to endocrine therapy.   
3.5.1.4. Molecular Subtyping and Response 
With the advent of molecular subtyping, ER
+
 breast cancer was subdivided into either 
luminal A or the more aggressive luminal B form (see section 1.1.3). Luminal B breast 




thought to represent a surrogate for a more aggressive disease phenotype which is less 
dependent on estrogen signalling and has been linked to reduced ER expression, spread 
to lymph nodes, higher proliferation and increased expression of EGFR and HER2 
[439]. Indeed, luminal B tumours have been linked to poor prognosis and lack of 
response to hormone therapy [439, 440]. In this study, tumours were profiled based on 
the Sørlie classifications for intrinsic subtypes [25]. Of the 73 patients 18% were 
classified as luminal B and of these 62% were non-responsive. Indeed, within the non-
responsive population only 42% of tumours were classified as luminal B. While the 
luminal B molecular profile is associated with non-response, it is not accurately 
predictive of response as the majority of non-responsive tumours were classified as 
luminal A and 38% of luminal B tumours responded well to endocrine therapy.  
3.5.1.5. HER2 as a Biomarker   
Over-expression of epidermal growth factor receptors, particularly HER2, have also 
been linked endocrine therapy resistance in breast cancer [182]. Indeed, HER2 
expression has been reported to be a prognostic factor and predictor of response to 
HER2 targeted therapy [441]. However, the ability of HER2 expression to predict 
response to neoadjuvant endocrine therapy is controversial [442]. In this study, HER2 
protein expression was determined immunohistochemically (see section 1.1.3) as part of 
routine histology at diagnosis for the majority of patients. Of the 70 patients tested, 23% 
were determined to be HER2
+
, 62% of which were clinically non-responsive. However, 
within the non-responsive population only 42% of patients were determined to be 
HER2-positive. In logistic regression analysis HER2 positivity was found to be 
significantly associated with non-response however is not robustly predictive of 
response as 38% of HER2-positive patients responded well to endocrine therapy. Instead 
HER2 signalling might represent a mechanism, active in a subset of non-responsive 
patients, which drives proliferation in a non-estrogen dependent manner. Such patients 
who gain only partial or no benefit from endocrine therapy may represent promising 




3.5.2. Proposed Predictors of Response  
3.5.2.1. Ki67 
Uncontrolled proliferation is regarded as a hallmark of cancer and a number of studies 
have linked proliferation to lack of response to endocrine therapy [50, 285, 292, 443, 
444]. Immunohistochemical assessment of the proportion of cells staining for the 
nuclear antigen Ki67 has become a widely used methodology for comparing 
proliferation between tumours [444]. Potential uses suggested include: prognosis, 
prediction of response or resistance to chemotherapy or endocrine therapy and 
estimation of residual risk. Ki67 has been shown to independently improve the 
prediction of response to chemotherapy and prognosis in a group of breast cancer 
patients [445] and together with HER2 status to predict pathological complete response 
in HER2-positive patients receiving neoadjuvant chemotherapy [446]. Interestingly, one 
study reported that post-treatment (chemotherapy) levels of Ki67 were more predictive 
of prognosis than pre-treatment levels [447]. With regard to endocrine therapy, a recent 
study of metastatic breast cancer reported that low Ki67 expression was associated with 
higher clinical benefit and longer time to progression on first-line endocrine therapy and 
longer survival after metastatic recurrence [448]. Another study investigated the 
association between early proliferation changes and clinical response to neoadjuvant 
letrozole. Proliferation was determined by both Ki67 immunohistochemistry and the 
gene expression grade index (GGI); a 97 gene algorithm designed to measure 
proliferation (see section 1.3.2.4.2). The study reported that low proliferation, 
determined by either Ki67 or the GGI, after 10-14 days of neoadjuvant letrozole was 
associated with a good clinical response in high grade but not low grade tumours [443]. 
In the current study, Ki67 was immunohistochemically determined at baseline, 14 days 
and 3 months in a subset of patients (n=55) as part of a previous study [292]. However, 
no significant associations between Ki67 expression levels or changes in expression and 
clinical response were found in our cohort. The potential for Ki67 as a surrogate of 
proliferation and predictor of response and prognosis has been demonstrated in a number 




some studies have shown early changes in Ki67 to be positively and significantly 
correlated with both clinical and pathological response, they have also eluded to 
discordancy occurring in a number of cases, rendering it a poor predictor of overall 
response [292, 303]. Furthermore, recent studies have suggested that enormous variation 
in the analytical practice of Ki67 measurement dramatically limits its value in this 
context [444, 449].  
3.5.2.2. Proliferation Gene Expression 
Hierarchical cluster analysis based on the most significantly down-regulated 
proliferation associated genes (n=60) over 3 months of therapy in the ‘quick stable’ 
response tumours revealed poor association with response at pre-treatment or based on 
changed expression by 14 days. However, expression of proliferation genes at day 14 
was found to be strongly associated with response, with the majority of non-responsive 
tumours expressing relatively high levels of proliferation genes. Despite the strong 
association, a number of responsive tumours also had high day 14 expression suggesting 
that while proliferation may constitute an important component of a predictive model, 
when considered independently, it is a poor predictor of overall response. Interestingly, 
these findings suggest that on- or post-treatment biomarkers may have more predictive 
power than at pre-treatment, a view supported by a recent review of biomarkers in breast 
cancer in preoperative studies [449]. 
3.5.2.3. Immune Signature and Leukocyte Infiltration 
The immune system has been shown to have both tumour supressing and tumour 
promoting roles [450]. Cytokines such as interleukins and interferons play a critical role 
in controlling the immune system. They are mainly secreted by lymphocytes and 
macrophages and work by modulating the function of target cells in a paracrine or 
autocrine fashion [451]. Several studies have shown that breast tumours are heavily 
infiltrated by leukocytes including T-cells, B-cells and tumour-associated macrophages 
(TAMs) [228, 452-456]. A recent study of leukocyte composition in breast cancer 




leukocytes in both chemotherapy treated and naïve patients. Interestingly, granzyme B 
expression was found to be low in the chemotherapy naïve cohort and in two thirds of 
the treated cohort suggesting negligible cytotoxic activity [457]. Indeed, a number of 
studies have suggested that despite the presence of lymphocytes, T-cell mediated anti-
tumour responses are impaired in breast cancer, potentially due to the action of 
inhibitory cytokines in the tumour microenvironment [451-453]. Despite the complexity 
surrounding the role of infiltrating leukocytes in mediating tumour behaviour, the 
presence of lymphocytes has been reported as an independent predictor of good response 
to cytotoxic chemotherapy in breast cancer [348] and infiltration of CD8 expressing T-
cells in particular was found to be an indicator of good clinical outcome in patients with 
ER
-
 breast cancer [458]. Contrary to this, a recent study reported that infiltrating 
leukocytes were associated with poor response to endocrine therapy in breast cancer. In 
addition, they suggested that infiltrating dendritic cells, which have been previously 
linked to breast tumorigenesis by a mechanism involving polarisation of CD4 expressing 
T-cells [459], could be involved in mediating a poor response to endocrine therapy in 
highly proliferative breast tumours. Interestingly, immunohistochemical staining for 
CD45 in this study also revealed a strong association between the presence of infiltrating 
leukocytes in pre-treatment tumour tissue sections and high expression of proliferation 
associated genes after 14 days of letrozole treatment. However, it should be noted that 
CD45 is expressed on the surface of most myeloid cells, lymphocytes and dendritic cells 
and therefore the hematopoietic lineage of the infiltrating leukocytes identified in this 
study remains unclear. Despite an association with high proliferation, the presence of 
infiltrating leukocytes was found to have a poor association with clinical response. 
Analysis of gene expression in ‘quick stable’ response tumours revealed a subset 
characterised by dramatic and consistent up-regulation of genes involved with 
immune/inflammatory and ECM/stromal remodelling at 3 months. However, infiltrating 
leukocytes were only found in approximately half of these tumours suggesting that these 
gene changes were largely leukocyte-independent and may instead be a feature of the 




study in 2007 reported an immune response gene expression signature which identified a 
good prognosis groups in ER
-
 breast cancer which was independent of leukocyte 
infiltration [36].   
3.5.2.4. Predictive Gene Expression Signatures 
The study by Harvell et al in 2008 [367, 368] represents one of the first focused on 
predicting response to neoadjuvant endocrine therapy using pre- and on-treatment 
matched biopsies in which the endpoint used was clinical response after extended 
therapy (4 months). They published a 50 gene signature which was later refined to a 25 
gene signature reported to predict clinical response to therapy after 4 months of 
treatment using pre-treatment gene expression levels. In this study both the 50 and 25 
gene signature were validated in the combined letrozole data using hierarchical 
clustering and were found to have no association with clinical response. The original 
study was based on expression profiles of only 6 patients: 3 responsive and 3 non-
responsive. Despite differences in drug protocol and experimental design, including 
assessment of clinical response, which exist between the original study and this, the 
limited sample number is likely to impact significantly on reproducibility of their 
findings (as discussed in sections 1.3.2.4.5, 1.3.3.1 and 3.5.5.1).  
The most closely related study to this using matched pre- and on-treatment biopsies and 
also using a clinical response endpoint (clinical response following 3 months of therapy) 
was published by Miller et al in 2009 [124]. They developed a gene signature based on 
205 early gene expression variables (including pre-treatment, 14 days or change by 14 
days) which was reported to distinguish between clinically responsive and non-
responsive tumours. At the time of publication their dataset represented the largest of its 
type, based on expression profiles of 58 patients, significantly larger than previous 
efforts by Harvell et al [367]. At the time no other sufficiently large datasets existed for 
validation purposes. Therefore, the first validation of their findings was carried out as 
part of this study; however, their original dataset comprises the Affymetrix component 
of what is now the combine letrozole dataset used in this study and for that reason it was 




their signature was found to be highly predictive in the training set (original data: 
Affymetrix component) in both centroid classification (CC) and logistic regression (LR) 
analyses despite differences in the criteria for clinical response used in this study (see 
sections 3.3.5.1, 3.4.2.1/2 and 3.5.5.2). However, in the test set (Illumina component) 
prediction of clinical response using their gene expression signature was poor. This is 
likely due to the analysis approaches used in the original study which led to findings 
which were largely dataset specific and not reproducible in independent datasets. 
Importantly, this study demonstrated the presence of bias in the Affymetrix dataset 
associated with variation in processing date (see sections 2.4.2.2 and 3.4.1) which was 
overlooked in the original study. The existence of such bias has been shown in several 
studies [369, 370, 376] to significantly impact on gene expression analysis and may be a 
contributory factor to the lack of reproducibility in the Miller et al [124] study.  
3.5.3. The 4 Gene CART Model for Predicting Response 
This study has reported a model which has been shown to accurately and robustly 
predict clinical response to aromatase inhibitors in the neoadjuvant setting. The model 
has been shown to out-perform currently used clinical and pathological parameters for 
response assessment and previously reported gene expression based models designed for 
the same purpose.  
Based on the expression of only 4 genes, the model presented in this study has 
significantly greater translational potential compared to predictive signatures from other 
studies comprising several genes, the assaying of which would be impractical in the 
clinical setting largely due to prohibitive costs and the time consuming nature of such 
assays. Furthermore, the 4 genes have been shown to be functionally relevant, involved 
in processes central to endocrine therapy response in breast cancer: immune signalling, 
proliferation and apoptosis. Indeed, all 4 genes have been linked to cancer in numerous 
studies (see section 3.5.4). Expression levels of the 4 genes were found to be 
significantly different between all responsive and all non-responsive tumours over time. 
Importantly, despite differences in early clinical response between ‘quick stable’ and 




different between these groups allowing for both to be distinguished at molecular level 
from the non-responsive tumours by day 14 of treatment.  
Interestingly, all but one of the tumours characterised by ‘acquired response/non-
response’ patterns of clinical response were predicted to be non-responsive. In the 
‘acquired response’ tumours a decrease in tumour volume may involve molecular 
changes which occur out-with the day 14 window for early prediction and as a result 
these tumours are predicted to be non-responsive. In the ‘acquired non-response 
tumours’ it is possible that, despite an initial reduction in tumour volume before 
dramatic regrowth, early gene expression profiles remain indicative of overall clinical 
response. The mechanisms underlying ‘acquired response/non-response’ to therapy 
remain unclear. Furthermore, with only 8% of patients in the study having transient 
clinical responses the performance of the 4 gene model within this subgroup is difficult 
to ascertain. However, given the aberrant nature of clinical response in these patients 
they may nonetheless gain clinical benefit from alternative or combination therapy and 
thus a prediction of ‘non-responsive’ may be appropriate for this group.     
Unlike previous models reported to predict response to endocrine therapy in the 
neoadjuvant setting, the model presented here has been independently tested under 
controlled blind conditions in a cohort of patients treated with neoadjuvant anastrozole 
and found to have 91% accuracy of clinical response prediction. This provides further 
evidence for the predictive power of the model. Indeed, compared to the previously 
published models which have now been validated as part of this study, the 4 gene model 
was shown to vastly out-perform these other models in independent validation analysis. 
In addition, the 4 gene model has been shown to predict response in patients treated with 
both letrozole and anastrozole, potentially suggesting a broader role for the model in 
predicting neoadjuvant clinical response to multiple single and combined anti-estrogen 




3.5.4. Genes in the 4 Gene CART Model 
3.5.4.1. Glycoprotein 130 (GP130) 
GP130 is a transmembrane protein belonging to the class of type 1 cytokine receptors, 
essential for signal transduction of cytokines in the interleukin 6 (IL6) family including: 
IL6, IL11, oncostatin M (OSM), leukaemia inhibitory factor (LIF) and ciliary 
neurotropic factor (CNTF) [460]. GP130 is known to mediate numerous homeostatic 
functions including the immune/inflammatory response, bone metabolism and 
haematopoiesis [461].  
GP130 has no intrinsic tyrosine kinase activity; instead it is phosphorylated on tyrosine 
residues after complexing with the cytokine ligand and other ligand-specific binding 
subunits, leading to activation of the JAK family of tyrosine kinases (JAK1, JAK2 and 
TYK2) which in turn stimulate multiple pathways including MAPK signalling, PI3K 
signalling and STAT signalling leading to transcriptional regulation of down-stream 
genes [460, 462]. An important target of GP130 is STAT3, a member of the STAT 
family of transcription factors [463, 464]. Following GP130 activation, STAT3 becomes 
phosphorylated on a tyrosine residue and homo- or heterodimerizes before translocating 
to the nucleus where it induces transcription of numerous genes involved in growth 
regulation, differentiation and cell cycle [463]. STAT3 is an oncogene which is 
constitutively activated in numerous solid tumours including breast cancer where it may 
act as a central mediator of malignancy. Its constitutive activation has been shown to 
involve epidermal growth factor (EGF) signalling and signalling through GP130 [465-
470].  
The cytokine ligands of GP130 have been reported to have numerous biological effects 
on breast cancer cells. IL6 and OSM have been shown to have both growth promoting 
and inhibiting effects [451, 471, 472]. They have also been shown to have a role in 
disrupting cell adhesion and thus increasing cell motility [473, 474]. Interestingly, IL6 
has been identified as a modulator of reductive 17β-hydroxysteroid dehydrogenase type 




potent estradiol following the aromatisation of androgens [475]. GP130 has also been 
reported to activate the estrogen receptor (ESR1) in breast cancer cells [476]. 
GP130 has also been shown to physically and functionally interact with EGFR family 
members. In a study of prostate cancer GP130 was found to form an IL6-dependent 
complex with epidermal growth factor receptor 2 (HER2) which is required for full IL6 
activity [477], a feature also found in breast cancer cells [473]. A study investigating 
OSM signalling in breast cancer cells also identified physical associations between both 
GP130 and oncostatin M receptor β and HER2 and epidermal growth factor receptor 3 
(HER3) [478]. Although the molecular mechanisms and biological significance of 
interactions between GP130 and EGFR remain poorly understood, a recent study 
suggested that GP130 signalling is essential for signalling down-stream of EGFR in 
breast cancer cells and that blocked GP130 signalling is linked with inhibition of 
invasion, metastasis and angiogenesis [479]. 
GP130 has been reported to be expressed in varying degrees in the majority of cell lines 
and primary breast cancer tumours [480, 481]. A study of a cohort of patients with 
tumours of varying type (breast, gastrointestinal, uterine, ovarian, renal and bladder) and 
stage, some of whom received chemotherapy and radiotherapy, revealed that blood 
serum levels of GP130 were significantly elevated in cancer patients (both treated and 
untreated) compared with healthy control subjects. Furthermore, serum GP130 levels 
were found to increase significantly with tumour stage [482]. One study reported GP130 
expression as a positive prognostic factor for overall survival and disease free survival in 
advance stage breast cancer [481]. Indeed, GP130 has also been included in the recent 
12-gene EndoPredcit assay, where increased expression is correlated with a lower risk of 
recurrence following endocrine therapy [345-348]. In the predictive model presented 
here, GP130 represents the primary splitter, partitioning the tumours into either 
responsive or non-responsive with 85% accuracy in the training set and 81% accuracy in 
the test set. GP130 expression is highly correlated with response to endocrine therapy 





3.5.4.2. Abnormal spindle-like microcephaly-associated protein (ASPM) 
Studies in mice and embryonic neuroblasts have shown the protein product of ASPM to 
be essential for mitotic spindle regulation during mitosis [483, 484]. In glioblastoma cell 
lines ASPM gene expression was found to be significantly down-regulated in response 
to ionizing radiation and subsequent investigations revealed that silencing of the gene 
impaired DNA double-stranded break repair suggesting an important role for ASPM in 
efficient non-homologous end joining [485]. Another study of gene expression in a panel 
of glioblastomas and astrocytomas showed that increase expression of ASPM is 
positively and strongly correlated with proliferation and tumour malignancy [486, 487]. 
Indeed several studies have implicated ASPM in DNA repair, DNA replication and cell 
cycle arrest [488, 489]. High concentrations of the APSM protein product have been 
found to localise at the spindle poles between the prophase and telophase stages of 
mitosis [490, 491]. In a gene expression study of 97 primary breast cancers, ASPM was 
identified as being significantly deregulated in relation to outcome in aggressive tumours 
and its expression was found to correlate significantly with CCNB2 which was 
identified as a potential biomarker of unfavourable prognosis over short-term follow up 
in aggressive breast cancer [492, 493]. Interestingly, another study of breast cancer cell 
lines showed that knockdown of the BRCA1 gene (germline mutations in which have 
been shown to confer increased risk for breast cancer [494, 495]) results in down-
regulation of cell cycle and proliferation associated genes including ASPM and 
attenuation of the mitotic spindle checkpoint in mitosis [496].   
3.5.4.3. Minichromosome Maintenance Complex Component 4 (MCM4) 
MCM4 encodes a highly conserved protein which is essential for DNA replication. 
During the initiation step of DNA replication at the origin of replication, it forms a 
heterohexameric protein complex with other members of the minichromosome 
maintenance (MCM) protein family (MCM2-7). The complex is a major component of 
the pre-replication complex together with other proteins including: members of the 
origin recognition complex family, CDC6 and CDT1. The MCM complex has ATPase 




double-stranded DNA and drives progression of the replication fork [497-499]. Aberrant 
fork progression can lead to stalled forks or fork collapse resulting in incomplete DNA 
replication and potentially introduction of double stranded breaks [498]. Additional 
chromatin bound MCM complexes also occupy dormant origin regions which can be 
activated to complete DNA replication in the event of stalled forks [500-502]. 
A recent study identified MCM4 as a potential biomarker for diagnosis of cervical 
squamous cell carcinomas after confirming significantly higher expression in tumour 
compared to control tissue [503]. Another study identified MCM4 as a potential 
therapeutic target in non-small cell lung cancer (NSCLC) after reporting its essential 
role in proliferation of NSCLC cell lines and its high correlation of expression with 
proliferation markers Ki67 and cyclin-E [504]. A study of cutaneous melanoma also 
reported high correlation of expression between MCM4 and Ki67 [505]. A genetic 
screen for chromosome instability in mice identified a mutation in the MCM4 gene 
resulting in destabilisation of the MCM complex which was found to cause exclusively 
mammary adenocarcinomas in 80% of homozygous female test mice suggesting that 
such mutations in MCM4 may increase risk of breast cancer in humans [506]. Other 
studies in mice have identified hypomorphic alleles of MCM4 which can give rise to 
tumorigenesis resulting from reduced MCM4 protein levels which promotes 
chromosome instability through a reduction in the number of dormant MCM complex 
which are available to activate in the event of replicative stress [507-510]. Another 
group identified a dominantly acting hypomorphic MCM4 allele, the protein product of 
which is viable and can incorporate into the MCM complex resulting in oncogenic 
chromosomal abnormalities during DNA replication [511]. 
3.5.4.4. Nerve Growth Factor Receptor Associated Protein 1 
(NGFRAP1/BEX3)  
BEX3, previously identified as ‘p75NTR-associated cell death executor’ (NADE), is a 
member of the brain expressed X-linked (BEX) family of proteins and although its 
functions remain incompletely understood, it has been implicated in several studies with 




member of the tumour necrosis factor (TNF) family which can mediate both cell 
survival and cell death in response to nerve growth factor (NGF). It is thought that 
BEX3 mediates apoptosis in response to NGF by interacting with the cell death domain 
of P75NTR. In neural cells, the interaction of BEX3 and P75NTR in response to NGF 
was shown to induce both caspase 2 and caspase 3 pro-apoptotic activities and resulted 
in fragmentation of DNA [512-514]. Indeed, in the brain, loss of function of BEX3 has 
been linked to development of tuberous sclerosis complex (TSC) and other tumour 
pathology [516].  
Studies using various human cancer cell lines and tissues revealed that BEX3 was more 
widely expressed than other members of the BEX family of proteins such as BEX1 and 
BEX2 whose expression is predominantly limited to the brain [517]. Interestingly, 
BEX3 was found to be highly expressed in endocrine-related organs. In breast cancer 
cell lines, forced expression of BEX3 was found to potently supress cellular growth by 
an unknown mechanism which was independent of NGF signalling [518]. One group 
investigated the role of BEX3 in alternative apoptosis pathways. They identified BEX3 
as a binding partner of the second mitochondria-derived activator of caspase (SMAC) 
which has been implicated in the activation of apoptosis in response to stress. The 
interaction between BEX3 and SMAC was found to promote TNF-related apoptosis-
inducing ligand (TRAIL)-induced apoptosis in breast cancer cells by blocking the X-
linked inhibitor of apoptosis protein (XIAP)-mediated ubiquitination of SMAC and its 
subsequent degradation [515]. As well as a role in induction of apoptosis potentially via 
discrete mechanisms, BEX3 has also been directly linked in at least one study to the 
cellular growth cycle, in particular mitochondrial DNA replication. In the study, 
silencing of the BEX3 gene was reported to result in significantly reduced growth of 
teratocarcinoma cells [519].  
Interestingly, in prostate cancer, BEX3 has been identified as a potential biomarker for 
diagnosis with significantly higher expression found in malignant compared to benign 
control prostate tissue [520]. With regard to response to anticancer therapy, a study of 




chemotherapy treatment [521]. Furthermore, a study of primary breast cancers revealed 
a novel subgroup of ERα-positive tumours with improved outcome after tamoxifen 
treatment which were characterised by over-expression of the BEX3 homologue: BEX2 
[522]. In breast cancer, NGF inhibits C2-induced apoptosis through binding of P75NTR 
and subsequent NF-κB activation [523, 524]. The study reports that BEX2 expression is 
necessary for the inhibition of C2-induced apoptosis and that high expression of BEX2 
is associated with enhanced efficacy of tamoxifen [522]. In this scenario, tamoxifen 
treatment reduces levels of estrogen such that BEX2 expression levels reduce reversing 
the inhibition of C2-induced apoptosis. Interestingly, BEX3 has also been shown to 
interact with P75NTR and modulate NGF signalling through activation of NF-κB [512-
514, 516, 522].   
3.5.5. Improving on Previous Work 
3.5.5.1. Increased Sample Number and Definition of Response 
One of the key advantages of this study over other previously published studies is the 
increased number of patients (n=89) with available pre- and on-treatment biopsies and 
clearly defined clinical responses based on 3 months of therapy. Previous studies have 
been limited by patient number. The study by Harvell et al [367, 368] was based on pre- 
and on-treatment samples from only 6 patients receiving neoadjuvant exemestane with 
or without tamoxifen while another study by Massarweh et al [525] analysed pre- and 
on-treatment samples from only 12 patients receiving neoadjuvant anastrozole plus 
fulvestrant with or without gefitinib. Studies such as these, severely limited by sample 
number, lack statistical significance and fail to account for the clinical and molecular 
heterogeneity known to exist in endocrine therapy treated breast cancer. As a result 
reproducibility of findings is often poor and therefore validation in an independent 
dataset unlikely at best.  
The largest study at the start of this thesis in 2009 was that of Miller et al [124], in 
which pre- and on-treatment samples were analysed from 55 patients receiving 




a more relaxed criteria then the current study (only 10/15 would be classified as non-
responsive using the more defined criteria in sections 3.4.2.1/2). The limited number of 
readily available matched pre- and on-treatment tumour tissue samples from patients 
with complete clinical follow-up restricts the generation of new large datasets. However, 
in order to significantly increase patient numbers and hence statistical significance in 
this study, a novel data integration approach was used to combine datasets. Data from 
the previous Miller et al [124] study and new data generated as part of this study were 
directly integrated using a previously described process pipeline which included XPN 
correction for inter-platform bias (see sections 2 and 3.4.1). This approach led to 
creation of the largest dataset of its type, comprising 89 patients, each with pre- and on-
treatment biopsies and full clinical response follow up over 3 months. Importantly, this 
combined dataset comprises the largest proportion of well-defined clinically non-
responsive patients (n=19).  
3.5.5.2. Improved Model Design 
3.5.5.2.1. Data Integration and Reproducibility of Findings 
This study has demonstrated that the reproducibility of findings from previous studies by 
Harvell et al [367, 368] and Miller et al [124] to predict clinical response to endocrine 
therapy is poor. Several factors may account for this, including limited sample number 
and the analysis approaches used potentially leading to dataset specific findings. It is 
postulated that the novel data integration approaches designed and implemented in this 
study may have additional advantages over and above increasing sample size and 
statistical significance. As part of the integration pipeline, during the pre-processing of 
individual datasets, probes are strictly filtered and re-annotated. In so doing only those 
with well-designed probe sequences for the gene of interest and a low chance of non-
specific hybridisation are retained. While a number of genes are lost at this step in the 
pipeline, those which remain are likely to have a consistent relative expression across 
datasets and consistent absolute expression following XPN correction in biologically 




refined list of accurately measured and consistently expressed genes across different 
microarray platforms may have improved reproducibility in independent datasets. The 
exact nature and magnitude of the contribution of data integration and XPN correction to 
reproducibility remains to be elucidated and is worthy of future work. 
3.5.5.2.2. CART Algorithm 
The use of a classification and regression tree (CART) algorithm represents a conceptual 
improvement in model design in this study compared with previous studies. The study of 
Miller et al [124] identified 205 variables which, when considered together, were 
reported to discriminate between responsive and non-responsive tumours. Application of 
these variables with centroid based classification yielded poor reproducibility of 
prediction accuracy in an independent dataset. This may be due to the molecular 
heterogeneity which has been reported to exist within the non-responsive population; by 
considering all non-responsive tumours as one group, accuracy of prediction is likely to 
be highly dependent on the composition of the training set. In this study, the issue of 
heterogeneity within the non-responsive tumours was addressed by increasing sample 
number in order to better represent the population, and importantly was accounted for by 
the CART algorithm. Rather than splitting data into only two groups, the algorithm 
employs exhaustive searchers and computer-intensive testing techniques to identify 
variables which can partition the data into homogeneous segments, each associated with 
either positive response or non-response to therapy.  
3.5.6. Clinical Application 
3.5.6.1. Clinical Need for an Early On-treatment Biopsy 
Another important finding of this study has been identifying the clinical need for an 
early on-treatment biopsy, as well as the pre-treatment biopsy routinely performed at 
diagnosis, for substantially improved prediction accuracy of overall response. 
Proliferation-associated gene expression in particular, which has been shown in 




comprises 2 of the 4 genes in the 4 gene CART model, has dramatically improved 
predictive power at day 14 on-treatment compared with pre-treatment.     
3.5.6.2. Treating Non-responsive Patients        
The majority of non-responsive patients have been shown to exhibit both poor clinical 
and pathological response to therapy compared with the responsive group. While some 
seem to gain little benefit from endocrine therapy and thus should be considered for 
alternative treatment, many gain partial benefit and may be suitable candidates for 
combination therapy. Reduced response to endocrine therapy in such tumours might 
suggest that proliferation and tumour development is less or only partially dependent on 
estrogen. Consistent with this hypothesis, a subset of non-responsive tumours in this 
study (42%) were identified as HER2
+
, suggesting an alternative mechanism involved in 





 at diagnosis and are predicted to be non-responsive to endocrine 
therapy alone may benefit from aromatase inhibitor therapy combined with anti-HER2 
therapy such as trastuzumab, pertuzumab or lapatinib. Other groups have studied 
alternative drugs, combination therapy protocols and treatment strategies (see section 
1.2.4) for potential roles in reversing endocrine therapy resistance with mixed success, 
doubtless due to the molecular and mechanistic heterogeneity of non-response. Rather 
than a ‘one approach fits all’, further study is required to elucidated the individual 
mechanisms which underlie non-response in distinct subsets of non-responsive patients 
and to stratify such patients in a move towards personalised medicine whereby the most 









4. Conclusions and Future Work 
This study has led to the development and validation of novel data integration 
approaches to increase sample size, and as a result statistical significance, for robust 
microarray data meta-analysis with potentially improved reproducibility and elucidation 
of platform-independent findings. Using this approach, 4 novel biomarkers for accurate 
and robust prediction of response to neoadjuvant aromatase inhibitor therapy by two 
weeks of treatment were identified. Using pre-treatment expression levels of the immune 
signalling and apoptosis related genes: GP130 and BEX3 respectively, and 14 day 
expression levels of the proliferation-associated genes: ASPM and MCM4, accuracy of 
prediction was found to be 96% and 91% in training (n=73) and validation (n=44) 
datasets. In particular, GP130 was identified as a key biomarker in the model, pre-
treatment expression of which was shown to have 85% and 81% prediction accuracy 
alone in training and validation datasets respectively. Importantly, the 4 gene model has 
been shown to significantly outperform currently used clinical and pathological 
parameters for assessing response and previously reported gene expression based models 
for the purpose. 
4.1. Applicability to Other Settings and Therapies 
4.1.1. Other Endocrine Therapies 
The 4 gene model has been shown to accurately predict response in patients treated with 
two different aromatase inhibitors (AIs): letrozole and anastrozole, potentially 
suggesting a broader role for predicting response to other AIs such as exemestane or 
even other anti-estrogen therapies such as tamoxifen or fulvestrant. Future work will 
elucidated the potential applicability of the model to predict response to other single and 
combined anti-estrogen agents. 
4.1.2. The Adjuvant Setting 
The 4 gene model was designed to predict response in the neoadjuvant setting. However, 




therefore it will be interesting to assess the applicability of the model to prediction of 
long-term outcome to adjuvant endocrine therapy. To that end a cohort of patients 
(n=50) with available pre-treatment and 14 day biopsy material, treated with 14 days of 
either neoadjuvant letrozole or anastrozole followed by surgery and adjuvant endocrine 
therapy (tamoxifen or AI) with long-term follow up have been identified. Future work 
will involve measuring expression of the 4 genes in these samples and determining 
association with long-term outcome. 
4.2. Translational Potential 
Based on expression of only 4 genes, the model has great potential for use in the clinical 
setting or as a commercially available test. Future work will focus on determining the 
applicability of the model to other endocrine therapies and the adjuvant setting, as well 
as establishing a clinical protocol for optimum patient care and the most appropriate 
assay and delivery thereof for robust, accurate and reproducible prediction.   
4.2.1. Technology 
4.2.1.1. Gene Expression Based Technology: qRT-PCR 
Given the restrictive associated costs and unnecessary coverage, commercial gene 
expression microarray is not the most suitable technology to assay expression of only 4 
genes for clinical application. Instead, tests such as Oncotype DX®, based on expression 
of 21 genes, employ qRT-PCR. However, complications can arise from analytical 
variation in qRT-PCR, which are likely to impact on predictive accuracy of the model 
across different sites. In the case of Oncotype DX®, these complications have been 
largely circumvented by providing the test at only one centralised location where 
measures of gene expression are derived using the same technology and strictly adhered 
to protocol. In the case of the 4 gene model it seems logical that a similar setup would be 
required should the test become commercially available. As a first step, expression 
levels of the 4 genes in the training set would have to be re-analysed using a chosen RT-
PCR technology and controlled methodology in order to establish new splitter values 





Alternatively, currently used biomarkers such as ER, PR and HER2 are routinely 
assayed at diagnosis by assessing protein level using IHC rather than gene expression. 
Thus, it will be advantageous to determine if variation at protein level of the 4 genes 
could be used as an alternative to gene expression to distinguish responsive from non-
responsive patients. If a protein-based test yielded positive results, there may be 
potential for employing the model in the clinical setting as part of routine histology. 
However, in order to cut down on analytical variation across sites, there would doubtless 
be a need to develop standard comprehensive protocols for analytical assessment 
(including selection of reliable validated antibodies), interpretation and scoring, akin to 
current efforts to standardise the analytical practice for Ki67 assessment [444].  
4.2.2. Collecting, Processing and Storing Tissue 
4.2.2.1. FFPE Tissue 
The move to qRT-PCR or IHC has another important advantage in that sufficient RNA 
for qRT-PCR or protein for IHC can be obtained from FFPE tissue, which unlike fresh 
frozen tissue is prepared routinely at diagnosis for every patient, can be transported 
easily in the event of a centralised qRT-PCR based test, is easier to work with and can 
be stored long-term at room temperature without degrading, unlike fresh frozen tissue 
which requires to be stored at -80
o
C. 
4.2.2.2. Final Needle Aspiration 
This study has demonstrated the clinical need for a 14 day biopsy for improved 
prediction of clinical response to endocrine therapy compared with pre-treatment gene 
expression alone. Given the importance of a 14 day sample to prediction and considering 
the cost and discomfort for the patient associated with taking a core biopsy there is a 
clinical need, for improved patient care, to determine if RNA sufficient for qRT-PCR 




expression analysis, in respect of the 4 genes, of patients treated with neoadjuvant 
letrozole with core biopsies taken at diagnosis and FNAs taken at day 14 of treatment.     
4.3. Understanding the Mechanisms underlying GP130 Expression 
GP130 has been identified as the key gene involved with predicting clinical 
responsiveness to endocrine therapy in this study and has an important role in 
determining risk of recurrence in the EndoPredcit assay, yet little is known about the 
biology underlying its relevance. A growing number of studies, including this, now exist 
which provide compelling evidence that high expression of GP130 is associated with 
both a good clinical response to endocrine therapy and better prognosis [345, 347, 481]. 
Indeed, the findings of this study indicate that withdrawal of estrogen has a more 
beneficial effect, in terms of clinical response, in tumours that have higher levels of 
GP130 at pre-treatment.  
While future work will help to elucidate the underlying mechanisms, hypothetically if 
high GP130 expression is indicative of increased GP130-mediated signalling either 
through the JAK/STAT, MAPK or PI3K pathways then one possible conclusion could 
be that disruption of the estrogen signalling pathway has a greater downstream effect 
when GP130 signalling is active due to crosstalk between the pathways. Increased 
expression of GP130 could indicate active cytokine signalling via one of its primary 
upstream activators: IL6 which has been shown to increase the activity of the aromatase 
enzyme and thus local estrogen production [526]. While crosstalk between the GP130-
mediated and estrogen signalling pathways remains poorly understood, in breast tumours 
the principle mechanism of STAT3, the downstream effector of IL6 signalling, 
activation has been shown to be via the IL6/GP130/JAK/STAT pathway and is 
associated with regulation of proliferation [527, 528]. While the expression of STAT3 in 
breast cancer has been reported as constitutive, studies have shown that estrogen can 
induce phosphorylation of STAT3 and that STAT-dependent transcription is itself 
dependent on estrogen-bound ESR1 and intact MAPK and PI3K pathways [529]. 
Withdrawal of estrogen may result in disruption of the estrogen signalling pathway and 




both having a concerted effect on downstream gene expression. Further work has to be 
done to confirm the presence of GP130-mediate signal transduction and its association 
with the estrogen signalling pathway which remains poorly understood. 
4.4. Investigating Mechanisms of Non-response 
Future work will also focus on gaining a better understanding of the mechanisms 
underlying non-response in a move towards better treatments, including new, alternative 
or combined therapies, to improve outcome of patients predicted to respond less well to 
endocrine therapy alone.  
4.4.1. HER2 Signalling 
Initial work will focus on establishing the role of HER2 signalling as a driver of 
proliferation in non-responsive tumours which over-express the HER2 gene, with a view 
to conducting a clinical trial to determine benefit from combined endocrine therapy and 
HER2 targeted therapy in the neoadjuvant setting.  
4.4.2. Immune and Stromal Cell Infiltration 
This study has also identified a subgroup of clinically responsive patients which 
following 3 months of endocrine therapy are characterised by increased expression of 
immune/inflammatory and ECM/stromal rearrangement associated genes. Future work 
will investigate the underlying mechanisms leading to increased expression of immune 
and stromal gene signatures in responsive tumours and the implications for clinical 
response. This will include establishing the extent to which infiltrating leukocytes and 
stromal cells such as fibroblasts, identified in some tumours, are involved and their 
importance to clinical response. Furthermore, a cohort of patients with pre-treatment and 
14 day biopsies taken before surgery following no-intervening treatment will also be 
assessed by gene expression to determine the extent to which early increases in 
immune/inflammatory and ECM/stromal gene expression are a result of an 
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#Pre-processing of Illumina Data 
############################################################################################### 
 
#QC data in GenomeStudio removing samples with less than 9000 detected genes below a detection P value of 0.05 
#Export Probe Profile from Genome Studio 
 
#Load required programs in R 
library(lumi) 
 
#Load data using lumiR function - do not convert IDs 
filename="Illum_SPPraw.txt" 
raw.lumi <- lumiR(filename, convertNuID = FALSE) 
 
#Log2 Transformation (Log2) 
#For other transformation methods change "log2" for: "vst", "cubicRoot" 
lumi.T=lumiT(raw.lumi, method=c("log2"), verbose=TRUE) 
 
#Quantile Normalisation (QN) 
#For other normalisation methods change "quantile" for: "rsn", "ssn", "loess", "vsn", "rankinvariant" 
lumi.N=lumiN(lumi.T, method=c("quantile"), verbose=TRUE) 
 




#Create an expression matrix of the normalised and filtered data 
data.processed <- exprs(lumi.N.Q) 
 
#Write data to directory as a .txt file (make sure that row names and column names are displayed correctly in file)  
write.table(data.processed,file="Illum_QN.txt", append=FALSE, quote=FALSE, sep="\t", row.names=TRUE, col.names=TRUE) 
 
#Filter Data 
#In Excel, use detection P values generated from GenomeStudio - remove probes which are not detected with a P-value of under 0.05 
in the total number of samples minus 3 
 
#Reannotate Data 
#In Excel reannotate each probe to an Ensembl (ENSM) gene ID. Use the 50mer probe sequences exported from GenomeStudio to 
look up mappings in the following resources 
#reMOAT: http://remoat.sysbiol.cam.ac.uk/search.php 
#BioMART: http://www.ensembl.org/biomart (Ensembl Human release 68 July 2012) 
#BLAST: http://www.ensembl.org/Homo_sapiens/blastview 
#Only retain probes where mappings to a an Ensembl gene agree with at least two of the resources 
 
#Combine Multiple Probes 
#In Excel ,where a single ENSM gene is represtend by multiple probes - calculate an average 
 
##################################### 
#Optional Batch Correction 
##################################### 
 
#Load filtered, reannotated ENSM data 
data.processed1=read.delim("Illum_QN_filt_ENSM.txt",header=TRUE, sep="\t", row.names=1) 
 
#Analysis for the presence of batch effects 
#Create multidimensional scaling (MDS) plot 














write.table(z, "L3_bg_QN_mds.txt", quote=F, sep="\t") 
 
#Correct with ComBat if necessary 
 
#Batch correction using ComBat 
#ComBat - Download ComBat R script from http://statistics.byu.edu/johnson/ComBat/Download.html and place the file in the 
directory 
#Create the Sample Information File and save as a .txt file to the directory 
source('Combat.R') 
ComBat('Illum_QN_filt_ENSM.txt','Sample Information File (Combat).txt',skip=1) 
 
#Load ComBat corrected data 
data.combat=read.delim("Illum_QN_filt_ENSM-ComBat.txt",header=TRUE, sep="\t", row.names=1) 
 
#Assess correction of data 
#Create multidimensional scaling (MDS) plot 











write.table(z, "Illum_QN_filt_ENSM-ComBat_mds.txt", quote=F, sep="\t") 
 
#Illumina data ready for integration 
 
############################################################################################### 
#Pre-processing of Affymetrix Data 
############################################################################################### 
 
#Place CEL files in the working directory 
 
#Load required programs 
library(affy) 
 
#Download the alternate_cdf from "http://brainarray.mbni.med.umich.edu/Brainarray/Database/CustomCDF/CDF_download.asp" 
#Place the alternate_cdf file in the root of the working directory 
#In this analysis I used alternate_cdf for ENSG version 15 
#Read .CEL files into R and load the required alternate_cdf file 
data<-ReadAffy(cdfname = "HGU133A_HS_ENSG") 
 
#Apply the Robust Multichip Average (RMA) Algorithm 
#.CEL files which contain expression values for each probe are combined by this alogirthm to give an expression for each probe set 
(transcript represented on the chip) 
#RMA Background Adjustment  
#Quantile Normalisation 













#Filter RMA data in Excel based on mas5 detection calls: Remove all are A or M in the total number of the samples 
#Present: p < 0.04 
#Marginal: p between 0.04 and 0.06 
#Absent: p > 0.06 
 
##################################### 
#Optional Batch Correction 
##################################### 
 
#Load the filtered and normalised Affyemtrix file 
data.filtered=read.delim("Affy-RMA_filt.txt",header=TRUE, sep="\t", row.names=1) 
 
#Analysis for the presence of batch effects 
#Create multidimensional scaling (MDS) plot 











write.table(z, "Affy-RMA_filt_mds.txt", quote=F, sep="\t") 
 
#Correct with ComBat if necessary 
 
#Batch correction using ComBat 
#ComBat - Download ComBat R script from http://statistics.byu.edu/johnson/ComBat/Download.html and place the file in the 
directory 
#Create the Sample Information File and save as a .txt file to the directory 
source('Combat.R') 
ComBat('Affy-RMA_filt_forComBat.txt','Sample Information File (Combat).txt',skip=1) 
 
#Load ComBat corrected data 
data.combat=read.delim("Affy-RMA_filt_ComBat.txt",header=TRUE, sep="\t", row.names=1) 
 
#Assess correction of data 
#Create multidimensional scaling (MDS) plot 











write.table(z, "Affy-RMA_filt_ComBat_mds.txt", quote=F, sep="\t") 
 
#Affy data ready for integration 
 
############################################################################################### 
#L2 Affymetrix and L3 Illumina Combined Data 
############################################################################################### 
 
#Combine Illumina and Affymetrix datasets in Excel - retaining only ENSM genes where data is available from both platforms. 





#Load Affy and Illumina combined data 
data.combined=read.delim("AffyIllumCombined.txt",header=TRUE, sep="\t", row.names=1) 
 
#View a box plot of expression for the combined dta 
boxplot(data.combined, main="Amplitude of Expression Plot - Combined Data") 
 
#Create multidimensional scaling (MDS) plot 











write.table(z, "AffyIllumCombined_mds.txt", quote=F, sep="\t") 
 
############################################################################################### 














#Batch correction using ComBat 
#ComBat - Download ComBat R script from http://statistics.byu.edu/johnson/ComBat/Download.html and place the file in the 
directory 
#Create the Sample Information File and save as a .txt file to the directory 
source('Combat.R') 
ComBat('AffyIllumCombined.txt','Sample Information File (Combat).txt',skip=1 
 
################################################################ 
#XPN correction  
################################################################ 
 




#DWD-standard correction  
################################################################ 
 








#Code for Similarity/Dissimilairy Heatmaps 
################################################################ 
 
#Drawing similarity/dissimilairy heatmap in R using Gplots 
#Determine correlation between columns of dataset 





breaks <- seq(from = 0.90, to = 1, length = 20) 
colors = "heat.colors" 
heatmap.2(data.cor, dendrogram="none", col=colors, Rowv=F, Colv=F, scale="none", key=TRUE, symkey=FALSE, 
density.info="none", trace="none", cexRow=1, cexCol=1, breaks=breaks)  
write.table(data.cor, "Data_cor.txt", quote=F, sep="\t") 
 
################################################################ 
#Differential gene expression analysis 
################################################################ 
 






































6.2. Proliferation Set Gene List 
ENSM Gene ID Office Gene Symbol Gene Name 
ENSG00000168274 HIST1H2AB histone cluster 1, H2ae; histone cluster 1, H2ab 
ENSG00000168274 HIST1H2AE histone cluster 1, H2ae; histone cluster 1, H2ab 
ENSG00000167325 RRM1 ribonucleotide reductase M1 
ENSG00000117724 CENPF centromere protein F, 350/400ka (mitosin) 
ENSG00000056736 IL17RB interleukin 17 receptor B 
ENSG00000122952 ZWINT ZW10 interactor 
ENSG00000138346 DNA2 DNA replication helicase 2 homolog (yeast) 
ENSG00000111602 TIMELESS timeless homolog (Drosophila) 
ENSG00000126803 HSPA2 heat shock 70kDa protein 2 
ENSG00000102384 CENPI centromere protein I 
ENSG00000164104 HMGB2 high-mobility group box 2 
ENSG00000104738 MCM4 minichromosome maintenance complex component 4 
ENSG00000164109 MAD2L1 MAD2 mitotic arrest deficient-like 1 (yeast) 
ENSG00000100479 POLE2 polymerase (DNA directed), epsilon 2 (p59 subunit) 
ENSG00000145386 CCNA2 cyclin A2 
ENSG00000101773 RBBP8 retinoblastoma binding protein 8 
ENSG00000131747 TOP2A topoisomerase (DNA) II alpha 170kDa 
ENSG00000164032 H2AFZ H2A histone family, member Z 
ENSG00000213066 FGFR1OP FGFR1 oncogene partner 
ENSG00000136518 ACTL6A actin-like 6A 
ENSG00000163808 KIF15 kinesin family member 15 
ENSG00000173473 SMARCC1 
SWI/SNF related, matrix associated, actin dependent regulator of chromatin, 
subfamily c, member 1 
ENSG00000126787 DLGAP5 discs, large (Drosophila) homolog-associated protein 5 
ENSG00000076003 MCM6 minichromosome maintenance complex component 6 
ENSG00000112312 GMNN geminin, DNA replication inhibitor 
ENSG00000087586 AURKA aurora kinase A; aurora kinase A pseudogene 1 
ENSG00000087586 AURKAPS1 aurora kinase A; aurora kinase A pseudogene 1 
ENSG00000073111 MCM2 minichromosome maintenance complex component 2 
ENSG00000138175 ARL3 ADP-ribosylation factor-like 3 
ENSG00000111666 CHPT1 choline phosphotransferase 1 
ENSG00000166451 CENPN centromere protein N 
ENSG00000154473 BUB3 budding uninhibited by benzimidazoles 3 homolog (yeast) 
ENSG00000066279 ASPM asp (abnormal spindle) homolog, microcephaly associated (Drosophila) 
ENSG00000134057 CCNB1 cyclin B1 
ENSG00000170312 CDK1 cell division cycle 2, G1 to S and G2 to M 
ENSG00000138160 KIF11 kinesin family member 11 




ENSG00000197061 HIST1H4D histone  
ENSG00000197061 HIST1H4F histone  
ENSG00000197061 HIST1H4H histone  
ENSG00000197061 HIST1H4I histone  
ENSG00000197061 HIST1H4J histone  
ENSG00000197061 HIST2H4A histone  
ENSG00000197061 HIST1H4A histone  
ENSG00000197061 HIST1H4B histone  
ENSG00000197061 HIST2H4B histone  
ENSG00000197061 HIST1H4E histone  
ENSG00000197061 HIST1H4K histone  
ENSG00000197061 HIST1H4L histone  
ENSG00000197061 HIST4H4 histone  
ENSG00000088325 TPX2 TPX2, microtubule-associated, homolog (Xenopus laevis) 
ENSG00000131153 GINS2 GINS complex subunit 2 (Psf2 homolog) 
ENSG00000110092 CCND1 cyclin D1 
ENSG00000140443 IGF1R insulin-like growth factor 1 receptor 
ENSG00000132646 PCNA proliferating cell nuclear antigen 
ENSG00000137804 NUSAP1 nucleolar and spindle associated protein 1 
ENSG00000106462 EZH2 enhancer of zeste homolog 2 (Drosophila) 
ENSG00000198087 CD2AP CD2-associated protein 
ENSG00000188486 H2AFX H2A histone family, member X 
ENSG00000149554 CHEK1 CHK1 checkpoint homolog (S. pombe) 
ENSG00000138180 CEP55 centrosomal protein 55kDa 
ENSG00000080986 NDC80 NDC80 homolog, kinetochore complex component (S. cerevisiae) 
ENSG00000031691 CENPQ centromere protein Q 
ENSG00000117399 CDC20 cell division cycle 20 homolog (S. cerevisiae) 
ENSG00000109084 TMEM97 transmembrane protein 97 
ENSG00000100526 CDKN3 cyclin-dependent kinase inhibitor 3 
ENSG00000162702 ZNF281 zinc finger protein 281 
ENSG00000163918 RFC4 replication factor C (activator 1) 4, 37kDa 
ENSG00000109805 NCAPG non-SMC condensin I complex, subunit G 
ENSG00000168061 SAC3D1 SAC3 domain containing 1 
ENSG00000171848 RRM2 ribonucleotide reductase M2 polypeptide 
ENSG00000196074 SYCP2 synaptonemal complex protein 2 
ENSG00000213005 PTTG3P pituitary tumor-transforming 3 
ENSG00000198901 PRC1 protein regulator of cytokinesis 1 





6.3. 131 Genes Input to CART Gene List 
ENSM Gene ID Offical Gene Symbol Gene Name 
ENSG00000196139 AKR1C3 
aldo-keto reductase family 1, member C3 (3-alpha hydroxysteroid 
dehydrogenase, type II) 
ENSG00000169744 LDB2 LIM domain binding 2 
ENSG00000111404 RERGL RERG/RAS-like 
ENSG00000138755 CXCL9 chemokine (C-X-C motif) ligand 9 
ENSG00000122952 ZWINT ZW10 interactor 
ENSG00000115414 FN1 fibronectin 1 
ENSG00000179041 RRS1 RRS1 ribosome biogenesis regulator homolog (S. cerevisiae) 
ENSG00000213088 DARC Duffy blood group, chemokine receptor 
ENSG00000113387 SUB1 SUB1 homolog (S. cerevisiae) 
ENSG00000133740 E2F5 E2F transcription factor 5, p130-binding 
ENSG00000112936 C7 complement component 7 
ENSG00000131747 TOP2A topoisomerase (DNA) II alpha 170kDa 
ENSG00000129226 CD68 CD68 molecule 
ENSG00000124831 LRRFIP1 leucine rich repeat (in FLII) interacting protein 1 
ENSG00000139629 GALNT6 
UDP-N-acetyl-alpha-D-galactosamine:polypeptide N-
acetylgalactosaminyltransferase 6 (GalNAc-T6) 
ENSG00000175745 NR2F1 nuclear receptor subfamily 2, group F, member 1 
ENSG00000112742 TTK TTK protein kinase 
ENSG00000163808 KIF15 kinesin family member 15 
ENSG00000039068 CDH1 cadherin 1, type 1, E-cadherin (epithelial) 
ENSG00000129596 CDO1 cysteine dioxygenase, type I 
ENSG00000170476 MGC29506 hypothetical protein MGC29506 
ENSG00000146278 PNRC1 proline-rich nuclear receptor coactivator 1 
ENSG00000087586 AURKA aurora kinase A; aurora kinase A pseudogene 1 
ENSG00000087586 AURKAPS1 aurora kinase A; aurora kinase A pseudogene 1 
ENSG00000168329 CX3CR1 chemokine (C-X3-C motif) receptor 1 
ENSG00000111666 CHPT1 choline phosphotransferase 1 
ENSG00000156234 CXCL13 chemokine (C-X-C motif) ligand 13 
ENSG00000158488 CD1E CD1e molecule 
ENSG00000107562 CXCL12 chemokine (C-X-C motif) ligand 12 (stromal cell-derived factor 1) 
ENSG00000186918 ZNF395 zinc finger protein 395 
ENSG00000122861 PLAU plasminogen activator, urokinase 
ENSG00000175445 LPL lipoprotein lipase 
ENSG00000097046 CDC7 cell division cycle 7 homolog (S. cerevisiae) 
ENSG00000066279 ASPM asp (abnormal spindle) homolog, microcephaly associated (Drosophila) 
ENSG00000164949 GEM GTP binding protein overexpressed in skeletal muscle 




ENSG00000109436 TBC1D9 TBC1 domain family, member 9 (with GRAM domain) 
ENSG00000170312 CDK1 cell division cycle 2, G1 to S and G2 to M 
ENSG00000074410 CA12 carbonic anhydrase XII 
ENSG00000067113 PPAP2A phosphatidic acid phosphatase type 2A 
ENSG00000216490 IFI30 interferon, gamma-inducible protein 30 
ENSG00000148154 UGCG UDP-glucose ceramide glucosyltransferase 
ENSG00000074416 MGLL monoglyceride lipase 
ENSG00000137947 GTF2B general transcription factor IIB 
ENSG00000131153 GINS2 GINS complex subunit 2 (Psf2 homolog) 
ENSG00000137804 NUSAP1 nucleolar and spindle associated protein 1 
ENSG00000060718 COL11A1 collagen, type XI, alpha 1 
ENSG00000164162 ANAPC10P1 
anaphase promoting complex subunit 10; anaphase promoting complex 
subunit 10 pseudogene 
ENSG00000164162 ANAPC10 
anaphase promoting complex subunit 10; anaphase promoting complex 
subunit 10 pseudogene 
ENSG00000129055 ANAPC13 anaphase promoting complex subunit 13 
ENSG00000108691 CCL2 chemokine (C-C motif) ligand 2 
ENSG00000153563 CD8A CD8a molecule 
ENSG00000160712 IL6R interleukin 6 receptor 
ENSG00000189221 MAOA monoamine oxidase A 
ENSG00000138180 CEP55 centrosomal protein 55kDa 
ENSG00000176887 SOX11 SRY (sex determining region Y)-box 11 
ENSG00000177565 TBL1XR1 transducin (beta)-like 1 X-linked receptor 1 
ENSG00000158402 CDC25C cell division cycle 25 homolog C (S. pombe) 
ENSG00000211445 GPX3 glutathione peroxidase 3 (plasma) 
ENSG00000123384 LRP1 low density lipoprotein-related protein 1 (alpha-2-macroglobulin receptor) 
ENSG00000128245 YWHAH 
tyrosine 3-monooxygenase/tryptophan 5-monooxygenase activation protein, 
eta polypeptide 
ENSG00000157404 LOC652799 similar to Mast/stem cell growth factor receptor precursor (SCFR) 
ENSG00000157404 LOC653882 similar to Mast/stem cell growth factor receptor precursor (SCFR) 
ENSG00000157404 KIT similar to Mast/stem cell growth factor receptor precursor (SCFR) 
ENSG00000165304 MELK maternal embryonic leucine zipper kinase 
ENSG00000171848 RRM2 ribonucleotide reductase M2 polypeptide 
ENSG00000158473 CD1D CD1d molecule 
ENSG00000198901 PRC1 protein regulator of cytokinesis 1 
ENSG00000175054 LOC648152 
ataxia telangiectasia and Rad3 related; similar to ataxia telangiectasia and 
Rad3 related protein 
ENSG00000175054 LOC651921 
ataxia telangiectasia and Rad3 related; similar to ataxia telangiectasia and 
Rad3 related protein 
ENSG00000175054 ATR 
ataxia telangiectasia and Rad3 related; similar to ataxia telangiectasia and 
Rad3 related protein 
ENSG00000091831 ESR1 estrogen receptor 1 
ENSG00000117724 CENPF centromere protein F, 350/400ka (mitosin) 




ENSG00000137563 GGH gamma-glutamyl hydrolase (conjugase, folylpolygammaglutamyl hydrolase) 
ENSG00000151725 MLF1IP MLF1 interacting protein 
ENSG00000163739 CXCL1 
chemokine (C-X-C motif) ligand 1 (melanoma growth stimulating activity, 
alpha) 
ENSG00000134352 IL6ST interleukin 6 signal transducer (gp130, oncostatin M receptor) 
ENSG00000138346 DNA2 DNA replication helicase 2 homolog (yeast) 
ENSG00000113558 SKP1 S-phase kinase-associated protein 1 
ENSG00000116478 HDAC1 histone deacetylase 1 
ENSG00000104738 MCM4 minichromosome maintenance complex component 4 
ENSG00000147257 GPC3 glypican 3 
ENSG00000164109 MAD2L1 MAD2 mitotic arrest deficient-like 1 (yeast) 
ENSG00000169032 MAP2K1 mitogen-activated protein kinase kinase 1 
ENSG00000145386 CCNA2 cyclin A2 
ENSG00000164754 RAD21 RAD21 homolog (S. pombe) 
ENSG00000123689 G0S2 G0/G1switch 2 
ENSG00000101773 RBBP8 retinoblastoma binding protein 8 
ENSG00000094880 CDC23 cell division cycle 23 homolog (S. cerevisiae) 
ENSG00000115641 FHL2 four and a half LIM domains 2 
ENSG00000123124 WWP1 WW domain containing E3 ubiquitin protein ligase 1 
ENSG00000197905 TEAD4 TEA domain family member 4 
ENSG00000090920 LOC100133944 
Fc fragment of IgG binding protein; similar to IgGFc-binding protein 
precursor (FcgammaBP) (Fcgamma-binding protein antigen) 
ENSG00000090920 FCGBP 
Fc fragment of IgG binding protein; similar to IgGFc-binding protein 
precursor (FcgammaBP) (Fcgamma-binding protein antigen) 
ENSG00000131471 AOC3 amine oxidase, copper containing 3 (vascular adhesion protein 1) 
ENSG00000105664 COMP cartilage oligomeric matrix protein 
ENSG00000172201 ID4 inhibitor of DNA binding 4, dominant negative helix-loop-helix protein 
ENSG00000006007 GDE1 glycerophosphodiester phosphodiesterase 1 
ENSG00000168040 FADD Fas (TNFRSF6)-associated via death domain 
ENSG00000085415 SEH1L SEH1-like (S. cerevisiae) 
ENSG00000104267 CA2 carbonic anhydrase II 
ENSG00000137033 IL33 interleukin 33 
ENSG00000166483 WEE1 WEE1 homolog (S. pombe) 
ENSG00000155792 DEPDC6 DEP domain containing 6 
ENSG00000137573 SULF1 sulfatase 1 
ENSG00000162604 TM2D1 TM2 domain containing 1 
ENSG00000073111 MCM2 minichromosome maintenance complex component 2 
ENSG00000135218 CD36 CD36 molecule (thrombospondin receptor) 
ENSG00000154473 BUB3 budding uninhibited by benzimidazoles 3 homolog (yeast) 
ENSG00000130303 BST2 NPC-A-7; bone marrow stromal cell antigen 2 
ENSG00000132341 RAN RAN, member RAS oncogene family 




ENSG00000172216 CEBPB CCAAT/enhancer binding protein (C/EBP), beta 
ENSG00000205336 GPR56 G protein-coupled receptor 56 
ENSG00000067225 LOC652797 similar to Pyruvate kinase 
ENSG00000067225 PKM2 similar to Pyruvate kinase 
ENSG00000123349 PFDN5 prefoldin subunit 5 
ENSG00000172724 CCL19 chemokine (C-C motif) ligand 19 
ENSG00000187288 CIDEC cell death-inducing DFFA-like effector c 
ENSG00000160752 FDPS 
farnesyl diphosphate synthase (farnesyl pyrophosphate synthetase, 
dimethylallyltranstransferase, geranyltranstransferase) 
ENSG00000131788 PIAS3 protein inhibitor of activated STAT, 3 
ENSG00000166681 NGFRAP1 nerve growth factor receptor (TNFRSF16) associated protein 1 
ENSG00000088325 TPX2 TPX2, microtubule-associated, homolog (Xenopus laevis) 
ENSG00000110092 CCND1 cyclin D1 
ENSG00000010610 CD4 CD4 molecule 
ENSG00000132646 PCNA proliferating cell nuclear antigen 
ENSG00000164128 NPY1R neuropeptide Y receptor Y1 
ENSG00000142684 ZNF593 zinc finger protein 593 
ENSG00000149554 CHEK1 CHK1 checkpoint homolog (S. pombe) 
ENSG00000108700 CCL8 chemokine (C-C motif) ligand 8 
ENSG00000134480 CCNH cyclin H 
ENSG00000197766 CFD complement factor D (adipsin) 
ENSG00000117525 F3 coagulation factor III (thromboplastin, tissue factor) 
ENSG00000117399 CDC20 cell division cycle 20 homolog (S. cerevisiae) 
ENSG00000161570 CCL5 chemokine (C-C motif) ligand 5 
ENSG00000109805 NCAPG non-SMC condensin I complex, subunit G 
ENSG00000167286 CD3D CD3d molecule, delta (CD3-TCR complex) 















6.5. R&D Approval 
 
